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Human Immunodeficiency Virus (HIV) is the etiological agent of AIDS and is 
responsible for the AIDS pandemic worldwide. According to UNAIDS, as of 2016, 
there were approximately 36.7 million people living with HIV globally, and 1.8 
million new infections that year. While antiretroviral therapies and education 
continue to reduce these numbers, a preventative vaccine is still required to curb 
this epidemic. The envelope glycoprotein trimer of HIV, which is the sole protein 
on the surface of the virus and facilitates entry of the virus into host cells, is of 
keen interest to the HIV vaccine and drug-development field. Recently, the 
structure of this trimer was solved which has opened the door for the design of 
new immunogens and drugs. These solved envelope protein trimer structures 
demonstrate that the major variable loops of the env protein are positioned at the 
apex of the trimer where they play a role in trimer stability. Data from our lab has 
shown previously that both the V2 and V3 loop contain elements that are critical 
for envelope trimer stability.  
The work presented in this dissertation expands on these initial studies and 
confirms that the V2 and V3 loops contribute to envelope trimer stability and 
functionality in HIV-1, HIV-2 and in Simian Immunodeficiency Virus (SIV) 
	species. We have demonstrated that the hydrophobic patch near the tip of the V3 
loop, which is present in all primate lentiviruses, is critical for trimer stability in 
subtype C HIV-1, HIV-2 and in SIV species. Additionally, we further explored the 
role of the twin-cysteine motif found in the V2 loop of HIV-2 and SIV species, but 
not in HIV-1. We have shown that this motif is critical for the stability of the 
envelope protein of these viruses. Both observations are supported by our 
experimental data and by molecular modeling. This work supports the released 
trimer structures and provides a further understanding of the forces that stabilize 
the envelope trimer of primate lentiviruses, and will aid in the development of 
stabilized envelope trimer based immunogens in the effort to develop an effective 
HIV vaccine.   
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Research Aims 
 The objective of this dissertation research was to further characterize the 
activity of the major variable loops (V2 and V3) of the primate lentiviral envelope 
protein in envelope trimer stability and functionality. The V2 and V3 loops have 
been shown previously to play an important role in the stability of the Human 
Immunodeficiency Virus (HIV) envelope trimer, and in turn, the functionality of 
this complex. The advent of near atomic structures of the trimer has revealed that 
V2 and V3 are packed tightly into the apex of the envelope trimer, where they 
exist as part of the trimer association domain [1-3]. Because of the potency and 
breadth of trimer specific broadly neutralizing antibodies (bNAbs), understanding 
the features of the envelope trimer structure and functionality can contribute to 
the design and development of a trimer based immunogen that could be used in 
the development of a successful vaccine and novel drugs that target the viral 
entry process [4].  
 Based on sequence homology, the V3 loop length is conserved in most 
primate lentiviral species and insertions or deletions to the length of the V3 loop 
have been shown to reduce envelope stability and functionality in subtype B HIV-
1 viruses. Additionally, a patch of three hydrophobic residues at the tip of the V3 
loop is conserved across primate lentiviruses. While the exact amino acid 
sequence of this motif is capable of some variability, the residues present are 
consistently hydrophobic. This hydrophobic patch motif has also been shown to 
contribute to envelope trimer stability and functionality in subtype B HIV-1 [5]. 
Because of the conservation of this length and hydrophobic patch in other HIV-1 
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subtypes and primate lentiviruses (PLVs), we sought to explore whether this 
function was conserved as well. Our hypothesis is that additions to the V3 loop 
length in subtype C HIV, HIV-2 and Simian Immunodeficiency Virus (SIV) 
species will result in a similar reduction in envelope stability and functionality. 
Additionally, substitution of the hydrophobic patch with hydrophilic and small 
neutral amino acids will also result in the destabilization of the envelope complex, 
regardless of PLV species. 
 Additionally, our lab recently identified and characterized a twin-cysteine 
motif (TCM) in the V2 loop of the SIVmac strain, SIVmac39. This motif is present 
in all SIV and HIV-2 species, except SIVcpz, where it is present in some strains, 
but not in others. This motif is notably absent from all HIV-1 strains. We showed 
that removal of either, or both, of these twin cysteines from SIVmac239 resulted 
in a dramatic decrease in envelope stability, indicated by an increase in gp120 
shedding. This decrease in stability correlated with a decrease in the envelope’s 
ability to initiate cell-cell fusion and viral entry [6]. We hypothesize that this twin 
cysteine motif is forming an important disulfide bond that stabilizes the envelope 
gp120 molecule, contributing to the overall stability of the trimeric complex. To 
further explore the role that these cysteines play, our hypothesis is that the 
removal of this motif from PLV envelopes where it is naturally present will result 
in a similar decrease in envelope stability and functionality, and that the addition 
of this motif to HIV-1 envelopes will further stabilize the envelope complex.   
 Understanding the structure and biological function of the primate lentiviral 
envelope is paramount to the development of innovative treatments and 
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preventative cures. In the development of an HIV vaccine, the envelope trimer is 
a strong candidate as an immunogen because of development of bNAbs. Many 
of these bNAbs target trimer specific epitopes and a trimer based, or trimer 
specific epitope based design will be required to generate these antibodies in a 
host. While the envelope modifications presented here may not singularly lead to 
the direct development of an envelope based HIV immunogen, these 
modifications could contribute to better design and development of a stabilized 
envelope trimer alongside other stabilizing modifications, which could be used as 
an HIV vaccine. The data in this dissertation contributes to the overall 
understanding of the stability and function of the viral envelope trimer and assists 
in validating the envelope trimer structures that have been released. 
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CHAPTER 1- LITERATURE REVIEW 
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Human Immunodeficiency Virus- Introduction 
Human Immunodeficiency Virus Type-1 (HIV-1) is a human retrovirus in 
the Retroviridae family, and is part of the lentivirus genus. This virus is the 
causative agent of Acquired Immunodeficiency syndrome (AIDS) and has been 
the cause of a major global epidemic for the past 37 years. HIV-1 primarily 
infects CD4+ T-lymphocytes and causes a slow, long-term infection, eventually 
depletes the CD4+ T cell population from its host, causing severe 
immunodeficiency in advanced cases. This immunodeficiency puts the host at 
major risk for co-infection by opportunistic infections and cancers. Despite 
extensive research and many clinical trials, there is currently no cure for the 
disease, or a sterilizing preventative vaccine for this virus, though significant 
advancements have been made in antiretroviral and prophylactic drugs. The 
World Health Organization estimates that as of 2016, there were 36.7 million 
individuals living with HIV worldwide, and that there were 1.8 million new 
infections. In the same year, it was estimated that there were 1.0 million HIV 
related deaths [7]. Fortunately, the number of new infections each year and the 
number of deaths per year continue to decline, however, HIV continues to be a 
major health crisis, and effective treatment and prevention strategies are 
necessary to effectively halt the spread of this virus. While the treatment of the 
HIV epidemic has been improving globally, HIV continues to be a major global 
pathogen, with a majority of infections occurring on the African continent, 
specifically in Eastern and Southern Africa [8]. 
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HIV was first discovered in 1983 as a retrovirus that was causing the AIDS 
epidemic occurring in gay men, intravenous drug users and hemophiliacs in the 
United States [9, 10]. Although HIV was first discovered in the US in the early 
1980s, phylogographic studies examining viral sequence divergence and human 
populations have demonstrated the origin of the HIV epidemic occurred in the 
early part of the 20th century in central Africa. It is likely that since the original 
zoonotic transmission of a Simian Immunodeficiency virus (SIV) that infects 
chimpanzees (SIVcpz) in the early 1900s that HIV-1 spread through Africa 
undetected for the next fifty years until it was finally detected in the United States 
and Europe in the 1980s where it spread rapidly [11]. 
 
Virion Structure 
HIV virions are typically between 120 and 150 nm in diameter, enveloped 
by a viral membrane derived from the host cell and have a cone-shaped core 
containing two copies of the viral RNA genome which is in complex with the 
nucleocapsid protein, p7 [12, 13]. The structural protein matrix (MA), p17 of Gag, 
is present immediately beneath the cellular membrane and binds to the cellular 
membrane forming the spherical outer shell of the core [14, 15]. The cone-
shaped core is made up of the Gag gene product CA (p24) and encapsulates the 
viral RNA genome, and is characteristic of lentiviruses [13]. Within the virion, 
copies of the viral enzymes protease, integrase, reverse transcriptase and select 
accessory proteins are present and are transported to the host cell upon infection 
[16]. Envelope protein trimers are embedded in the membrane of the virion, with 
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10-15 envelope complexes per virion [17, 18] (Figure 1.1) The HIV-1 genome is 
approximately 9.7 kb single stranded RNA and contains nine open reading 
frames of three primary structural genes and enzymes, yielding a total of nine 
essential proteins for viral structure and replication (Gag proteins- Matrix, Capsid, 
p6, Nucleocapsid; Pol enzymes- Reverse Transcriptase, Integrase, Protease; 
and Envelope subunits- gp120, gp41), two essential regulatory elements (Rev, 
Tat) and four accessory proteins that enhance viral pathogenesis (Vif, Vpr, Vpu, 
Nef) [19, 20]. Flanking both the 5’ and 3’ ends of the viral genome is a sequence 
known as the long terminal repeat (LTR). This sequence contains the promoter 
region for transcription and is the binding site for cellular transcription factors and 
regulatory elements, as well as the poly-adenylation sequence (which is only 
functional on the 3’ end of the genome) [20, 21]. The terminal ends of the 
genome are also important for the process of reverse transcription, as the 5’ and 
3’ ends both contain repeated sequences, which allow for the first jump in the 
process of reverse transcription to occur, which results in the formation of the 
sequentially identical LTR in the integrated provirus [22]. Additionally, the LTRs 
are the targets of integration into the host genome [23, 24]. A schematic of the 
viral genome structure is shown in Figure 1.2 [19]. 
 
HIV Replication Cycle 
The HIV life cycle begins with binding of the envelope protein on the 
surface of the virus to the primary receptor, CD4, at the outer membrane of a 
host cell. Prior to specific interaction between Env and CD4, non-specific 
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interactions with other cellular proteins including DC-SIGN, α4β7 integrins and 
heparans have been observed, but are not required for viral entry [25-27]. 
Following CD4 binding, a conformational change occurs within the envelope 
trimer on the virus, exposing the binding site for the coreceptor [28]. This allows 
envelope to engage with the coreceptor for the virus, either CCR5 or CXCR4. 
Next, fusion of the viral and cellular membranes occurs, which allows the release 
of the viral capsid into the cytoplasm of the cell. This is a pH independent 
process, and is thought to occur at the cellular membrane, but there have been 
reports that fusion may occur in endosomes [29-31]. Following fusion, the viral 
capsid is released into the cytoplasm, and partial uncoating occurs. At this point, 
reverse transcription begins to occur within the partial capsid. Reverse 
transcription is carried out by the viral reverse transcriptase enzyme present in 
the virion, and ultimately generates a double stranded DNA molecule from the 
viral RNA [32-34]. After reverse transcription, viral proteins, including Gag 
components, Vpr and cellular proteins come together to transport the double 
stranded viral DNA genome to the nucleus, this conglomeration is referred to as 
the pre-integration complex (PIC) [20, 35, 36]. Once in the nucleus, the viral DNA 
is integrated into the host genome via the activity of the viral integrase enzyme 
[37, 38]. Following integration, the viral genome serves as a template for 
transcription by host transcription machinery, producing full length viral RNA 
strands. Some of these strands are partially or completely spliced to produce 
viral proteins through translation [20]. Viral RNAs are exported from the nucleus 
by the activity of the Rev protein, which interacts with the rev response element 
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(RRE) located within an intron located the env gene sequence [20, 39, 40]. 
Translation of viral proteins occurs primarily in the cytoplasm, with Gag and Gag-
Pol precursors being transported to the cellular membrane for post translational 
virus assembly [16, 41]. Simultaneously, the envelope protein is translated on the 
rough endoplasmic reticulum, and is glycosylated, cleaved by furin proteases and 
transported through the Golgi apparatus. Envelope trimers then interact with the 
MA protein at the cell surface and are incorporated by an unknown mechanism 
[15, 42]. Viral RNA dimers interact with the Gag precursor and are packaged into 
budding virions [43, 44]. Viral budding occurs from the cellular membrane and 
requires activity of the cellular endosomal sorting complexes required for 
transport (ESCRT) machinery, releasing immature viral particles from the cell 
[45]. Following viral particle release, maturation of the viral core occurs via the 
action of the HIV protease (PR) enzyme which is packaged into virions. PR 
proteolytically cleaves the Gag precursor into MA, CA, NC and p6 which results 
in the formation of the characteristic cone shaped core, and renders the viral 
particle infectious [16, 46, 47]. 
 
HIV Gene Products 
Gag 
The gag gene produces a precursor protein, pr55. This polyprotein is 
cleaved by the protease enzyme into the MA (p17), CA (p24), NC (p7) and p6 
during viral maturation following budding from the host cell. Prior to maturation, 
the gag polyprotein makes contact with the cellular membrane via a 
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myristoylated glycine residue at the N-terminus of the Gag precursor [48]. This 
cleavage and maturation is absolutely required for viral infectivity [47, 49].  
Interestingly, expression of the gag gene individually is sufficient to form viral 
particles [14, 50]. MA is the matrix protein and is located at the N terminus of the 
Pr55 precursor, it forms the outer shell of the virus and remains bound to cellular 
membrane. MA has also been shown to play a role in Env recruitment and 
interacts with envelope via the cytoplasmic tail of gp41 [15]. Directly to the C-
terminal end of the MA domain is the capsid protein, CA (p24). Following 
cleavage, the capsid oligomerizes into primarily hexamers, and forms the inner 
cone-shaped core, a crystal structure of this the HIV cone-shaped capsid has 
been published which reveals the arrangement of this protein [46]. C-terminal to 
the CA protein is the nucleocapsid protein, NC (p7) which has a two zinc finger 
domains and is bound to the viral RNA [12]. NC plays a critical role in recruiting 
viral RNA to assembling virions by binding to the packaging signal (Psi), a series 
of four stem loops located in the 5’ untranslated region (UTR), which is located 5’ 
to the gag gene sequence [51-53]. The final gene product of the gag gene is p6, 
a protein domain found primarily in primate lentiviruses. This small protein 
appears to play an important role in viral budding and in the packaging of the 
accessory protein, Vpr into viral particles [41, 54-56]. 
Pol 
The pol gene is synthesized along with the gag gene from a single RNA 
molecule that is the result of a ribosomal frameshift in the gag gene that occurs in 
only at a rate of about 5%. Because of this, a ratio of 20:1, Gag to Gag-Pol 
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proteins are maintained and are important for viral genome dimerization and 
function [57]. This produces a single Gag-Pol polyprotein from which some Gag 
products and the viral enzymes, protease (PR), reverse transcriptase (RT) and 
integrase (IN) are produced [16, 58]. The enzymes produced by pol are essential 
for infection and are packaged into virions [16, 47]. The viral protease enzyme is 
responsible for the cleavage of the Gag and Pol polyprotein precursors. This 
enzyme is a functional dimer and is essential for viral maturation and infectivity 
[47]. Because the action of PR is vital for viral function, it is a desirable target for 
anti-HIV drug development and several protease inhibitors are used with great 
effectiveness [59]. Despite this, because of the high mutation rate in HIV, 
resistance to protease inhibitors occurs [60].  
RT is a multifunctional enzyme with RNA dependent DNA polymerase and 
DNA dependent DNA polymerase activities, which combined synthesize a double 
stranded DNA molecule from the viral RNA genome to be incorporated into the 
host genome [32, 34]. RT also has RNAseH activity, which is utilized to digest 
the viral RNA template in RNA-DNA intermediate molecules that are generated 
during reverse transcription [33, 61]. All these activities are critical for viral 
genome reverse transcription [34, 62]. This enzyme is a heterodimer of two 
proteins, p66 and p51 for which the crystal structure has been solved [63, 64]. 
Importantly, the RT lacks proofreading capabilities, so errors are made during the 
process of reverse transcription at a high rate, leading to the vast genetic 
diversity of HIV [65].  Again, because RT is essential for viral function, it is the 
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target of several FDA-approved antiretroviral drugs and is the source of 
continued drug development [66, 67].  
Integrase (IN) incorporates the double stranded viral DNA product 
following reverse transcription. This occurs in two-steps: 3’ end processing, in 
which two nucleotides are removed from the 3’ end of both sides of the viral 
DNA, followed by DNA strand transfer, in which two strand breaks are made in 
the host genome, followed by attachment of the viral DNA to the host 
chromosome [37, 38, 68]. This activity is likely followed by host DNA repair 
mechanisms to remove the two base flap that is left by the action of IN, ultimately 
sealing the viral genome into the host genome permanently [69].  
Env 
The env gene produces the major glycoprotein complex that is present on 
the surface of the virion. This gene is initially translated into a 160 kD precursor 
protein, which is cleaved by furin proteases in the Golgi apparatus, into two viral 
protein products- gp41, the transmembrane protein (TM), and gp120 the surface 
glycoprotein (SU) [42, 70]. These two proteins are assembled into the envelope 
glycoprotein trimeric complex which is a trimer of heterodimers, in which three 
gp41 molecules are non-covalently attached to three gp120 molecules. About 
half of the mass of this protein is made up of N-linked glycans, which are 
important for immune evasion [71, 72]. Envelope trimers are then incorporated 
into budding virions via an unclear mechanism, though it has been shown that 
the activity of cytoplasmic tail of the gp41 subunit of envelope and the MA protein 
are both necessary for proper incorporation into virions [15]. The envelope trimer 
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is the primary immunogen on the virus, and is the primary target for antibody 
development [73, 74]. The primary function of the envelope protein is to bind to 
the cell surface receptors and facilitate fusion and entry into the cells. The 
specific binding of the envelope protein to cellular receptors determines cellular 
tropism [75]. The structure and biological function of the envelope protein will be 
further discussed at length later in chapter 1, on pages 20-26. 
Tat 
The tat gene encodes for the trans-activator of transcription, or Tat 
protein. This protein is 14kDa and is an essential regulatory element in the viral 
genome, and deletion of this protein results in replication-deficiency [76, 77]. The 
primary function of the Tat protein is to bind the Trans-Activation Response 
Region (TAR) at the 5’ end of viral RNAs and increase the rate of transcription by 
interacting with cellular factors that increase the phosphorylation of the RNA pol 
II [20]. Viral transcription initially occurs without the action of Tat, ultimately 
resulting in the initial transcription and translation of Tat protein, which drastically 
increases the amount of transcription of viral gene products [20]. Interestingly, 
Tat protein is also secreted and contributes to HIV pathogenesis by encouraging 
the growth of Kaposi’s sarcoma lesions and by initiating apoptosis in T-
lymphocytes [78-80]. 
Rev 
The second regulatory protein encoded by HIV is Rev, a 19 kDa protein 
responsible for nuclear export of viral RNAs. Rev stands for Regulator of 
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Expression of Viral Proteins, and this protein is essential to the viral life cycle [39, 
40]. The Rev protein interacts primarily with a three-dimensional stem loop 
structure in RNA transcripts within the env gene sequence called the Rev 
Response Element (RRE) [20, 39]. Rev binds to the RRE and aids in the export 
of viral RNAs to the cytoplasm, where efficient translation of viral proteins can 
occur [81, 82]. 
Vif 
The vif gene codes for a 23 kDa protein called Vif, or Viral Infectivity 
Factor. The primary role of Vif is to counteract the action of cellular APOBECs, a 
family of cytidine deaminases, which cause hyper mutations of C to U in the HIV 
viral genome. The APOBECs serve as potent restriction factors of HIV infection, 
but their action is reduced by the presence of Vif [83, 84]. Initially, the role of Vif 
in the viral life cycle was somewhat unclear, but it was known that Vif was 
essential in making some cells susceptible to HIV infection, and that the 
presence of Vif was important for the generation of infectious particles. It was 
later discovered that Vif was likely counteracting the action of a cellular factor, 
which prevented HIV infection, later revealed to be APOBEC [85-87]. Vif 
counters the action of APOBEC by targeting it for degradation, which prevents 
APOBEC from being packaged into budding virions, where it can initiate C to U 
mutations.  Vif also appears to play a role in viral morphology and RNA 
packaging and viral assembly [88, 89]. 
Vpr 
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The vpr gene codes for a 14kDa protein called Viral Protein R, or Vpr [90-
92]. Vpr is a protein with multifaceted functions during the viral life cycle. Vpr is 
packaged into budding virions via interaction with the p6 domain of the Gag 
polyprotein precursor [93]. One of the functions of Vpr is to play an important role 
in the transport of the pre-integration complex. Vpr has been shown to localize at 
the nucleus and is important for import of the PIC into the nucleus [94-96]. Vpr 
has also been shown to be involved in trans-activation of the LTR and to interact 
with various other transcription factors [92, 97, 98]. Additionally, Vpr has been 
implicated in the G2 cell cycle arrest which is important for early events in viral 
infection. This has been shown to be mediated via an interaction between Vpr 
and cell cycle proteins [99-101]. 
Vpu 
Viral Protein U (Vpu) is encoded by the HIV accessory gene, vpu, and is a 
16 kDa viral protein that resides in the cellular membrane [102]. Vpu is 
associated with two primary functions. The first is the degradation of cellular CD4 
in infected cells by targeting CD4 to the E3 ubiquitin ligase complex [103-105]. 
Degradation of CD4 is thought to reduce interactions between CD4 and envelope 
proteins, which can inactivate the envelope protein and prevent its incorporation 
into forming virions [106]. The second function that is associated with Vpu is to 
counter the action of the viral restriction factor Tetherin (which is also known as 
BST-2), resulting in more efficient budding and release of new virions [107, 108]. 
Tetherin is a protein that inhibits viral infection by preventing the complete 
release of virions by tethering budding virions to the cell surface [107]. Like its 
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action on CD4, Vpu encourages the degradation of Tetherin by targeting it for 
ubiquitination and subsequent degradation in the proteasome, though there is 
evidence that this degradation also can occur in lysosomal compartments [108-
110].  
Nef 
The nef gene overlaps by about 50% with the 3’ LTR and encodes the 
Negative Factor protein (Nef), which is about 37kDa and is incorporated into HIV 
virions [20]. Nef appears to play an important role in viral pathogenesis, as Nef 
mutations have been associated with reduced pathogenesis in humans. 
Additionally, nef deleted SIVs are unable to maintain infection in the macaque 
experimental model, indicating an important role in viral pathogenesis [111]. Nef 
also plays a role in the down regulation of CD4 by functioning as a bridge 
molecule between CD4 and the clathrin adaptor protein, AP-2. This ultimately 
results in the lysosomal degradation of CD4 [112, 113]. In addition to CD4 
downregulation, Nef alters the display of other cell surface molecules including 
MHC-I, DC-SIGN, CD28 and CTLA-4 to help the virus evade immune recognition 
and disrupt normal immune function [114-117]. Nef has been shown to interact 
with several cellular protein kinases, and may play a role in cell signaling, though 
the effect of these interactions is not well characterized [118-120]. Nef is clearly 
an important protein for viral pathogenesis, but it is still unclear exactly which of 
these activities are so critical for viral infection in vivo. 
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The Evolution of HIV 
HIV-1 
HIV-1 originally entered the human population via a zoonotic event, 
wherein a related Simian Immunodeficiency Virus that infected chimpanzees 
(SIVcpz) crossed the species barrier to infect humans [121, 122]. There are over 
40 species of non-human primates that are infected by SIVs, and the disease 
range in natural hosts varies greatly [123]. For example, African green monkeys 
infected with their natural SIV counterpart, SIVagm, do not develop any notable 
disease despite having very high viral titres and having an estimated prevalence 
rate of over 50%, with females more commonly infected than males [124]. In 
contrast, chimpanzees, when infected with SIVcpz, often develop Simian AIDS, 
which has been observed both in captivity and in the wild [125-127]. Importantly, 
when SIV infects non-natural hosts, immunodeficiency is much more common 
[128-131]. SIVsmm, the species of SIV that infects sooty mangabeys, does not 
cause notable disease in its host, despite a high viral load and prevalence of over 
50% [132, 133]. SIVsmm crossed into a macaque population due to co-habitation 
in a primate facility performing experiments on Kuru [134], resulting in SIVmac, 
an SIV species that causes simian AIDS in macaques which often serves as an 
experimental animal model for HIV-1 infection [135, 136]. Cross-species 
transmission and co-infection can also result in recombination of these viruses, 
resulting in new strains with altered pathogenicity. SIVcpz itself likely derived 
from a recombination of SIVrcm (the SIV that infects red capped mangabeys) 
and SIVgsn (the SIV that infects greater spot nosed monkeys) [137]. 
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HIV-1 has entered the human population on at least four separate 
occasions giving rise to the four main HIV-1 groups M, N, O and P [11]. Group M 
is the major group and accounts for more than 90% of worldwide HIV-1 infections 
[138]. Group O, the outlier group, is responsible for tens of thousands of 
infections, but has not spread as notably as group M HIV-1. Group O infections 
are primarily restricted to central African countries, specifically Cameroon [139-
142]. Groups N and P infections are far fewer and are restricted to a few 
individual infections [143-146]. Group N HIV-1, like Group M is derived from a 
strain of SIVcpz [146-148] but Group O and P HIV-1 are very closely related to 
an SIV found in gorillas, SIVgor [149-151]. It is important to note that SIVgor is 
very closely related to a specific species of SIVcpz, there is a postulation that 
rather than direct transmission of SIVgor to humans, groups O and P HIV are 
actually SIVcpz derived, and this SIVcpz was transmitted to both gorillas and 
humans [152]. Because group N and group P HIV-1 are found in so few 
individuals, these viruses are geographically restricted to Cameroon and the 
surrounding countries [146, 151]. Studying SIVs is important because of the 
number of different SIV species, and their potential to continue to be transferred 
into the human population. Also, understanding the interactions between SIV 
species and the host immune system could help to develop more effective HIV 
therapies and prevention strategies.  
Phylogeographical and molecular clock studies have projected that Group 
M HIV-1 crossed the species barrier during the early part of the 20th century in 
Central Africa [153]. This virus then diversified rapidly, dividing into 9 subtypes 
	 19 
(A-H) that are characterized by a difference in genome sequence of 30% [154]. 
Of the subtypes (or clades), subtype C is the most prominent, accounting for 
almost 50% of HIV-1 infections globally. This subtype is the predominant strain in 
sub-Saharan Africa and southeast Asia, while subtype B predominates in 
Western countries [155]. Because subtype B is more prevalent in the United 
States and Western Europe, it is the subtype that has been used for most 
foundational studies on HIV-1, though more and more studies are considering a 
diverse array of subtypes. There is evidence that there are differences in the 
transmission and pathogenesis of different subtypes, specifically subtype C [156-
162]. Because subtype C is responsible for most global infections, it is important 
that this subtype be included in drug development and in work to develop a 
broadly neutralizing vaccine.  
The diversity of HIV-1 is further complicated by the ability of HIV to 
undergo recombination within a host. Circulating recombinant forms (CRFs) 
result when an individual is dually or coinfected with multiple HIV-1 subtypes at 
once, giving rise to an unlinked recombinant form (URF) of HIV-1. When this 
URF is found in more than three individuals, it is reclassified as a CRF [154]. The 
diversity of CRFs is vast and expanding, and CRFs currently account for about 
20% of HIV-1 infections worldwide [155]. 
HIV-2 
 HIV-2 also entered the human population via zoonotic events, where SIV 
that infects sooty mangabeys (SIVsm) crossed into the human population [163]. 
This cross-species transmission has occurred at least 8 times, accounting for the 
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8 subtypes of HIV-2 (A-H), with evidence of a ninth group indicating that SIVsm 
continues to cross the species barrier [164, 165]. Molecular clock evidence 
suggests that the primary circulating types of HIV-2 entered the human 
population in the middle part of the 20th century, around 1940 [166]. At this point, 
HIV-2 is primarily restricted to West African countries, and subtypes A and B are 
the most prominent, as subtypes C-H have not spread beyond isolated infections 
[167, 168]. Subtypes C-H appear to be restricted to single infections, though 
there is evidence that subtype F has been found in two patients [169]. HIV-2 
does not cause as severe of disease in humans and individuals who are HIV-2 
positive often remain long-term non-progressors [170]. HIV-2 infection is also 
characterized by a higher level of neutralizing antibodies, lower proviral load and 
immune control [165, 171-175]. This is echoed in natural SIVsmm infections of 
sooty mangabeys, as infected animals carry a high viral load but don’t have 
symptoms of immunodeficiency [132]. It has been shown that SIVsmm can cause 
AIDS like symptoms, but these reports usually consider virus that has been 
isolated in macaques prior to infection [176]. One report has shown that SIVsmm 
can cause disease, as researchers discovered an animal in captivity that 
developed symptoms of immunodeficiency after 18 years of SIVsmm infection. 
This provided evidence that the progression to an AIDS like state takes longer 
than the natural life span of the animal [177]. 
 
HIV Envelope Protein Biology and Function 
	 21 
 The envelope protein of primate lentiviruses, including both HIV species 
and SIVs is of great interest in the HIV field because it is the only viral protein on 
the virus that is exposed to the immune system, and is highly immunogenic, as a 
result, the envelope trimer is an attractive prospect for a protein based HIV 
vaccine. Additionally, the process of viral entry, which is facilitated by the 
envelope protein, is an attractive target for anti-HIV drugs because its action 
does not require infection of the cell before it becomes effective [178]. Envelope 
is an HIV protein that is uniquely capable of handling a high level of mutation, 
and shows an incredible level of diversity, attributed to the error-prone RT 
enzyme [22, 65]. This characteristic contributes to pathogenesis by allowing the 
virus to evade immune recognition [179]. As such, the entry of HIV is targeted by 
several anti-retroviral drugs that are included in highly active antiretroviral 
therapy (HAART), including Enfuvirtide, which binds to gp41 complexes and acts 
as a membrane fusion inhibitor, and Maraviroc, a drug that binds to CCR5 on the 
host cell and prevents gp120 contact with the coreceptor [180, 181]. Recently, 
the native envelope trimeric structure has been solved, which is an important 
step in understanding the envelope trimer’s function and in the development of 
effective novel anti-retroviral drugs and a broadly neutralizing vaccine [2, 3].  
HIV Entry 
 The primary function of the envelope protein of HIV is to bind to receptors 
on the surface of the cell and to facilitate entry via viral and cellular membrane 
fusion, and this process occurs in several well-characterized steps [31, 182]. 
Prior to specific interaction between the envelope protein and cellular receptors, 
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the virus often contacts a susceptible cell through non-specific interactions with 
cell surface molecules, though this step is not required for viral entry. Molecules 
that have been shown to interact with the HIV envelope protein and play a role in 
this initial attachment include heparan sulfate, dendritic cell-specific intercellular 
adhesion molecular 3-grabbing non-integrin (DC-SIGN) or α4β7 integrin [25-27, 
183]. This adsorption process brings the virus and cell into proximity, which 
allows specific interactions between envelope and cellular receptors to occur. 
Next, the envelope trimer binds to the primary receptor, CD4 on the surface of a 
susceptible cell. Following binding, the trimer undergoes a conformational 
change which exposes the coreceptor binding site [184-186]. In this 
conformational change, the monomeric gp120 subunits spread apart from each 
other and the variable loops (V1, V2 and V3) undergo rearrangement [28, 187]. A 
result of this rearrangement is the formation of the bridging sheet, a four β-strand 
domain which connects the inner and outer domains of gp120 which plays a role 
in maintaining the correct conformation for coreceptor binding [28]. Part of this 
conformational change is the exposure of the V3 loop, which forms the 
coreceptor binding site along with the bridging sheet [28, 188-190]. The newly 
formed coreceptor binding site contacts either CCR5 or CXCR4. Coreceptor 
usage is determined largely based on the sequence of the V3 loop, and viruses 
that utilize either CCR5 or CXCR4 are termed R5-tropic or X4-tropic, 
respectively, while viruses that can use both CCR5 and CXCR4 are termed 
R5X4 or dual-tropic [191]. Following binding to the coreceptor, the gp41 
molecules transition to an extended form, which insert into the cellular membrane 
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and tether the viral and cell membranes to one another [192-194]. Next, the 
heptad repeat regions of gp41 (HR1 and HR2) fold onto themselves, forming the 
6-helix bundle (6HB), which brings the two membranes into close contact with 
one another, resulting in fusion of the two membranes [192-194]. Following 
membrane fusion, the viral capsid and genetic material are released into the host 
cell where reverse transcription, replication, integration and viral assembly can 
occur. A schematic of the viral entry process is shown in Figure 1.3. The location 
of entry for HIV remains somewhat unclear. Initially, studies suggested that entry 
occurs at the cell membrane, however, additional research has shown that entry 
can occur in the endosomal compartment, but that acidification is not required for 
this process [29, 30].  
Cell Tropism 
The cellular tropism for HIV is primarily determined by the binding and 
fusion activity of the envelope protein, and the expression of viral receptors on 
the target cell membrane. HIV specifically infects cells that express CD4 and a 
suitable coreceptor, CCR5 or CXCR4. A small minority of viruses have been 
shown to interact with alternate coreceptors, though their relevance to HIV 
cellular tropism remains unclear [195]. Sexual transmission of HIV relies on the 
use of the coreceptor CCR5 as this initial transmission usually requires infection 
of tissue resident macrophages, but later in infection, some viruses develop the 
use of CXCR4 through viral evolution [196, 197]. Cells that express the receptors 
required for HIV infection are the primary targets of the virus. This includes 
macrophages, and most notably, CD4+ T-lymphocytes. Additionally, subsets of 
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dendritic cells express CD4 as well as CCR5 and CXCR4, have been shown to 
be susceptible, albeit at a low level, to HIV infection [198, 199]. Macrophages 
and dendritic cells, including Langerhans cells in the mucosa are early targets of 
viral infection in sexual transmission, and contribute to the spread of HIV within 
the host as infected cells travel to the lymph nodes where productive infection of 
macrophages and CD4+ T cells can occur [200-205]. Transmission of HIV-1 
appears to be restricted primarily to R5 and R5X4 tropic viruses, with X4 viruses 
appearing within a patient late during infection [197, 206]. A shift to the use of X4 
as a coreceptor also is usually accompanied by an increase in disease 
progression [207]. Macrophages often serve as reservoirs for HIV infection, and 
contribute to the spread of the virus even years into infection [208]. Following 
productive infection, CD4+ T cells are killed, and eventually the population of this 
subset of cells is depleted from the host, resulting in severe immunodeficiency 
and increased susceptibility to opportunistic infections [196]. 
Envelope Trimer Structure 
Historically, a major effort in the field has been to generate an atomic level 
structural image of the native HIV envelope trimer. Solving the structure of the 
envelope trimer has been an attractive prospect because the information can be 
useful for the development of drugs and vaccines in addition to a more thorough 
understanding the viral entry process. In 2009, the HIV trimer was listed as one 
of Nature magazine’s most important structures yet to be solved, since then, 
significant progress has been [209]. One of the first structures of the envelope 
protein solved was the ectodomain of gp41, which revealed a triple-coil structure 
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with similarities to the pH induced conformation HA2 of the influenza virus. Two 
research groups generated similar structural models in the same year, and both 
came to very similar conclusions about the role gp41 plays [192, 193]. In 1998, a 
crystal structure of the gp120 core (with the variable loops removed) bound to 
CD4 and a CD4 induced conformational antibody, 17b. This structural study 
revealed the inner and outer domains of the gp120 core, as well as the bridging 
sheet [28]. Generating a structure of the envelope protein trimer has been 
complicated, because it is membrane bound, heavily glycosylated, is 
conformationally flexible and is a non-covalently attached trimer, all of which 
have made X-ray crystallography challenging. However, significant 
advancements have been made in this area using cryo-electron microscopy and 
X-ray crystallography techniques. One study has generated a cryo-EM structure 
of an uncleaved envelope trimer that has a mutation preventing gp120/gp41 
cleavage and a truncated cytoplasmic tail [210, 211], though this structure was 
the subject of extreme controversy among those in the field [212-215]. This 
structure of the envelope trimer revealed three primary points of contact between 
subunits at the gp41 transmembrane region, the gp41 ectodomain, and 
importantly, the gp120 trimer association domain, which consisted primarily of 
the V1, V2 and V3 domains, at the apex of the trimer. Additionally, this envelope 
structure revealed the presence of a large space at the center of the trimer, 
which was consistent with previous lower resolution structures (Figure 1.4) [210]. 
A cryo-EM and crystal structure of a cleaved trimer, from the subtype A virus 
BG505, that has been solubilized was described in the same year [1-3]. This 
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envelope trimer contains a disulfide bridge between the gp120 and gp41 
subunits, and includes an isoleucine to proline mutation in gp41 to aid in trimer 
stabilization [216, 217]. Trimers with these two modifications are referred to as 
SOSIP trimers, and have been the subject of extensive study into immunogen 
design in recent years and have shown some promise [218-220]. This trimer 
structure differed substantially from the uncleaved envelope trimer previously 
described, primarily in the positioning of the gp120 core and gp41 helices. 
Notably, these trimeric structures did not include the open-space at the center of 
the complex (Figure 1.5). Many subsequent structural studies have been 
performed with the SOSIP trimer and have included envelopes from viruses of 
other clades, as well as additional modifications. These studies have further 
characterized the presence and conformation of the glycan shield and bNAb 
binding sites [1, 221, 222]. Additionally, in 2016, a cryo-EM structure of a fully 
glycosylated, uncleaved native trimer based on the JRFL envelope in contact 
with the bNAb PGT151 was released. This structure revealed striking similarity to 
the SOSIP structure, and included the membrane proximal external region 
(MPER), which was notably absent from the SOSIP structures released earlier 
[223].  
Despite specific differences in the structures of the envelope trimer, an 
important consistency in all the structures is that the variable loops are packed 
into the apex of the trimer in a specific conformation, and contribute to trimer 
association, which is consistent with molecular stability studies (Figure 1.5, 1.6) 
[5, 6, 224]. In earlier structural studies, the variable loops were considered 
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dispensable components of the trimer, and were flexible, so they were often 
removed from the envelope, but the current structures demonstrate that they are 
indeed fixed in the apex prior to CD4 binding and fusion, and may play a role in 
the trimerization of the envelope protein, though the exact conformation of the 
loops is slightly different in each structure.  
Envelope Processing 
The env gene product is produced as a single gp160 precursor protein. 
This precursor protein is covered with N-linked glycans, which account for almost 
half of the molecular weight of the envelope trimer and cover the surface of the 
glycoprotein [71, 223]. This glycan shield is important for viral immune evasion, 
but several well characterized bNAbs rely on the presence of specific N-linked 
glycans, namely, those antibodies in the PGT family which include the glycan at 
N332 proximal to the V3 loop in their binding site [225]. The gp160 molecules are 
then processed and trafficked to the cell surface through the Golgi apparatus, 
where they are cleaved by furin proteases into gp120 and gp41 at a K/R-X-K/R-R 
motif by furin proteases [42, 70]. Trimerization then occurs and three gp120 
molecules are joined and are non-covalently attached to three gp41 molecules. 
These trimers are then transported to the plasma membrane where they are 
incorporated into virions. Though the exact mechanism of envelope incorporation 
into virions is still somewhat unclear, it has been shown that this process relies 
on both the activity of the cytoplasmic tail of gp41 and the matrix protein [15, 42]. 
Envelope Stoichiometry 
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The envelope stoichiometry for entry into a cell is an area that is of 
interest. An HIV virion contains between 5 and 15 envelope trimers, but the 
number of trimers required to bind and enter the cell is yet to be determined in 
the literature as different assays have yielded differing results [17, 226, 227]. This 
work requires mathematical modeling to identify the stoichiometry required for 
viral entry, as visualization techniques are either unable to distinguish between 
individual trimers in real time, or require samples to be fixed to slides or frozen 
[227]. Some models have suggested that as few as a single envelope trimer is 
sufficient for entry, while others suggest as many as 19 trimers are required for 
successful entry [227-231]. Electron microscopy tomography has revealed the 
formation of the “entry-claw”, a group of five to seven complexes at the interface 
between virus and cell. It is unclear whether all the complexes in the claw are 
required for entry, or even represent functional trimers, but this work has 
revealed the interactions between virus and cell in higher resolution than ever 
before [232]. The stoichiometry of individual viral strains can differ, which drives 
the efficiency of entry for these viruses and may be related to the energy required 
to initiate membrane fusion. Identifying the number of trimers required for entry 
by HIV, and specifically by a given viral strain helps to enhance the knowledge of 
the viral entry process, and in turn contributes to the design of more effective 
envelope and entry inhibitors. This information will also help to elucidate the 
required stoichiometry of neutralizing antibodies. Additionally, an understanding 
of envelope stoichiometry can help elucidate to elucidate the amount of protein 
	 29 
required for the entry process within individual species, which could reveal the 
role of entry in the initial infection and spread of HIV.  
 
Primate Lentiviral Envelope Variable Loops 
The HIV envelope protein is divided into five conserved regions and five 
variable regions (Figure 1.6). As their name implies, the conserved regions are 
well conserved in length and sequence, and are named C1-C5. The variable 
loops, named V1-V5 have more variety in sequence, but several of the loops 
have fixed lengths and conserved motifs [5, 6, 233, 234].The variable loops were 
once thought to have flexible conformations because of their variability, and 
because in early structural studies, they were often found in differing 
conformations, and as such were intentionally truncated or removed in many 
early gp120 structural studies [235]. With the advent of atomic trimer structures, it 
is apparent that these loops, specifically V1/V2 and V3 have fixed, important 
structural roles within the trimeric complex, found in the apex of the trimer where 
they are clearly exposed on the virus, and appear to make inter-protomer 
contacts [1-3, 210, 211]. Importantly, research has shown that although the 
variable loops typically take a fixed structural role, point mutations to the 
envelope protein can cause the V1/V2 and V3 loops to move out of these 
structurally constraining positions, and that the V3 loop is able to move 
independently of the V2 loop, which is surprising, as the V3 loop is positioned 
directly underneath the V2 loop according to the SOSIP structures [236, 237]. 
The variable loops were often somewhat disregarded in terms of form and 
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function early in the study of envelope, due to their variability and perceived 
flexibility [28], but have since become an important focus as they are integral 
functional components of the envelope, and as targets for epitope based 
vaccines as well as entry inhibiting drugs and small molecules.  
V1/V2 Loop 
The V1 and V2 loops are often considered in combination because of the 
double loop structure that forms them. While there have been some 
characterized monoclonal antibodies to the V1 loop, its antigenic potential is 
somewhat limited because its sequence and length is widely variable among 
HIV-1 species. Because of this high level of sequence length and variability 
[238], it has been proposed that the structure of the V1 loop is more flexible than 
its other variable loop counterparts, though high resolution trimeric structures 
suggest that it is packaged into the apex of the envelope trimer with the V2 loop 
[2, 3]. The V1 loop is involved in forming the coreceptor binding site, but does not 
dictate coreceptor usage. The V2 loop is essential for trimer stability and entry by 
HIV-1 [6, 239, 240], though early studies suggested that viruses can overcome 
deletion of the entire V1/V2 loop during long term infections [241]. Other reports 
have shown however that deletion of the V1/V2 loop completely disables 
functionality of the envelope protein, as these mutants are unable to initiate viral 
entry or fusion, and causes Env proteins to be more susceptible to binding by 
CD4 binding site antibodies [239, 240]. There is evidence that V2 loop also 
contributes to the early dissemination and spread of HIV-1 by binding to the α4β7 
integrin receptor, which is involved in the homing of HIV infection to gut tissue 
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and activation of LFA-1. The activation of LFA-1 promotes the formation of the 
virological synapse and cell-cell spread [26], although studies suggest that this 
feature may be limited to only a few HIV-1 species [242]. The V2 loop has a 
much higher antigenic potential than the V1 loop because it is the target of many 
broadly neutralizing, quaternary specific monoclonal antibodies including 2909, 
PG9 and PG16 [243, 244]. Based on high resolution structural analysis, the V2 
loop is packaged into the apex of the envelope trimer, and plays an important 
role in trimerization of gp120 [6]. The length of the V2 loop is relatively well 
conserved between viral species and is typically around 40 residues. There are 
some viruses that have V2 loops longer than 40 residues, but very few that have 
V2 loops less than 40 residues in length. This suggests that structurally, the 
envelope complex can tolerate slightly longer V2 loops, but not shorter [238]. 
Because of the position of the V2 loop in the trimeric apex, its antigenic 
potential and its relationship to well-characterized broadly neutralizing antibodies, 
it is an attractive candidate for the development of vaccines targeting the 
envelope trimer [245]. The V2 epitope approach is supported by analysis of the 
RV144 Thai vaccine trial which showed that V1/V2 antibody responses 
correlated with a lower risk of infection [246]. Further analysis of patient samples 
from the RV144 vaccine trial showed the presence of antibodies to V2 loop 
epitopes early after vaccination at higher levels than naturally infected individuals 
[247]. Additional V2 loop based vaccine studies have characterized SOSIP 
based immunogens based on viruses that have a ‘glycan hole’ in the envelope 
trimer apex, which lack the N-linked glycosylation site at N130 in the V1 loop, as 
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well as in the V2 loop hypervariable region. These immunogens elicited 
neutralizing autologous antibodies by taking a V2 focused approach [219]. 
Another group has used an adenoviral capsid display method to generate a 
vaccine based on the sequence of the V1/V2 loops together as well as the V2 
loop by itself. Follow up analysis of mice that were exposed to the variable loop 
displaying Ad5 vectors showed the presence of a strong anti-V2 antibody 
response, suggesting that V2 antibodies may be successfully elicited by relying 
on the V2 loop sequence individually [248]. Altogether, there is evidence that 
targeting the immune system to V2 specific epitopes may be an effective HIV 
vaccine strategy. 
V3 Loop 
The V3 loop, like the V2 loop, is a β-hairpin loop created by a disulfide 
bond positioned in the apex of the envelope trimer and is an important functional 
component of the envelope protein. This loop is divided into three primary 
regions, the base, the stem and the crown (or tip). The base and crown of the V3 
loop are very well conserved, and most sequence variation occurs in the stem 
[249]. The V3 loop is the major determinant of coreceptor usage, which is largely 
based on the specific amino acid sequence of the hypervariable region of the 
loop. Although there is much research into this topic, and much data concerning 
the use of specific coreceptors, the selection of a coreceptor appears to be a 
multifaceted process dependent on structural elements, specific amino acid 
residues and electrostatic charge [250-252]. Deletion of the V3 loop abolishes 
infection and drastically reduces envelope function, indicating that this region is 
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an essential component of the envelope protein [239, 240, 253]. The V3 loop has 
also been shown to play a role in the stability of the envelope trimer in HIV-1 
subtype B species [5], a fact which is supported by the near atomic structures of 
the HIV-1 envelope trimer [2, 3]. The length of the V3 loop is largely conserved in 
HIV-1 species at 34-35 amino acids, and alterations to this length result in 
massive destabilization of the envelope trimer [5].  
The V3 loop is highly immunogenic, and has been considered an epitope-
based vaccine candidate because of its exposed nature, important structural role 
and the fact that there are important conserved elements in its sequence. The V3 
loop is an immunodominant regions, and is the target of a large proportion of 
antibodies, especially early in infection [238, 254, 255]. Some studies have 
shown that V3 loop antibodies have promise, with the V3 mAbs 2219, 2557 and 
3074 neutralizing around 30% of pseudoviruses they were tested against from 
both tier 1 viruses, which are sensitive to antibody neutralization, and tier 2 
viruses, which are more resistant to antibody neutralization, including 
representatives from clades A, B and C [256]. This indicates that V3 does may 
have the potential to serve as a neutralization target for a plethora of viruses, 
despite its characterization as a region with high variability. Primarily, antibodies 
generated against the V3 loop bind to residues in the crown of the loop, which 
contains a highly conserved GPGQ/R sequence that facilitates the turn of the 
loop. Many of the neutralizing antibodies that target the V3 loop bind to residues 
near this motif, suggesting that the crown is an important structure to consider 
when generating epitope based vaccines [234].  
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Recently, the SOSIP soluble trimers have been used as immunogens and 
have revealed more about the antigenicity and immunodominance of the V3 loop. 
Studies using the SOSIP.664 trimer as an immunogen have recently 
characterized the V3 loop as an antigenic distraction because its presence in 
trimer constructs results in the generation of antibodies that do not neutralize 
either autologous or heterologous tier 1 viruses, but do neutralize tier 2 
heterologous viruses [220]. Some work has been done showing that the V3 loop 
can be stabilized through the addition of a tryptophan residue at amino acid 
position 316 [257], and by adding hydrophobic residues to the already 
hydrophobic crown [258]. These stabilization mutations lock the loop in the pre-
fusion state, preventing its exposure, resulting in lower induction of V3 non-NAbs.  
 
HIV Envelope Protein as a Vaccine Candidate 
Although anti-retroviral drugs have significantly improved the lives of those 
infected with HIV, there were still 1.8 million new HIV infections in 2016, 
indicating clearly that a preventative vaccine for this virus is paramount [8]. 
Despite decades of work, an effective HIV vaccine remains elusive. A successful 
HIV vaccine will likely result in the development of bNAbs capable of neutralizing 
viruses of multiple subtypes. To date, six vaccine candidates have entered 
human trials, taking a wide array of approaches, none of which have been 
efficacious enough to move forward for clinical use. The first two of these trials 
were VAX003 and VAX004, which utilized the AIDSVAX B/E and B/B designs, 
respectively. AIDSVAX B/E was a combination of recombinant gp120 from a 
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subtype B strains (MN) and a subtype CRF01_AE (A244); AIDSVAX B/B was 
composed of recombinant gp120 from two subtype B strains (MN and GNE8). 
Overall, these were unsuccessful attempts, and were considered non-efficacious 
[259-261]. The STEP and Phambili vaccine trials relied on the use of a 
combination of replication deficient Adenovirus vectors expressing HIV gag, HIV 
nef or HIV pol. These trials were preliminary ended because there was evidence 
of increased HIV infection in some participants [262, 263]. The most successful 
HIV vaccine trial to date has been the RV144 trial conducted in Thailand. This 
vaccine trial utilized a canarypox vector expressing HIV Gag and Pro proteins as 
well as HIV envelope protein. This was followed by two boosts with the AIDSVAX 
B/E immunogen. This trial did show efficacy at 31%, and the presence of 
antibodies specific to the V1/V2 loop of HIV gp120 was inversely correlated with 
HIV infection [246, 247, 264]. The results from the RV144 trial elicited new 
interest in the V2 loop as a potential immunogen, and supported a significant role 
for the variable loops in the development on neutralizing antibodies [245, 265]. 
The most recent HIV vaccine trial was a DNA vaccine, HVTN 505. This trial 
included a DNA prime consisting of six plasmids coding for viral genes. Clade B 
Gag, Pol and Nef genes were included as well as env gene plasmids from clade 
A, B and C. This was followed up with a boost with Ad5 vectors expressing the 
Gag-Pol precursor from subtype B viruses and env from clades A, B and C. 
Again, although the vaccine initiated a specific immune response, including HIV 
specific T-cell responses and production of reactive IgG, this was not efficacious 
and the trial was ended prematurely [266]. In all, the trials that have entered 
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human trials have been largely disappointing, indicating the need for new and 
innovative immunogen design and immunization strategies. 
In addition to these studies that have gone to clinical trials, countless 
immunogen studies using the envelope protein as the central immunogen have 
been performed with varying degrees of success. A current focus of vaccine and 
immunogen design is the use of trimeric envelope proteins [220, 267-272]. gp120 
trimers are of specific interest as an immunogen because they have been shown 
to be more immunogenic than monomeric gp120, and because of the discovery 
and development of broadly neutralizing antibodies that specifically target trimer 
specific (quaternary) epitopes [271, 273-278]. Varying conformations of the 
SOSIP trimer have shown promise, but have not resulted in the production of 
antibodies that neutralize tier 2 viruses beyond the homologous strain used to 
create the immunogen [220]. In natural infection and immunization with intact 
envelope trimers, many antibodies are generated against the V3 loop because it 
is very immunogenic and can move somewhat independently to the outside of 
the trimer [237, 255]. However, these antibodies are not broadly neutralizing and 
are not a measure of a successful immunogen, so effort has been taken recently 
to stabilize the V3 loop to reduce the number of non-neutralizing V3 antibodies. 
These efforts have indeed been successful in stabilizing the V3 loop, though they 
have yet to yield an immunogen with the capability to initiate broadly neutralizing 
antibodies [257, 258, 270]. The HIV envelope trimer is clearly a solid candidate 
for the development of an effective HIV vaccine because of its surface exposure 
on the virus and its natural immunogenicity, but further antibody and structural 
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studies of this trimer are required for the development of an immunizations 
strategy that will successfully neutralize HIV of multiple origins. 
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FIGURE 1.1 
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FIGURE 1.1. Schematic of an HIV virus. In an HIV virion, the outer membrane 
is host derived and typically 5-15 HIV envelope trimers are embedded. Directly 
interior to the membrane is the MA protein derived from the Gag precursor 
protein, which forms an outer shell for the virus. The characteristic cone-shaped 
viral capsid of lentiviruses is located within the virion and contains two viral RNA 
genomes in contact with the NC protein. Additionally, copies of the viral enzymes 
reverse transcriptase (RT), integrase (IN), and protease are packaged into 
virions. Figure adapted from Hedestam et. al., 2008 [279]. 
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FIGURE 1.2 
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FIGURE 1.2. HIV genome structure and protein products. The HIV genome is 
approximately 9.7 kb and includes 9 open reading frames that code for 15 
functional proteins. Subunits of the Gag, Pol and Env precursor proteins are 
indicated by the presence of a dotted line. Figure from Los Alamos National 
Laboratory HIV Sequence Database [19]. 
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FIGURE 1.3 
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Fig. 1. Schematic of HIV gp120 and gp41 envelope proteins. The gp120 protein contains five conserved (C1–C5) and five variable (V1–V5) domains. Positions of conserved
N′ linked glycosylation sites are indicated by branched structures. The lighter colored regions in the C1, C2, and C4 domains represent the bridging sheet minidomain that is
formed following CD4 binding. The gp41 protein contains an N′ terminal fusion peptide (FP), two heptad-repeat domains (HR1 and HR2), and a transmembrane anchor (TM).
The location of the hinge region and the membrane proximal region (MPR) are also depicted.
only viral proteins that project from the membrane of the virion.
Noncovalently associated homotrimers of gp120 and gp41 subunits
assemble into between 8 and 14 functional spikes on the surface of
virions (Zhu et al., 2003, 2006, 2008), though it is not known how
many are needed to elicit themembrane fusion process (Magnus et
al., 2009; Yang et al., 2005).
Since the structure of the Env proteins is crucial to an under-
standing of the entry process, a brief review of their key features is
essential (Fig. 1). The gp120 and gp41 proteins are initially synthe-
sized as a single polypeptide precursor, gp160, which is cleaved
during transit to the cellular membrane. The gp120 subunit of
Env mediates attachment, CD4 binding, and coreceptor binding,
and consists of five conserved (C1–C5) and five variable (V1–V5)
domains (Starcich et al., 1986). The conserved regions form the
core of gp120 and contain many of the domains critical for bind-
ing to host cells. In contrast, the variable domains are located near
the surface of gp120, with V1–V4 forming exposed ‘loops’ that are
anchoredat their bases bydisulfidebonds (Leonardet al., 1990). The
variable loops, along with numerous glycosylation sites, provide
constantly evolving epitopes for the humoral immune response,
but their function is not strictly for immune evasion: the V1/V2 and
particularly theV3 loophave important roles in Envbinding to core-
ceptor. The gp41 subunit of Env encodes the molecular machinery
that drivesmembrane fusion. The protein contains a large extracel-
lular ectodomain, a transmembrane spanning anchor, and a large
cytoplasmic domain on the inside of the virion membrane. The
ectodomain contains a hydrophobic, N′ terminal fusion peptide and
two heptad-repeat domains (HR1 and HR2) that are critical to the
fusion process (Dubay et al., 1992; Wild et al., 1994).
2. The HIV entry process
Infection of target cells by HIV is a complex, multi-stage pro-
cess involving attachment to host cells and CD4 binding, coreceptor
binding, and membrane fusion (Fig. 2). The initial interaction
between HIV and a target cell may be facilitated by nonspecific
interactions between positively charged domains on the gp120
protein and negatively charged proteoglycans on the cellularmem-
brane (Mondor et al., 1998; Moulard et al., 2000) or by specific
interactions with cell surface lectin binding proteins such as DC-
SIGN. Such attachment factors, while not needed for infection, can
enhance the efficiency of virus infection (Geijtenbeek et al., 2000).
The primary receptor for HIV is CD4, amember of the immunoglob-
ulin superfamily that is expressed onmonocytes,macrophages, and
on subsets of T cells and dendritic cells. HIV interaction with CD4
occurs at a structurally conserved, recessed surface on gp120 that
is formed by epitopes that are discontinuous in the primary pro-
tein sequence (Kwong et al., 1998). Unlike many other regions of
gp120, this CD4-binding site consists of residues that are highly
conserved and devoid of carbohydrate, properties that make it a
logical target for inhibitors of gp120-CD4 binding. Upon engage-
ment of CD4, gp120 undergoes a dramatic conformational shift that
has several important consequences. First, two sets of!-sheets that
are spatially separated in unbound gp120 are brought together by
CD4 binding into a four-stranded !-sheet minidomain called the
bridging sheet (Chen et al., 2005; Kwong et al., 1998). Second, CD4
binding results inmovement andexposureof theV1/V2andV3 loop
structures. Third, binding of CD4 changes the orientation of gp120
such that the bridging sheet and the V3 loop are directed towards
the host cellmembrane,where they can subsequently interactwith
coreceptor (Huang et al., 2005; Trkola et al., 1996; Wu et al., 1996).
Thus, CD4 binding is a prerequisite to the formation and exposure
of the coreceptor binding site of gp120.
Inhumans, theprimary coreceptors forHIV-1 are the chemokine
receptors CCR5 and CXCR4, members of the seven-transmembrane
G protein-coupled receptor family (Alkhatib et al., 1996; Choe et
al., 1996; Deng et al., 1996; Doranz et al., 1996; Dragic et al., 1996;
Feng et al., 1996; Oberlin et al., 1996; Zhang et al., 1998). These
proteins are integral membrane proteins with seven transmem-
brane helices, an extracellular N′ terminus and three extracellular
loops (ECLs) that forma small pocket. TheN′ terminusof chemokine
receptors contains sulfated tyrosine residues and elements within
and around ECL2 that are critical for gp120 binding (Atchison et
al., 1996; Edinger et al., 1997; Rucker et al., 1996). These spatially
separated domains of CCR5 interact with distinct regions of gp120:
the N′ terminus with the bridging sheet and the base of the V3
loop, and ECL2 with the tip of the V3 loop (Basmaciogullari et al.,
2002; Cormier and Dragic, 2002; Cormier et al., 2001; Hoffman et
Fig. 2. Model of the multi-step process of HIV entry. The CD4 and coreceptor molecules are located in the host membrane (bottom), while the gp120 and gp41 proteins are
associated with the viral membrane (curved, top). HIV entry is initiated by attachment of gp120 to CD4, which results in conformational changes in gp120 that result in the
formation of the bridging sheet minidomain and extension of the V3 loop. The interaction between gp120 and coreceptor involves interactions between (1) the base of the
V3 loop and adjacent regions and the N′ terminus of the coreceptor and (2) the crown of the V3 loop and the extracellular loops of the coreceptor. Following engagement of
coreceptor, gp120 undergoes further conformational changes that allow for the insertion of the gp41 fusion peptide into the host membrane. Interaction between the HR1
and HR2 domains results in the formation of the six-helix bundle which brings the host and viral membranes into close proximity and creates a fusion pore, allowing entry
of the HIV capsid into the host cell.
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FIGURE 1.3. Primary steps in the HIV entry process. HIV viral entry is initiated 
by binding of the native envelope trimer to the primary receptor CD4 (green). 
Following binding to CD4, a conformational change in the envelope protein 
occurs, resulting in the rearrangement of the variable loops, exposing the 
coreceptor binding site. The V3 loop contacts the coreceptor (CCR5 or CXCR4- 
shown in blue) and a second conformational change occurs, which allows for 
fusion of the viral and cellular membranes. Figure from Tilton and Doms, 2010 
[182]. 
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FIGURE 1.4 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
secondary structure elements and, in conjunction with available
structural information, to approximate the tertiary organization of
Env (Fig. 1). However, as expected, the adjacent strands within the
β-sheets were not separable at this resolution. Connecting loops
often exhibited poor clarity or were not separable from nearby
structures, preventing a complete backbone trace from being
unambiguously derived at the current resolution. In addition to
the appearance of features indicative of secondary structure ele-
ments, the rigid-body fitting of the X-ray crystal structure of the
gp120 outer domain into the density supports the validity of the
cryo-EM reconstruction (see below).
Overview of Env Molecular Architecture. The gp120 and gp41 sub-
units and their intersubunit interfaces were discernable and ap-
proximately defined by map segmentation (Fig. 1 C and D). The
gp120 subunit demonstrates three domains: the outer domain,
inner domain, and trimer association domain (TAD). The gp41
subunit is composed of the ectodomain and the membrane-
interactive region, which includes a long membrane-spanning
helix. The gp120 inner domain and themembrane-distal end of the
gp41 ectodomain mediate the gp120–gp41 interactions within
each protomer. The interprotomer interactions that potentially
stabilize the unliganded Env trimer are limited to three regions: (i)
the gp41 transmembrane region is involved in a trimeric interface
within the viral membrane; (ii) the gp41 ectodomain forms di-
meric contacts between adjacent protomers, creating a torus-like
topology; and (iii) the gp120 TAD mediates interactions among
the gp120 subunits at the membrane-distal end of the trimer.
Remarkably, this arrangement of interprotomer contacts
leaves a large empty space surrounding most of the trimer axis.
Unliganded gp120 and CD4-Induced Conformational Changes. The
CD4-bound gp120 core consists of an inner and outer domain, as
well as a bridging sheet (16). The full-length unliganded gp120
subunit shown in our cryo-EM map exhibits a conformation dif-
ferent from that observed in the CD4-bound gp120 core (16). The
improved resolution of the current map allows positioning of the
secondary structure elements in gp120 and a detailed assessment
of the conformational changes collectively associated with Env
cleavage and CD4 binding (25–28).
Multiple crystal structures of the monomeric gp120 core in-
dicate that the conformation of the outer domain is minimally
affected by ligand binding (15, 16, 29–32). Consistent with this, the
crystal structure of the outer domain from the CD4-bound gp120
core fit well into the cryo-EM density as a rigid body (Fig. 2 A and
B, Fig. S3 A and B, and Table S1). Two gp120 elements, the β20/
β21 strands and the V3 variable region, project from the same
β-sheet in the outer domain (16). Density associated with these
elements is evident in the cryo-EMmap, and the size difference of
these elements (∼14 residues vs. 35 residues, respectively) allows
their provisional assignment. In the unliganded Env trimer, the
β20/β21 strands project toward and abut the gp120 inner domain,
whereas the V3 region joins the gp120 TAD. Upon CD4 binding,
β20/β21 becomes part of the bridging sheet, and the V3 region is
redirected toward the target cell, where it engages the chemokine
receptor (33).
In contrast to the outer domain, the crystal structure of the gp120
inner domain did not fit into the cryo-EM density as a rigid body.
However, we approximated the secondary structure organization of
the gp120 inner domain in the cryo-EM map by flexibly fitting the
crystal structure of the gp120 inner domain in the CD4-bound
conformation to our cryo-EM map (Fig. 2 C–E). Although the
limited resolution precludes a complete backbone trace of the gp120
inner domain, most of the secondary structure elements in the CD4-
bound gp120 inner domain seem to be retained in the cryo-EM
structure of the unliganded Env trimer (Fig. 2 C and D, Fig. S3 C
and D, and Table S1). However, comparison of the secondary
structure organization of the gp120 inner domain between the
unliganded precursor and CD4-bound states suggests marked dif-
ferences in the tertiary arrangements of these secondary structure
elements (Fig. 2 E and F and Fig. S4). Relative to the gp120 outer
domain, the β-sandwich in the gp120 inner domain is rotated by∼60°
in the unliganded precursor state compared with the CD4-bound
state (Fig. 2 E and F). The α0, α1, and α5 helices are rotated ∼110°,
40°, and 60° relative to their orientations in the CD4-bound con-
formation, respectively (Fig. S4). These observations are consistent
with previous studies suggesting that layered movement occurs
within the gp120 inner domain upon CD4 binding (17, 25, 28).
A recent study suggested that the bridging sheet (β2/β3 and
β20/β21), which was observed in the crystal structure of the mo-
nomeric gp120 core in the CD4-bound state (16), is not well
formed in the unliganded full-length gp120 monomer in solution
(34). Consistent with this suggestion, flexible fitting of the CD4-
bound gp120 core structure to our unliganded Env precursor map
failed to maintain the bridging sheet in its CD4-bound confor-
mation (Fig. 2E and Fig. S3). Instead, the β2/β3 motif, from which
the gp120 V1/V2 region emanates, must extend from the inner
domain toward the trimer axis to accommodate the folding of the
V1/V2 and V3 regions (see the following section) (Fig. S3 E and
F). The map density associated with β20/β21 suggests that it
projects from the outer domain toward the inner domain, oriented
nearly orthogonally to β2/β3 (Fig. 2 D and E). Thus, both the
bridging sheet and the inner domain represent dynamic elements
of the gp120 subunit, undergoing significant changes in confor-
mation in response to CD4 binding.
Architecture of gp120 Trimer Association. Previous studies have
suggested that the gp120 V1, V2, and V3 regions (20, 23, 24) are
located at the membrane-distal apex of the Env spike and
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Fig. 1. Architecture of the HIV-1 Env trimer. (A) Cryo-EMmap of the HIV-1JR-FL
Env trimer in a surface representation, viewed froma perspective parallel to the
viral membrane. (B) Cryo-EMmap of the HIV-1JR-FL Env trimer, viewed from the
perspective of the target cell. (C and D) Domain organization of the Env pro-
tomer, revealed by segmentation of the density map. The gp120 domains are
colored as follows: outer domain, blue; inner domain, orange; and TAD, red.
The gp41 domains are colored as follows: ectodomain, green; and trans-
membrane region, cyan.
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FIGURE 1.4. Cryo-EM structure of the uncleaved HIV envelope trimer. This 
cryo-EM structure of the uncleaved HIV envelope trimer reveals a hollow center 
of the trimer and the positioning of the variable loops in the “trimer association 
domain” at the central apex of the envelope trimer (shown in red). A, side view of 
the trimer; B, top down view of the trimer. Trimer association domain, red; gp120 
outerdomain, cyan; gp120 inner domain, gold; gp41 ectodomain, green; gp41 
membrane interactive region, light blue. Figure adapted from Mao, et. al., 2013. 
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FIGURE 1.5 
	
	
	
	
	
	 	
	
	
	
	
	
	
	
	
	
	
	
During Env synthesis, gp160 precursors trimerize
and are subsequently cleaved by proteases of the
furin family into gp120 and gp41 subunits, which
associate noncovalently before the native com-
plex reaches the surface of infected cells and is
then packaged onto virions (13). Cleavage is ob-
ligatory for Env trimers to function in viral in-
fection of target cells (14). Virus-cell fusion is
a multistep process involving three major Env
conformations, each with distinct roles: (i) prefu-
sion (interacts with CD4 receptor); (ii) extended
gp41 intermediate (interacts with CCR5 or CXCR4
co-receptors); and (iii) gp41 six-helix bundle (hemi-
fusion of viral and cell membranes) (15).
The requirement for the cleaved, native Env
trimer to undergo conformational changes during
receptor binding and fusion makes it metastable,
which has substantially hindered both structure
determination and vaccine development. The
extensive N-linked glycosylation (on average,
81 sites per trimer) creates additional compli-
cations for x-ray structural studies. Moreover,
membrane-associated forms of Env are more
difficult to express and purify in appropriate quan-
tities and qualities than soluble versions. Our
approach to these various problems has been to
express soluble (that is, truncated before the
gp41 transmembrane domain), cleaved forms of
trimeric Env (SOSIP gp140) that are engineered
to improve their stability and homogeneity. Spe-
cifically, a disulfide bond (termed SOS) between
gp120 residue 501 (HXB2 numbering) and gp41
residue 605 covalently links these subunits, where-
as an Ile-to-Pro change at position 559 (termed IP)
strengthens gp41-gp41 associations (16). A re-
cent version of the SOSIP gp140 trimer, based
on a tier-2 subtype A virus (BG505) (17), was
further engineered to delete all but four residues
of the hydrophobic membrane proximal external
region (MPER) of gp41 (17–20). Together, these
various modifications allow the expression of a
thermostable, nonaggregating, and homogeneous
soluble Env trimer, BG505 SOSIP.664 gp140,
suitable for structural characterization by x-ray
crystallography (Fig. 1A). These trimers are re-
active with a large panel of diverse broadly neu-
tralizing antibodies (bnAbs), including those to
quaternary epitopes, while being minimally reactive
with non-neutralizing antibodies that preferen-
tially recognize individual gp120/gp41 subunits
and/or uncleaved, non-native trimer forms (17, 18).
The near-native antigenic properties of the BG505
SOSIP.664 gp140 trimer suggest that its struc-
ture resembles the native viral spike, although we
cannot completely rule out slight conformational
differences resulting from engineered features,
such as truncation of the gp41 MPER and trans-
membrane domain (19). Here, we show that the
BG505 SOSIP.664 gp140 trimers could be suc-
cessfully crystallized with a highly potent bnAb,
PGT122, that targets the glycan-dependent Asn332
(N332) supersite of vulnerability on gp120 (21).
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Fig. 1. Overall architecture of a soluble, cleaved, recombinant HIV-1
Env trimer in complex with bnAb PGT 122. (A) Schematic of the HIV-1
Env BG505 SOSIP.664 construct in comparison to full-length gp160. N-linked
glycans are shown and numbered on their respective Asn residues. The con-
stant (C1 to C5) and variable (V1 to V5) regions in gp120 and the FP, HR1
and HR2 helices, MPER, transmembrane (TM), and cytoplasmic (CT) elements
in gp41 are indicated. The SOSIP mutations are shown in red, as well as the
added N332 glycan site. The color coding is preserved in (B) to (D). (B) Side
view of the soluble Env trimer complex with PGT122 showing two of the three
Env gp140 protomers associated with PGT122 Fab (blue). A 2Fo-Fc electron-
density map contoured at 1.0s is shown as a gray mesh around the leftmost
gp140 protomer. The membrane to which gp41 is attached would be at the
bottom of the figure. (C) Side view of the Env trimer. For one of the three
protomers on Env, core gp120 is shown in yellow, whereas V1/V2 and V3
regions are highlighted in orange and red, respectively. The main gp41 helical
elements are colored in different shades of green. Protein components are
rendered according to their secondary structure, and glycans are depicted as
spheres. (D) View of Env down the trimer axis. Loops of high variability in
gp120 (V1 to V5) all map to the periphery of the trimer and are labeled.
Glycans have been omitted for clarity. Dashed lines indicate the location of
gp120 V2 and V4 loops for which electron density was absent or ambiguous.
The figure was generated with PyMOL (63).
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FIGURE 1.5. Crystal structure of the BG505 SOSIP.664 HIV envelope trimer. 
The trimer structure of the SOSIP trimer reveals no central space within the 
trimer and the V1/V2 and V3 loops are positioned at the apex of the trimer as 
shown in crystal structure. A, side view; B. top view. V1/V2 loop, orange; V3 loop, 
red; gp120 core including V4 and V5 loops, yellow; gp41 segments, green. 
Figure adapted from Julien, et. al., 2013. 
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FIGURE 1.6 
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FIGURE 1.6. Schematic of the variable loops and conserved regions of the 
HIV gp120. The HIV gp120 protein is divided into five conserved regions (white 
circles), as indicated in this figure by C1-C5, and five variable loop regions (grey 
circles), indicated as V1-V5. Disulfide bonds that form the variable loops are 
indicated by bold lines connecting two amino acids, and conserved glycosylation 
sites are indicated. Figure adapted from Sanders, et. al., 2008. 
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CHAPTER II- MATERIALS AND METHODS 
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Cell Lines 
293T cells (ATCC) were used for envelope expression experiments, as 
effector cells for the fusion assay and to produce the single-round virus for entry 
assays [280]. 293T were grown in complete Dulbecco’s modified Eagle Medium 
(DMEM) containing 10% fetal bovine serum, 8mM L-Glutamine and 100 μg/mL 
penicillin/streptomycin solution.  
TZM-bl cells (NIH AIDS Reagent Program) were also grown in complete 
DMEM and were used as the target cells for the fusion assay as well as entry 
assays using single-round, replication deficient virus. This virus is capable of 
infecting a cell, but due to a deficiency in the envelope gene, is not able to 
reproduce in cells. TZM-bl cells are engineered HeLa cells that stably express 
human CD4 and CCR5 [281-283]. They also stably express firefly luciferase and 
β-galactosidase genes under a Tat-inducible promoter, so that when Tat protein 
is present in the cells (by transient means or via a virus), both the luciferase and 
β-galactosidase enzymes are expressed as reporters [284].  
Cf2Th-CD4/CCR5 and Cf2Th-CCR5 (Dr. J. Sodroski Laboratory) are 
canine thymus cells that stably express CD4 and CCR5 and CCR5 under 
antibiotic selection, respectively [5, 285]. Cf2Th-CD4/CCR5 cells were also 
grown in complete DMEM supplemented with 50 µg/μL g418 and 150 μg/mL. 
Cf2Th- CCR5 cells were also grown in complete DMEM supplemented with 50 
µg/μL. 
 
	 52 
Envelope Expression Plasmids  
Plasmids for envelope expression were generated by subcloning. The 
ZM249MB_10 (ZM249), HIV-2 ST and SIVagmTan1 envelope expression 
plasmids were generated by PCR amplification of the envelope gene from 
existing envelope expression plasmids or proviral constructs and ligated into 
pCDNA3.1+ for expression in mammalian cells. The env gene of ZM249 was 
amplified from the plasmid pZM249MB_10 (NIH AIDS Reagent Program) by PCR 
using primers that added a 5’-HindIII site, and 3’-EcoRI site. The HIV-2 ST env 
gene was amplified from the pHIV2/ST molecular clone adding a 5’-AflII site and 
a 3’-BamHI site and subcloned into pCDN3.1+ [286, 287]. The SIVagmTan-1 env 
gene was amplified from the pSIVagmTan-1 molecular clone (NIH AIDS Reagent 
Program), adding a KpnI site to the 5’ end of the gene and an EcoRI site to the 3’ 
end of the gene, by including these sequences on the 5’ and 3’ ends of the 
amplification primers respectively (Appendix I), followed by subcloning into 
pCDNA3.1+ [288]. 1084i (Dr. C. Wood Lab) was subcloned into the pSVIII 
HXBc2 env construct via the conserved KpnI and BamHI sites. A BamHI site 
corresponding to the existing BamHI site in HXBc2 was introduced to 1084i by 
site directed mutagenesis. Following subcloning, all envelope constructs were 
verified by sequencing the env gene to identify any mutations in the sequence. 
V3 loop hydrophobic patch mutations were also made directly to pZM249M_B10 
for pseudovirus production. HIV-1 ADA, JR-FL and YU2 envelope expression 
plasmids (pSVIII) were previously available (Dr. J. Sodroski Lab), and any 
mutations made to these were made directly by site directed mutagenesis. A 
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complete list of plasmids and mutations used in these studies is available in table 
2.1. All ligations were performed using the T4 DNA Ligase enzyme and buffers 
from NEB. Sequences of primers used for gene amplification are shown in 
Appendix I. 
 
Envelope Gene Cloning by Reverse Transcriptase PCR 
The SIVagm155-4 envelope gene was cloned into the pCDNA3.1+ 
expression vector by RT-PCR using live virus (NIH AIDS Reagent Program) 
[289]. First, viral RNA was extracted and purified. from virus containing 
supernatants using the QIAmp Viral RNA Mini Kit (Qiagen). A cDNA library was 
generated from this viral RNA using the Superscript III Reverse Transcriptase kit 
(Invitrogen), substituting oligo(dT)20 to serve as the primer for the reaction. This 
cDNA library was then subjected to gene amplification PCR using env gene 
specific primers, containing a 5’-XhoI site and a 3’-XbaI site for subcloning, using 
the TaKaRa ExTaq kit (Takara). The resulting DNA band of the correct size 
(2307 bp) was gel extracted using a gel extraction kit (Qiagen), digested with 
XhoI and XbaI, and subcloned into the pCDNA3.1+ vector using T4 DNA Ligase 
(NEB). The resulting clones were verified by restriction digest with XhoI and XbaI 
to verify the appropriate insert size, and the env gene was fully sequenced to 
verify the sequence identify any potential mutations gained in the cloning 
process.  
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Site-Directed Mutagenesis 
V3-loop hydrophobic patch and twin cysteine mutations were made to the 
primate lentiviral envelope expression constructs by site-directed mutagenesis, 
using PfuUltra (Agilent) and the QuikChange XL protocol. Primers for 
mutagenesis were synthesized by Integrated DNA Technologies (IDT). A 
complete table of envelope constructs and their mutations is shown in Table 2.1. 
A list of the primers used to introduce mutations to the V3 loop hydrophobic 
patch of ZM249 can be found in Appendix A. A complete list of primers used to 
introduce V3 mutations to 1084i is found in Appendix B. Mutagenesis primers for 
the V3 loop hydrophobic patch in HIV-2 ST, SIVagmTan-1 and SIVmac239 are 
found in Appendix C, D and E respectively. The primer sequences used to 
introduce the twin cysteine motif (TCM), a pair of cysteines at positions 183 and 
191 in the V2 loop) into HIV-1 are listed in Appendix F; the primers used to 
initiate the V2 Swap mutations to the HIV-1 species in Appendix G. The primer 
sequences used to remove the twin cysteine motif from HIV-2 ST, SIVagmTan-1 
and SIVagm155 are all listed in Appendix H. 
 
Overlapping PCR 
An overlap extension PCR based method was used to generate the V2 
swap mutations discussed in chapter 3. Initially, two segments were generated in 
two PCR reactions. Fragment 1 was generated using primer A, a forward primer 
extending from the 5’ end of the HIV-1 (ADA or JRFL) envelope gene sequence, 
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containing the 5’-KpnI site for cloning, and primer B, a reverse primer extending 
from the V2 loop twin cysteine region. Primer B contained the SIVmac239 or 
HIV-2 V2 twin cysteine sequence in place of the HIV-1 V2 twin cysteine region in 
frame. Fragment 2 was generated using primer C, a forward primer that 
overlapped with primer B at the V2 twin cysteine region from SIVmac239 or HIV-
2 in frame with the HIV-1 envelope sequence, and primer D, a reverse primer 
that amplified the 3’ end of the HIV-1 envelope gene, containing the BamHI site 
for subcloning. Both fragments were generated using the E7/ADA or E7/JRFL 
WT envelope plasmids. Each fragment was gel purified and included as the 
template in a second round of PCR, which used primers A and D to amplify the 
entire envelope gene with the V2 twin cysteine region replaced. The resulting 
envelope gene was digested with BamHI and KpnI and subcloned into the 
original pSVIII vector. Positive colonies were screened for the swap mutation by 
sequencing, and were then amplified for use in transfections. This process is 
diagrammed and explained in detail in Figure 2.1, and the primers sequences 
used are listed in Appendix G. V2 swap constructs are designated by listing the 
HIV-1 species first, followed by an abbreviation of the species the V2 region is 
derived from and designated as “V2Swap”. For example, the ADA envelope 
containing the SIVmac239 V2 twin cysteine region is termed “ADA macV2Swap”. 
Agarose gels showing the resulting PCR bands and sequencing results are 
shown in Figure 2.2. 
 
Cell-cell Fusion Assay 
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On Day 0, 293T cells were plated at a density of 3.5x105/well in a 6-well 
plate. The following day, the cells were transfected with 2 μg of WT or mutant 
envelope expression constructs and 1 μg Tat-expressing plasmid using 
polyethylynamine (PEI). 24 hours post transfection, the media was changed on 
transfected cells and TZM-bl cells were set in an opaque, black 96-well plate at a 
density of 1.0x104 per well. On Day 3, the transfected 293T cells were detached 
from the plate using gentle pipetting and counted in a hemocytometer. The 
transfected effector cells were set on top of the previously plated TZM-bl cells at 
a density of 1.0x104 and were co-incubated for 16 hours. Following co-
incubation, the cells were washed once with PBS and lysed using 1X Passive 
Lysis Buffer (Promega) and frozen at -80°C. The plates were read for luciferase 
activity following thaw using the beetle luciferin substrate (Promega) and data 
was collected using a Veritas luminometer and the Veritas software. Values for 
WT were set to 100 percent and mutant values are expressed as a percentage of 
the WT value. Each fusion data set is representative of three separate 
experiments performed in quadruplicate. 
 
gp120 Shedding Assay 
293T cells were set at a density of 3.5x105/well in a 6-well plate. The 
following day, the cells were transfected to express a WT or mutant envelope 
protein. One day post transfection, the cells were metabolically labeled overnight 
using the EasyTag EXPRESS35S Protein Labeling Mix [35S] (PerkinElmer). 
Following labeling, the supernatants were harvested and clarified of cell debris by 
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gentle centrifugation. Separately, the cells were lysed using an NP-40 based 
lysis buffer. The cell lysates were precleared using appropriate uninfected serum 
for 8 hours as previously described [6]. Following preclear, the cell lysates and 
supernatant fractions were separately subjected to immunoprecipitation with PLV 
infected patient serum from the corresponding host [290-292] and pull down was 
completed using protein-A sepharose beads (GE Health Sciences). The samples 
were run on SDS-PAGE and the gels were dried and exposed to phosphor 
screen for 12 hours at room temperature. Phosphor screens were developed 
using a personal molecular imager (Biorad) and analyzed using the QuantityOne 
software (Biorad). Values for the supernatant and cell lysate band were 
determined and the association index was calculated as previously described 
[293]. 
 
Pulse-Chase Assay 
On day 0, 293T cells were set at a density of 5.0x106/well in a 6-well plate. 
24 hours later, four wells were transfected to express WT ADA envelope, or ADA 
envelope with the twin cysteine substitution mutation. The following day, the cells 
were serum starved for thirty minutes by adding serum free media. After serum 
starvation, the expressed proteins were labeled by adding 1 mL cys- met- media 
containing EasyTag EXPRESS35S Protein Labeling Mix [35S] (PerkinElmer) for a 
1 hour pulse. The pulse media was removed and replaced with non-labeled 
complete media, and the cell lysates and supernatants were harvested 
separately at 0 h, 2 h, 4 h and 8 h post pulse. Once all harvests were complete, 
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immunoprecipitation was performed on the cell lysates and supernatants 
separately using HIV infected patient serum, and analyzed by SDS-PAGE. 
 
Generation of Pseudoviruses 
293T cells were plated at a density of 3.5x105 cells per well in a 6-well 
plate. 24 hours later, the cells were transfected with a WT or mutant envelope 
expression plasmid and an envelope deficient viral backbone (pSG3ΔEnv [72, 281] 
in the case of ZM249 and SIVmac239 constructs or pHIV-Luc  and pCMV Gag-
Pol packaging plasmid [5, 294, 295] for 1084i constructs) using polyethylynamine 
(PEI) at a stock concentration of 1 μg/μL. One day following transfection, 
additional media was added to the wells and 3 days post transfection, the 
supernatants were harvested, briefly spun down to remove cell debris and stored 
at -80° C. The pseudovirus containing supernatants were then quantified using 
the RT assay. 
 
Reverse Transcriptase Activity Assay  
To quantify the amount of pseudovirus in a sample, the reverse 
transcriptase assay was performed. In duplicate, 500μL of pseudovirus 
containing supernatant was spun at 14,000xg for 2 hours at 4° C. Following the 
spin, the supernatant was removed and the viral pellet was resuspended in a 
Triton X-100 based suspension buffer and vortexed followed by a rapid freeze-
thaw cycle a total of three times to properly lyse the virus. 50μL reaction mix was 
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added, which contained Oligo-dT Poly-A (Roche), and 3H-dTTP (PerkinElmer) 
and the samples were incubated at 37° C for 1 hour in a heat block. Following 
incubation, the samples were pipetted onto cut squares of DEAE Filtermat paper 
(PerkinElmer), followed by three ten-minute washes in 2X SSC buffer, and one 
ten second wash in absolute ethanol. The filters were dried at room temp and 
then analyzed using a scintillation counter to quantify the CPM of 3H-dTTP that 
was incorporated by the RT enzyme. The average CPM values from each 
duplicate were then used to normalize the amount of viral supernatant that was 
used in subsequent single-round viral entry assays.  
 
Single Round Viral Infection Assay 
Cf2Th-CD4/CCR5 or TZM-bl cells, which express both CD4 and CCR5 
were set at a density of 8.0x103 per well (Cf2Th that stably express CD4 and 
CCR5 in the case of 1084i pseudoviruses or TZM-bl in the case of ZM249, ADA, 
JR-FL and SIVmac239 pseudoviruses). The following day, a normalized volume 
of virus was added to each well based on the level of RT activity in the 
supernatant in a final volume of 100μL, diluted in complete DMEM. One day post 
infection, the viral supernatants were removed, the cells were gently washed one 
time with PBS and fresh complete media, containing 10% FBS, 
penicillin/streptomycin and L-glutamine, was added to each well. On day 3 post 
infection, the supernatants were removed, the cells were washed once with PBS 
and the cells were lysed in 1X Passive Lysis Buffer and frozen at -80° C. The 
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plates were then thawed and luciferase activity was measured using the Veritas 
luminometer and Beetle luciferin substrate (Promega).  
 
CD4 Binding Assay 
35S labeled soluble gp120 proteins were assessed for CD4 binding by 
performing an immunoprecipitation assay using CD4-Ig. Input quantities were 
determined by immunoprecipitation using the same volume of supernatant and 
appropriate patient serum. For the CD4 binding of HIV-2ST, three times volume 
of supernatant was used in comparison to the WT because of a reduced level of 
binding to CD4-Ig compared to HIV-1 species [296-298]. Following IP with CD4-
Ig, the bands were quantified using the Quantity One software (Biorad) and the 
volumes were compared to the volumes of the input gel. The ratios from WT was 
adjusted to 1, and the amounts of mutant protein species were compared to the 
WT. 
 
CCR5 Binding Assay 
Supernatants (~1.8 mL) containing 35S labeled gp120 from WT or mutant 
envelope proteins were co-incubated for 1 hour at room temperature with 8 μg 
sCD4 and 5.0x106 CCR5 expressing Cf2-Th cells in a 2 mL reaction volume. 
Expression of human CCR5 on these cells was confirmed by flow cytometry. The 
cells were then spun down, lysed with a non-denaturing lysis buffer and cell 
debris was removed. An immunoprecipitation with the appropriate serum from 
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infected patients was then performed for one hour at room temperature and the 
results were analyzed by SDS-PAGE followed by exposure to a Personal 
Molecular Imager (Biorad), and the bands were analyzed using the QuantityOne 
software (Biorad).  
 
Statistical Analysis 
For all statistical analyses of cell-cell fusion and single round viral infection 
assays, experimental groups were compared using the Student’s T-test. Each 
experiment was performed three separate times, with quadruplicate values. Each 
mutant was converted to percentage of the WT value, which was set to 100%. 
Significant differences between the average value of the WT and the mutants 
were determined using a p-value of ≤0.05. All statistical analysis was performed 
using the Prism 6 software (GraphPad). 
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The 1084i env gene, and clade C patient serum was a generous gift from Dr. 
Charles Wood. Cf2-Th-CD4/CCR5 and Cf2-Th-CCR5 cells, and pSVIII ADA, 
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FIGURE 2.1 
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FIGURE 2.1. Overlapping PCR method to generate V2 swap mutants. 
Overlapping PCR was used to generate HIV-1 V2 swap mutants where the V2 
twin cysteine regions from SIVmac239 and HIV-2 ST were swapped into both 
ADA and JRFL. The primers used for overlapping PCR are included in Appendix 
G. This figure only shows the swap process into HIV-1 ADA, but these steps 
were also performed using JRFL as the template. Dotted lines indicate non-HIV-1 
V2 twin cysteine sequence.  
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FIGURE 2.2  
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FIGURE 2.2. Overlapping PCR to create HIV-2 ST V2 Swap Mutants. (A) 
Round 1 PCR produced fragments 1 and 2 from ADA and JRFL with the V2 
region from HIV-2 ST. Fragment 1 was generated by PCR using primer A and 
Primer B. Expected size for both ADA and JRFL is 573 bp. Fragment 2 was 
generated by PCR using primer C and D. Expected band for JRFL was 2049 bp 
and ADA was 2067 bp. (B) Second round PCR included both fragments from 
round 1 and produced the full length JRFL and ADA env gene containing the V2 
region from HIV-2 ST. Expected size for JRFL was 2598 bp, and ADA was 2616 
bp. (C) Sequencing confirmed the presence of the HIV-2 ST V2 swap for ADA 
and JRFL. 
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TABLE 2.1 
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TABLE 2.1. Complete listing of env genes, point mutations and plasmids 
generated for the studies in this dissertation. 
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CHAPTER 3- ASSOCIATION OF THE gp120 V3 LOOP WITH ENVELOPE 
TRIMER STABILIZATION IN PRIMATE LENTIVIRUSES 
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INTRODUCTION 
 Entry of HIV-1, HIV-2 or SIV is facilitated by the envelope protein trimer 
complex which is displayed on the surface of the virus. This complex is 
composed of three molecules of gp120, the surface glycoprotein (SU), non-
covalently bound to three molecules of gp41 which are transmembrane proteins 
(TM). The gp120 first binds to CD4 which initiates a conformational change in the 
gp120 molecule to expose the coreceptor (CCR5 or CXCR4) binding site [299-
301]. Following coreceptor binding, gp41 undergoes an additional major 
conformational change, which brings the host and viral membrane into proximity, 
to initiate membrane fusion.  
 The V3 loop is one of five variable regions in the HIV envelope protein 
which plays a major role in contacting the coreceptor for viral entry. Thus, the V3 
loop is essential for the function of the envelope protein as deletion of the V3 
loop results a complete reduction of envelope initiated fusion and viral entry [240, 
241]. The length of this loop is well conserved across viral strains at 34-35 amino 
acids [234, 238, 249, 302, 303]. The V3 loop can be divided into three parts:  the 
base, stem and tip. The base and tip are usually more conserved in sequence, 
while the stem region is more variable and flexible [234, 249, 304]. The sequence 
of the V3 loop determines the coreceptor selection of CCR5 or CXCR4 [302, 
305-309]. In addition to its role in coreceptor binding, the V3 loop has also been 
found to be associated with envelope trimer stabilization [5, 236]. This work 
revealed that insertions or deletions in the V3 sequence cause a major 
destabilization of the envelope complex as indicated by increased envelope 
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gp120 shedding. Additionally, conserved hydrophobic residues in a region known 
as the “hydrophobic patch” in the tip of the V3 loop have also been shown to 
contribute to the stability of the envelope trimer, as substitution of these residues 
with neutral amino acids, or hydrophilic amino acids results in a similar decrease 
in envelope trimer stability [5]. This was the first study to show that the variable 
loops may play a significant role in envelope stability, as the variable loops were 
originally thought to have a flexible conformation and were thus removed from 
the protein in early structural studies of this protein [28]. It is important to note 
that the effect of the hydrophobic patch has been shown exclusively in subtype B 
HIV-1 species. Subtype B is the subtype predominantly responsible for HIV-1 
infections in the United States and Western Europe, and has been studied most 
extensively. Subtype C however, accounts for approximately 50% of HIV-1 
infections globally, as it is the subtype that accounts for most of the HIV-1 
infections in sub-Saharan Africa and India [155, 310]. Additionally, there is 
evidence that HIV subtype C differs from subtype B in terms of transmission, 
pathogenesis and disease progression, which stresses the importance of 
understanding the biology of subtype C viruses [156, 158, 311, 312]. 
 Several near atomic structures of the HIV-1 envelope trimer have been 
released and have helped to make important progress in the field of HIV entry 
research and vaccine development. These structures show that the V3 loop is 
packaged into the apex of the trimer as part of the trimer association domain, 
which supports the finding that the V3 loop plays an important structural role in 
envelope trimer stabilization [2, 3, 210, 275]. The V3 loop is also highly 
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immunogenic, and is an important target of antibodies both in natural infection 
and in vaccination studies [255, 306, 313-315]. Because of this, recent efforts to 
use the SOSIP trimer as a vaccine immunogen have shown that non-cross 
neutralizing V3 antibodies are generated in high numbers [220, 257, 272, 277]. 
To reduce this effect, recent efforts have sought to further stabilize the V3 loop to 
reduce its exposure and antigenicity, while still generating heterologous 
neutralizing antibodies [257, 270, 272, 277]. Strategies have included from the 
targeted addition of glycans and additional hydrophobic residues flanking the 
hydrophobic patch described previously, indicating the importance of this 
hydrophobic region in the positioning of the V3 loop in the envelope protein 
complex [258, 270, 277]. 
 Although the sequences and lengths of the V3 loops are variable between 
primate lentiviral species (including HIV-2 and SIV), the hydrophobic patch 
residues remain conserved [5]. There are some variations in the exact amino 
acid sequence at these positions, but these residues remain hydrophobic 
regardless of lentiviral species. This indicates that the hydrophobic patch is an 
evolutionarily relevant motif, and plays an important structural role. It is important 
to note, as HIV-2 represents an entirely separate transmission of an SIV into the 
human population, and because SIVs from other primate species often behave 
exceptionally different from HIV-1 in terms of pathogenesis, immune evasion, 
and antibody development [11, 123, 165]. The relationship between HIV-1 and 
SIV species is an important area to study, as fully understanding the way SIV 
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species function in the hosts will help provide understanding of the pathogenesis 
and transmission of HIV-1. 
 In this work, the role of the V3 loop hydrophobic patch in both HIV-1 
subtype C, HIV-2 species, and SIV nonhuman primate lentiviruses were 
examined. The hypothesis that the V3 loop plays an important role in the stability 
of the unliganded envelope trimers of HIV-1 subtype C, HIV-2 and SIV 
nonhuman primate lentiviruses is tested through mutational studies of the 
envelope on its stability and functionality, as evidenced by the ability to initiate 
envelope fusion and infection into cells.  
RESULTS 
Generation of V3 Hydrophobic Patch Mutants in Primate Lentiviral Species 
Based on the first report on the V3 Hydrophobic Patch in HIV-1 subtype B 
strains published in 2010 [5], an alignment of the V3 loops of multiple species of 
primate lentiviruses, the hydrophobic patch region is conserved across HIV-1 
subtypes as well as in HIV-2 and SIV. Although there is some variability in the 
residues present at amino acid positions 307, 309 and 317, those residues are 
consistently hydrophobic (Figure 3.1.A). The hydrophobic patch residues are 
positioned in the tip of the V3 loop, with 307 and 309 on one side of the turn 
sequence, and 317 directly across these residues on the other side of the turn 
(Figure 3.1.B-C). Based on this sequence alignment, the recent structural models 
and our previously published data, it is our hypothesis that the hydrophobic 
nature of these residues contributes to the stability of all primate lentiviral 
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envelope trimers. To test this hypothesis, a panel of hydrophobic patch mutants 
was generated in two HIV-1 subtype C species, ZM249MB_10 (ZM249) and 
1084i. In each of these subtype C strains, a glycine (G) insertion mutant was first 
generated to observe the effects on envelope shedding and decreased 
functionality between amino acids T303 and R304. V3 insertion mutations are 
known to decrease envelope complex stability, as they change the overall length 
of the V3 loop. Additionally, an alanine (A) substitution was generated at amino 
acids 307, 309 and 317 individually to represent a change to a relatively neutral 
amino acid. A glutamic acid (E) substitution was generated at each position to 
represent a change to a hydrophilic amino acid and a leucine (L) substitution was 
generated to represent a hydrophobic to hydrophobic change. All mutations were 
generated by site directed mutagenesis. Based on the natural hydrophobicity of 
the WT residues, our hypothesis is that the alanine and glutamic acid 
substitutions will cause a decrease in envelope stability and in turn cause a 
decrease in cell-cell fusion and infectivity, and that the leucine substitution will 
not cause as significant of an overall change, though small decreases or 
increases in stability and functionality may occur.  
To broaden the scope of this study, a wider panel of primate lentiviruses, 
including HIV-2 and SIVs, was also included (Figure 3.1). Glycine insertion 
mutations between corresponding residues 303 and 304 and alanine substitution 
mutations to the hydrophobic patch were made to HIV-2 ST, SIVagmTan-1 and 
SIVmac239. A complete table of strains used and mutations introduced can be 
found in Table 2.1 in Chapter 2. 
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Neutral and Hydrophilic Substitutions to the V3 Loop Reduce Stability and 
Functionality of HIV-1 Subtype C Envelope Complex. 
To observe the effect of the hydrophobic patch mutations on the stability 
and functionality of the envelope proteins, the gp120 shedding assay was used 
to assess the stability of the envelope trimer and is shown for ZM249 in Figures 
3.2.A-D. In this assay, an immunoprecipitation of 35S labeled proteins is 
performed on both the cell lysate and supernatant fraction of transfected cells. 
The amount of gp120 in the cell lysate fraction is compared to the amount of 
gp120 in the supernatant, and the association index is an established method to 
quantify the difference in gp120 between WT and mutant PLV envelopes [293]. 
Insertion of a glycine residue in the V3 loop resulted in a massive increase in 
gp120 shedding. Based on these results, it is evident that the length of the V3 
loop is important for envelope trimer stability in subtype-C HIV-1, as was seen in 
subtype-B viruses [5]. Neutral and hydrophilic amino acid substitutions caused a 
significant decrease in envelope stability at all the hydrophobic patch locations. 
The hydrophobic residue (isoleucine, I or phenylalanine, F) to hydrophobic 
residue (leucine, L) mutations did not cause an increase in gp120 shedding. This 
suggests that hydrophobicity at this position is required, but not a specific residue 
in the hydrophobic patch. According to the SOSIP structure, the V3 loop 
hydrophobic patch appears to interact with other hydrophobic residues in the 
gp120 core which stabilizes the envelope trimer structure by reinforcing the 
overall monomeric gp120 structure.  
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To further understand the effect of these mutations, we assessed the 
ability of these envelopes to initiate cell-cell fusion. Correlated with the results of 
the shedding assay, the level of cell-cell fusion was largely reduced by all the 
mutants except the leucine mutations. The isoleucine or phenylalanine to 
Leucine mutations showed a much lower reduction in the fusion, just as they 
showed no major change in gp120 shedding (Figure 3.2.E-H). This reduction in 
fusion is the result of the decrease in envelope stability. The glycine insertion 
mutation caused a significant decrease in envelope fusion as expected (Figure 
3.2.E).  
Finally, to evaluate the effects of these mutations on viral entry, the WT 
and mutant envelopes were used to generate pseudotyped viruses and 
normalized infections based on an RT activity assay were carried out on TZM-bl 
cells. These pseudoviruses are only capable of entering a cell, not replicating, so 
this assay provided a clear picture of the entry process facilitated specifically by 
the envelope trimer. The results followed a very clear trend wherein the glycine 
insertion, alanine and glutamic acid substitution mutations caused a decrease in 
viral entry to the level of background, and an intermediate level of entry was 
achieved in the envelopes with leucine mutations (Figures 3.2.I-L). The leucine 
mutations at positions 307 and 309 did significantly reduce the entry of these 
viruses (Figure 3.2.J, K), although to a lesser degree than the alanine and 
glutamic acid mutations. The leucine mutation at position 317 did not cause a 
significant change in the entry of these single-round viruses (Figure 3.2.L).  
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Importantly, the mutations to the ZM249 V3 loop did not appear to affect 
the ability of this envelope protein to bind CD4. CD4-Ig was used to 
immunoprecipitate labeled gp120 from transfected supernatants, and no 
significant difference in binding compared to an input quantity was observed 
between the WT sample and the mutants (Table 3.1). In this experiment, alanine 
mutations were used to represent the larger panel of hydrophobic patch 
mutations. This indicates that the mutations made did not drastically affect the 
overall shape of the protein regarding the CD4 binding site, and that the reduced 
functionality is not due to impaired CD4 binding. 
 Although the binding of CD4 was not drastically reduced, the binding of 
the alanine mutants to CCR5 was undetectable. This is not surprising, as 
significant reduction in CCR5 binding was also observed in subtype B viruses 
with the same mutations [5]. One of the biological roles of the V3 loop is to 
determine coreceptor usage and form the coreceptor binding site, and mutations 
to this region likely alter the binding to CCR5. A CCR5 expressing cell based 
assay was used in this experiment to bind shed gp120 from the supernatants of 
35S labeled envelope expressing cells. It should be noted that because ZM249 
envelope naturally sheds gp120 at a low level. Because of this, it was difficult to 
detect binding of WT gp120 to CCR5 from the supernatant of WT envelope in 
this assay, so WT HIV-1 YU2 envelope (which does shed rapidly, similar in scale 
to the hydrophobic patch mutants themselves) was used as a positive control (an 
example of these results is shown in Figure 3.3). It is hard to conclude that the 
level of CCR5 binding was reduced in the hydrophobic patch mutations 
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compared to WT, however, the binding between the mutants and CCR5 was 
clearly undetectable, which is likely because the hydrophobic patch mutations 
are a contributing factor to the reduced level of cell-cell fusion and entry. 
Consistent results were obtained when the 1084i envelope strain was 
used to perform the same experiments. Shedding (Figure 3.4.A-D), fusion 
(Figure 3.4.E, G-H) and viral entry (Figure 3.4.I, K-L) of 1084i with the panel of 
mutations at position I309 and F317 follow the same trend as ZM249. Alanine 
and glutamic acid mutations significantly reduced envelope stability, fusion and 
viral entry, which were affected to a lesser degree by leucine mutations. 
However, there were a few notable exceptions at position 307 in 1084i strain. 
The M307L mutation resulted in a significant increase in viral entry which was 
much higher than the WT, though its fusion ability was comparable to the WT. 
Another discordance is that the mutations of M307A and M307E at position 307 
did not cause a significant change in the ability of this envelope to initiate cell-cell 
fusion (Figure 3.4.F, J). For the time being, we do not have an explanation for 
why the M307L mutant has an extremely high level entry or why the 
hydrophobicity reduction mutants at this position of 307, M307A and even M307E 
(a hydrophilic residue change) did not reduce the fusion ability, though increased 
affinity to either CD4 or more likely CCR5 is likely the cause of this change. This 
is certainly an interesting question but further investigation is needed to answer 
it.  
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Alanine Substitution Mutations to the V3 Loop Hydrophobic Patch of HIV-2 
ST Reduce Envelope Stability and Functionality. 
We next assessed the importance of the V3 loop hydrophobic patch in the 
HIV-2 strain, ST. Alanine mutations were made to the amino acid residues at 
positions 307, 309 and 317, and a glycine insertion was made between amino 
acids T303 and R304. As expected, all mutations caused a significant increase in 
gp120 shedding (Figure 3.5.A). As with the HIV-1 subtype C samples, this 
decrease in envelope stability correlated with a decrease in cell-cell fusion 
capability, the mutations significantly reduced the cell-cell fusion to the level of 
background (Figure 3.5.B). It is surprising that the Alanine mutations at positions 
309 and 317 and the 303G insertion showed a significant decrease in the ability 
to bind to CD4-Ig, however, the overall binding of the HIV-2 ST envelope to CD4 
is much lower than HIV-1 [296, 298], so even a minor reduction in binding 
appears to be significant (Figure 3.4.C). Overall, this data suggests that the 
structural role and function of the V3 hydrophobic patch is preserved in HIV-2 
species, supporting our hypothesis.  
 
The role of the V3 loop hydrophobic patch is conserved in nonhuman 
primate lentiviruses. 
To determine whether the structural role of the V3 loop hydrophobic patch 
is also conserved in non-human primate lentiviruses, we tested the effects of 
these mutations in the SIVmac species. We generated a V3 loop glycine 
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insertion mutant, as well as a panel of alanine mutations to each of the residues 
in the hydrophobic patch in the SIVmac239 envelope (Figure 3.1.A), and carried 
out the same assays that were previously described (Figure 3.6.A-D). 
Interestingly, in SIVmac239, the I309A mutations resulted in less gp120 shedding 
than the 303G, V307A and the F317A mutations, as indicated by a much higher 
association index (Figure 3.6.A). This trend correlated with the fusion and entry 
data from these mutations, as fusion of I309A was not significantly different from 
WT envelope (Figure 3.6.B), and there was a much reduced but detectable level 
of entry by the I309A viruses, whereas the other mutations did not facilitate entry 
above background level (Figure 3.6.C). The binding of these envelopes to CD4-
Ig was examined, and the level of binding by the mutants was not significantly 
different, indicating that our mutations did not initiate a major conformational 
change in the protein structure that affected the binding of this envelope to CD4. 
As in ZM249, the V3 mutants did not bind to CCR5 notably. WT SIVmac239 
envelope was undetectable in this assay due to its low level of gp120 shedding, 
so WT YU2 gp120 was used as a positive binding control. The fact that I309 was 
not affected as majorly as the other residues in this strain of SIV is further 
evidence that there is a degree of strain specificity associated with the V3 loop 
hydrophobic patch. Although the role of the patch appears to be well conserved, 
some strains are more capable of carrying less hydrophobic amino acids at these 
positions. Clearly, SIVmac239 is more capable of carrying an alanine residue at 
position 309 than at positons 307 and 317, and is certainly more capable of 
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carrying this mutation than the other PLVs studied in this work, but the role of the 
hydrophobic patch in trimer stability is consistent. 
 
The stability of the SIVagmTan-1 envelope is decreased by alanine 
substitution mutations to the V3 loop hydrophobic patch. 
We also tested another SIV strain, SIVagmTan1, a typical SIV strain that 
naturally infects the African green monkey. A glycine insertion mutation was 
made between residues T303 and V304, and alanine mutations were made to 
each of the hydrophobic patch residues at amino acids 307, 309 and 317. The 
data from the insertion mutant 303G and the three hydrophobic patch mutants 
(V307A, I309A and F317A) supported our hypothesis and showed the same 
effect as in HIV-1. These mutations showed a very clear decrease in envelope 
stability as assessed by gp120 shedding (Figure 3.7.A), and this correlated to a 
significant decrease in cell-cell fusion initiated by these mutant envelopes (Figure 
3.7.B). It is important to note that the overall levels of fusion initiated by the 
SIVagmTan1 envelope was quite low compared to the other strains described 
previously, though the mutations fused at levels very close to background. This 
may be a result of the TZM-bl target cells expressing human, not African green 
monkey, CD4 and CCR5. 
 
Molecular modeling supports the role of the V3-loop hydrophobic patch in 
envelope trimer stabilization. 
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Our observations are supported by structural modeling of the envelope 
trimer complex. According the SOSIP envelope trimer structure in the native 
state (PDB 4ZMJ, [1]), it is clearly seen that the V3 loop (shown in magenta) sits 
in the apex of the trimer, where it plays a role in the association of the trimer 
along with the V2 loop (shown in cyan) (Figure 3.9.A, top-view). The interaction 
of the V2 and V3 loops in the CD4 unbound (native) state is depicted in Figure 
3.9.B-C. The hydrophobic patch residues of the V3 loop sit perfectly in a 
hydrophobic cavity formed by the residues including F159, M161 and V172 in the 
V2 loop, forming a tight hydrophobic contact. Mutation of these residues to 
neutral, or hydrophilic residues disrupts these hydrophobic interactions, resulting 
in destabilization. Additionally, additions to the length of the V3 loop clearly will 
result in a crash of the V3 loop with the V2 loop, disrupting the fit conformation of 
these loops for trimer stability.  
 
DISCUSSION 
 Previously, it has been shown that the V3 loop hydrophobic patch 
influences HIV-1 envelope stability using prototypic HIV-1 subtype B strains [5]. 
This work demonstrates that this conserved sequence region also has a 
conserved function in subtype C HIV-1, HIV-2, and SIV species. In subtype C 
species, we demonstrated that mutation of the hydrophobic residues at amino 
acid positions 307, 309 and 317 to hydrophilic or neutral amino acid residues 
resulted in a significant increase in gp120 shedding into the media, indicating a 
lack of envelope trimer stability. Our data supports envelope trimer structural 
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models, as the V3 loop is consistently packaged into the apex of the envelope 
trimer in these structures [1-3, 210, 211]. This work supports the fact that the V3 
loop plays a structural role, likely stabilizing the envelope monomers to help them 
achieve trimeric conformation.  
The changes seen in gp120 envelope stability correlate very closely to 
functional data. When envelope stability is disrupted by these mutations, similar 
detrimental effects are seen in cell-cell fusion and viral entry. We posit that this is 
an effect of the decreased stability of the envelope complex and a decrease in 
CCR5 binding. Because the mutant envelope trimers are less stable, and 
shedding increases drastically, significantly less envelope protein is present on 
the surface of the cell or the viral particle to facilitate these processes. 
Additionally, molecular modeling predicted that the effects of addition to the V3 
loop and hydrophobic patch will be drastic in both the CD4 unbound and bound 
states. In the unbound state, the hydrophobic patch fits perfectly into the 
hydrophobic cavity of the V2 loop, due to hydrophobic interactions (Figure 3.8). 
Additions to the V3 loop destabilize the envelope trimer because of a crash with 
the V2 loop. This moves the hydrophobic patch out of the hydrophobic cavity, 
and the trimer dissociates due to a lack of stability. CCR5 binding is dependent 
on two contacts with the V3 loop, which are made possible by the conformational 
change initiated by CD4 binding [5, 306]. In the bound state, the V3 loop is 
exposed outside of the envelope trimer. In this bound state, the hydrophobic 
patch contacts the extracellular loop 2 (ECL2) of CCR5, participating in CCR5 
binding. A sulfated tyrosine 14 (sTyr14) at the N-terminus of CCR5 makes 
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contact with N302 which is positioned in the V2 cavity to accommodate this 
sulfated tyrosine in the CD4-bound state [316, 317], and the sulfated tyrosine 173 
(sTyr173) of the V2 loop of gp120 in the unliganded state, for which the 
electrostatic interactions are characterized [318]. The second contact is with the 
ECL2 for the hydrophobic patch by which the non-specific hydrophobic 
interactions are assumed [319-321]. Based on molecular modeling, when 
insertions are made to the loop, the hydrophobic patch is moved into a position 
where it is unable to contact CCR5, and fusion does not occur. The exact nature 
of the interaction between the V3 loop with the ECL2 of CCR5 is unknown, and 
this interaction will be explored in future studies. 
 An interesting result of these studies was found in HIV-1 1084i. A leucine 
substitution to the methionine residue at position 307 resulted in a very significant 
increase in viral entry, and the hydrophilic and neutral substitutions had no effect 
on cell-cell fusion. This is an interesting phenomenon and is likely due to strain 
specificity. 1084i as a pseudovirus does not enter cells at a high level when 
compared to other viruses, so this mutation may be useful when a highly 
infectious subtype C virus is required in the laboratory. Future experiments to 
study this phenomenon would be to substitute other hydrophobic amino acids to 
position 307 to determine whether other amino acids would initiate the same 
effect, though preliminary results do not show the same increased infection 
phenotype with an isoleucine substitution to this residue. 
There are several directions to take the results of this work to better 
improve structural understanding of the envelope proteins of SIV and HIV. The 
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first is to continue to pursue hydrophobic residues that are not part of the V3 
loop, but are close in physical proximity. Importantly, the V3 loop hydrophobic 
patch appears to be part of a much larger hydrophobic region we have coined 
the “hydrophobic core”, which contains elements of both the V1/V2 and V3 loop 
as well as other conserved regions in gp120. It appears that this region plays a 
similar role in HIV envelope structural stability, as mutations to these residues 
cause similar decreases in envelope trimer association. Another area that will be 
interesting to pursue in this research is the idea of species specificity to address 
the reasons why the hydrophobic patch of some primate lentiviral species is 
more capable of carrying mutations than others. It would be very interesting to 
consider the long-term fitness of SIVmac239 carrying an alanine at position 309 
compared to the naturally occurring isoleucine residue. Does a single residue 
change like this affect the pathogenesis of the virus, or is this simply an 
interesting anomaly compared to other species studied in this work? Finally, this 
data will hopefully inform the development of new epitope and envelope trimer 
based vaccines. While not the direct intention of this study, identifying residues 
that could naturally stabilize the envelope in a trimeric state could be exploited in 
the development of a better vaccine against HIV-1.  
In conclusion, our data clearly demonstrates that the V3 loop plays an 
important role in the stabilization of the envelope trimer in primate lentiviruses. 
The envelope trimer stability is controlled, in part, by the length of the V3 loop 
and the positioning of the hydrophobic patch in both the CD4 bound and 
unbound conformations. Additionally, the length of the V3 loop and the 
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hydrophobic patch are essential for proper function of the envelope trimer, 
alterations to either of these results in a very clear reduction of the functionality of 
the envelope. 
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FIGURE 3.1 
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FIGURE 3.1. Alignment of the V3 loop sequences of primate lentiviral 
species. A. Numbering was assigned according to standard HXBc2 numbering, 
which is included as a reference point [322]. The hydrophobic patch residues that 
were altered in the study are shown in yellow, and the location of glycine 
insertions are between the residues indicated by an arrow. B. Structural ribbon 
model of the V3 loop, highlighting the hydrophobic patch. The positions involved 
in the hydrophobic patch are circled in red, and the locations of insertion 
mutations are indicated with an arrow. C. Surface hydrophobicity model of the V3 
loop and hydrophobic patch. The hydrophobic patch residues are indicated by a 
red circle. More hydrophobic areas are indicated in gray, and more hydrophilic in 
blue.  
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FIGURE 3.2. Envelope stability, cell-cell fusion, and viral entry in HIV-1 
ZM249 with hydrophobic patch mutations. (A-D). gp120 shedding assay. 
SDS-PAGE analysis of immunoprecipitated cell lysate and supernatant fractions 
from cells expressing WT or mutant envelope ZM249 proteins. The gp160 and 
gp120 bands are indicated. The association index value was calculated as 
previously reported. Note that the gel shown in Figure 2A has been spliced and 
reformatted for presentation purposes. (E-H). Cell-cell fusion capabilities of the 
WT and mutant envelopes are expressed as percentages based on luciferase 
values as described in the materials and methods section. All figures are 
represented of at least three separate experiments performed with quadruplicate 
values. (I-L). Entry of WT or mutant envelope expressing pseudotyped virus is 
shown as a percentage based on luciferase values as indicated in the materials 
and methods section. All figures are representative of at least three separate 
experiments performed with quadruplicate values. Significance was determined 
by the student’s T-test (*p<0.05). 
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FIGURE 3.3 
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FIGURE 3.3. Example of CCR5 Binding capabilities of hydrophobic patch 
mutations. Soluble monomeric gp120 was taken from the supernatant of WT 
and mutant PLVs and immunoprecipitated with appropriate patient serum to 
determine the input volume of gp120 (top panel). The same volume of 
supernatant was co-incubated with sCD4 and CCR5 expressing Cf2-Th cells for 
one hour. The R5 cells were then isolated, lysed and immunoprecipitation with 
patient serum of this lysate was carried out to determine the amount of CCR5 
bound gp120 (bottom panel). 
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FIGURE 3.4 
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FIGURE 3.4. Envelope shedding, fusion and viral entry of HIV-1 subtype C 
strain 1084i with hydrophobic patch mutations. (A-D). Envelope gp120 
shedding assay. The supernatant and cell lysate fractions of cells transfected with 
WT or mutant 1084i and 35S labeled were harvested and immunoprecipitation was 
performed on each separately using infected patient serum, samples were 
analyzed by SDS-PAGE. The association index was calculated as previously 
described [293]. A low association index is an indicator of a less stable envelope 
complex and an increased level of gp120 shedding. (E-H). Cell-cell fusion assay 
to detect WT and mutant envelope functionality. Each fusion sample was 
performed in quadruplicate wells, and the graph is representative of three separate 
experiments. Significance was determined by using the Student’s T-test (*p<0.05). 
(I-L) The WT and mutant envelope proteins were used to generate single-round 
luciferase tagged viruses and titer was calculated using the RT activity assay. A 
normalized amount of virus was used to infect CD4/CCR5 expressing CF2-Th cells 
and luciferase activity was measured as an indicator of viral entry. This was 
performed with quadruplicate values and the means are representative of three 
separate experiments. Significance was determined using the Student’s T-test 
(*p<0.05). 
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FIGURE 3.5 
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FIGURE 3.5. Envelope stability and cell-cell fusion of alanine substitution 
mutations to the hydrophobic patch of HIV-2 ST. (A). HIV-2 ST WT or mutant 
envelope constructs were expressed in 293T cells, labeled and harvested as 
described in the materials in methods. Immunoprecipitations of the cell lysates 
and supernatants were analyzed by SDS-PAGE. The gel shown is representative 
of three separate experiments, and the association index is the average value of 
those experiments. (B). The cell-cell fusion assay was performed using the WT 
or mutant envelopes and the results are included as a percentage of the WT 
luciferase values. This experiment was performed three separate times in 
quadruplicate. (C). Labeled WT or mutant gp120 protein was precipitated using 
CD4-Ig and the percent binding was calculated by comparing the quantified 
bands to an input immunoprecipitation with HIV-2 ST antiserum. The binding 
ratio of the WT was then compared to the binding ratio of the mutants. This figure 
is representative of three separate binding experiments.  Significance was 
determined by the student’s T-test (*p<0.05). 
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FIGURE 3.6 
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FIGURE 3.6. Envelope stability, viral entry and cell-cell fusion of SIVmac239 
with alanine substitutions to the hydrophobic patch. (A) Envelope protein 
shedding assay was performed by 35S labeling WT or mutant envelopes and 
harvesting the cell lysate and supernatant separately followed by 
immunoprecipitation with SIV patient serum. Association index values presented 
are the average of three separate experiments. (B) Fusion assay is 
representative of Tat-induced luciferase expression following fusion of envelope 
and tat protein expressing 293T cells with TZMbl. Mean cell-cell fusion values 
are representative of three separate experiments performed with quadruplicate 
replicate wells. (C) SIVmac239 pseudoviral particles were generated, and RT 
values were normalized prior to infection. Percent entry was determined by 
luciferase expression. Viral entry experiments were performed three times with 
quadruplicate values. (D) CD4 binding was determined by the amount of 
envelope protein precipitated by CD4-Ig compared to the amount of envelope 
protein bound by SIV infected monkey serum. Significance was determined by 
the student’s T-test (*p<0.05). 
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FIGURE 3.7 
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FIGURE 3.7. V3 loop hydrophobic patch mutations in the stability and 
functionality of the envelope complex of SIVagmTan-1. (A) 35S labeled gp120 
from SIVagmTan-1 precipitated in the supernatant fraction compared to the cell 
lysate fraction of the V3 mutant envelopes. Association index was calculated as 
previously described and is represented as the mean of three separate 
experiments. The immunoprecipitation was performed using a combination of 
SIV infected serum and HIV infected serum to increase pull-down. (B) Fusion 
assay with SIVagmTan-1 envelope was performed as previously described and 
is representative of three separate experiments performed, each with 
quadruplicate values. Significance was determined by the student’s T-test 
(*p<0.05). 
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FIGURE 3.8 
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FIGURE 3.8. Molecular modeling of the HIV envelope trimer and the 
interaction between V3 and V2 loops. (A) HIV-1 trimer structure in the 
unbound (native) state (PDB: 4ZMJ). V3 loop is shown in magenta; V2 loop is 
shown in cyan. (B) Ribbon structure of the V2 and V3 loops showing their 
interaction with emphasis on the V3 hydrophobic patch residues at positions 307, 
309 and 317. (C) V2 surface model showing the hydrophobic cavity (circled in 
cyan) and its interaction with the V3 loop hydrophobic patch. Gray, hydrophobic; 
Blue, hydrophilic.  
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FIGURE 3.9 
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FIGURE 3.9. Molecular modeling of the V3 loop shifting in the CD4 bound 
and unbound state of gp120. Model of superimposed gp120 structures in the 
CD4-unbound (gray) and CD-bound (cyan) states, showing the V3 loop shifting 
from CD4 unbound to the bound state. The hydrophobic patch residues of 307, 
309 and 317 are labeled in red. The V3 base residue N302 is also indicated in 
red. Part of V2 loop in the unbound state is omitted for better presentation of the 
bridging sheet and V3 loop. The X-ray structures used for superimposition are 
PDB: 4ZMJ [1] for the unbound (native) state and PDB: 2QAD [317] for the CD4-
bound state 
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TABLE 3.1 
 
Env and Mutation Association Index a
Cell-cell Fusion 
(Percent) b
Viral Entry 
(Percent) c
CD4 Ig 
Binding d
1084i
 WT 1.00 100.0 100.0 n.d.
303G- 0.50 5.4 * 3.2 * n.d.
322G- 0.56 27.6 * 3.9 * n.d.
M307A 0.77 88.7 16.9 * n.d.
M307E 0.68 93.9 3.6 * n.d.
M307L 1.15 89.8 * 573.5 * n.d.
I309A 0.79 55.7 * 2.5 * n.d.
I309E 0.55 5.0 * 0.7 * n.d.
I309L 1.13 76.1 * 35.9 * n.d.
F317A 0.86 58.6 * 2.7 * n.d.
F317E 0.65 35.2 * 3.4 * n.d.
F317L 1.13 80.7 * 65.2 * n.d.
ZM249M-B10
WT 1.00 100.0 100.0 1.00
303G- 0.15 2.5 * 0.6 * 0.98
I307A 0.08 12.2 * 0.6 * 0.97
I307E 0.05 6.2 * 0.6 * n.d.
I307L 0.29 67.9 * 72.1 * n.d.
I309A 0.08 2.4 * 0.7 * 1.03
I309E 0.13 2.8 * 0.5 * n.d.
I309L 0.82 57.4 * 36.3 * n.d.
F317A 0.13 5.3 * 0.6 * 0.90
F317E 0.21 2.7 * 0.5 * n.d.
F317L 0.40 38.8 * 105.2 n.d.
SIVmac239
WT 1.00 100.0 100.0 1.00
303G- 0.14 11.5 * 1.0 * 0.71
V307A 0.19 49.8 * 1.1 * 1.03
I309A 0.48 99.3 5.0 * 0.92
F317A 0.14 33.5 * 1.2 * 0.89
SIVagmTan1
WT 1.00 100.0 n.d n.d.
303G- 0.45 30.2 * n.d n.d.
V307A 0.41 41.3 * n.d n.d.
I309A 0.46 46.9 * n.d n.d.
F317A 0.53 51.4 * n.d n.d.
HIV-2 ST
WT 1.00 100.0 n.d 1.00
303G- 0.43 6.0 * n.d 0.65
I307A 0.33 8.3 * n.d 1.03
L309A 0.34  5.1 * n.d 0.67
F317A 0.37 6.3 * n.d 0.63
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TABLE 3.1. Phenotypes of primate lentivirus V3 loop mutants. 
a. The association index is a measure of the envelope stability as indicated by 
the amount of radiolabeled WT or mutant gp120 shed into the media. The 
association index was calculated as follows: ([mutant gp120]cell x [wild-type 
gp120]supernatant)/([mutant gp120]supernatant x [wild-type gp120]cell). The association 
index of the mutants is shown as a proportion of the WT envelope, which is set to 
1.0. 
 
b. Cell-cell fusion was assessed by coincubation of 293T cells expressing WT or 
mutant envelope and tat protein with TZMbl target cells in a ratio of 1:1, and 
luciferase was measured. Cell-cell fusion values of the respective WT strains 
were set to 100%, and mutants were expressed as a percentage of the WT 
value. *, indicates significant difference compared to WT Env, as determined by 
student’s T-test (p<0.05).  
 
c. Viral entry was measured as by infecting CD4+CCR5+ cells with replication 
deficient viruses expressing WT or mutant envelope proteins. Luciferase was 
measured as an indication of viral entry. Viral entry values of WT viruses were 
set to 100% and the values for the mutants are shown as a percentage of the WT 
value. *, indicates significant difference compared to WT, as determined by 
student’s T-test (p<0.05). 
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d. CD4-Ig binding of WT gp120 was established by comparing the quantity of cell 
supernatant bound by CD4-Ig to the total gp120 immunoprecipitated by infected 
host serum; values for the mutants were compared to this value. n.d. not 
determined. 
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CHAPTER 4- CHARACTERIZATION OF THE TWIN CYSTEINE MOTIF IN THE 
V2-LOOP REGION OF gp120 IN PRIMATE LENTIVIRUSES 
 
 
 
 
 
 
 
 
 
 
 
 
Data from this chapter were published in Virology, 2018. Volume 519, June 2018, 
Pages 180-189. 
Contributing authors to this publication include:  
Dane Bowder, Jesse Thompson, Kate Durst, Haley Hollingsead, Duoyi Hu, 
Wenzhong Wei, Shi-Hua Xiang  
	 109 
INTRODUCTION 
Based on phylogeographic studies which consider sequence divergence 
and the rate of mutation in HIV, the major group of HIV-1 entered the human 
population via zoonotic transmission into humans by SIVcpz, the SIV species 
that is associated with chimpanzees [122]. Statistical analyses have indicated 
that this transmission event likely occurred in southern Cameroon in the early 
part of the twentieth century [153]. Group M HIV-1 accounts for the vast majority 
of infections with HIV-1, but there have been 4 transmissions of SIVs from 
chimpanzees or gorillas to humans accounting for group O, N and P infections 
[11], though they account for a very small minority of infections with HIV-1 
globally [141, 142, 146, 148, 323]. HIV-2, a typically less pathogenic human 
lentivirus that is restricted primarily to West Africa represents a transmission of 
SIVsmm, the SIV species that primarily infects sooty mangabeys, into humans 
[163, 324]. This transmission of SIV from sooty mangabeys has occurred at least 
eight times, giving rise to eight clades of HIV-2 [164, 165]. Importantly, infection 
with HIV-2 typically does not result in AIDS, though immune suppression is seen, 
albeit to a much lower extent [170]. Patients with HIV-2 also show a marked 
increase in neutralizing antibodies compared to patients infected with HIV-1 [325-
327].  
 It has been well-known for years that the envelope complex of HIV and 
SIVs exist as a trimer of heterodimers, but the structure of this complex was only 
recently solved in 2013. The SOSIP envelope trimer structure, based on the HIV-
1 subtype A strain BG505, is a near native trimer that has an engineered 
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disulfide bridge added to the interface between gp120 and gp41 as well as an 
isoleucine to proline mutation in the heptad repeat 1 (HR1) region of gp41. The 
SOSIP trimer structure was solved through both X-ray crystallography as well as 
cryo-electron microscopy, resulting in a model of the HIV-1 envelope complex at 
an atomic level [1-3]. The development of these high-resolution structures has 
aided in the development of trimer based immunogens that have shown some 
levels of success and specificity by producing higher proportions of autologous 
trimer specific antibodies, though most of these antibodies do not neutralize 
heterologous tier 2 viruses [220]. Generating an immunogen that initiates 
neutralization of a broad spectrum of viruses, including tier 2 viruses is a 
continued challenge, and will be an important feature of a successful vaccine. 
Additionally, these structures have revealed specific epitopes for broadly 
neutralizing antibodies that were previously unknown [328-332]. Further 
understanding of the higher order structure of the envelope glycoprotein 
complex, and its interaction with broadly neutralizing antibodies will be crucial for 
the design of more effective envelope-based vaccine candidates to elicit broadly 
neutralizing antibodies against multiple strains. 
 The HIV envelope region is divided into five conserved regions and five 
variable regions [233, 333]. As their nomenclatures imply, the sequence of the 
conserved regions remains relatively well conserved in different HIV-1 strains, 
and the variable regions have more sequence variability. However, it is now 
known that the variable regions are more conserved than initially suggested, and 
consist of a relatively set number of residues and include conserved features and 
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residues [5, 6, 238, 318, 334]. The length of the variable loops is important for 
viral infection, as insertions or deletions to the loops can result in loss of 
envelope functional activity [238], and deletion of the loops altogether has a 
drastic effect on envelope function [239]. The advent of the envelope trimer 
structure has revealed that the variable loops are packaged into the apex of the 
HIV envelope trimer [2, 3, 275], which is consistent with reports that these loops 
contribute to the stability of the trimer complex [5, 6] and with similar near-atomic 
structure of the uncleaved, membrane-bound envelope trimer [211]. The V2 loop 
is of interest because of its role in envelope stability, and because it is an 
important immunogen in HIV infection. In the modestly successful RV144 Thai 
HIV vaccine trial, protection against infection with HIV correlated with the 
presence of V2 antibodies [247], which has stimulated significant interest in the 
potential of the V2 loop in the design of envelope based vaccines and anti-HIV 
drugs [219, 245, 248, 335]. 
 Recently, our group identified a pair of cysteine residues present in the V2 
loop of SIV species and in HIV-2 that are notably absent from the V2 loop of 
SIVcpz and HIV-1 species. We showed that the removal of this twin-cysteine 
motif (TCM) from SIVmac239 resulted in a major decrease in envelope stability, 
supporting our hypothesis that these cysteine residues form a disulfide bond that 
stabilizes the envelope trimer complex [6]. This study seeks to explore the twin-
cysteine motif in more depth and to characterize its role in more SIV strains and 
in HIV-2. Additionally, this work seeks to determine the impact of adding the TCM 
back to HIV-1 strains.   
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RESULTS 
The removal of the twin cysteine motif from HIV-2/ST results in a decrease 
in envelope stability.  
HIV-2, like SIVmac, is originally derived from SIVsmm [11, 134, 336, 337], 
but unlike HIV-1, the twin-cysteine motif is preserved in HIV-2 through this cross-
species transmission (Figure 4.1). Therefore, it is believed that the twin-cysteine 
motif in HIV-2 strains should play the same role as in SIVmac strains, such as 
SIVmac239. To further characterize the role of the twin cysteine motif in Primate 
Lentivirus (PLV) species where it is naturally present, the cysteines were 
removed by substitution with alanine residues both singly and doubly from the 
HIV-2 ST envelope glycoprotein gp120. A shedding assay was then performed 
on each of these removal mutants, where a clear increase in gp120 shedding (as 
indicated by less gp120 in the cell lysate fraction and more gp120 in the 
supernatant) and a decrease in the association index was seen (Figure 4.2.A). 
This decrease in envelope trimer stability correlated well with a decrease in 
envelope functionality, as the cell-cell fusion capability of these mutations 
dropped to the level of background (Figure 4.2.B). This indicates that the twin 
cysteines play a role in the stability of the envelope trimer in both SIVmac239 
and HIV-2 ST and that this phenomenon is conserved.  
 
Alteration to the twin cysteine motif changes envelope processing in 
SIVagm.  
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The SIVagm lineage is a separate lineage of PLV which is closely related 
to SIVsyk [338]. In this lineage, the twin-cysteine motif is also present in all 
SIVagm strains. For this experiment, SIVagmTan-1 was selected and the TCM 
was removed by substituting the cysteine residues with alanine residues, both 
individually and in tandem. A shedding assay was then performed with these 
mutations, and an unexpected phenotype arose. A clear accumulation of gp160 
and reduction in gp120 in the cell lysate fraction occurred, along with a complete 
absence of gp120 found in the supernatant. It is important to note that 
SIVagmTan-1 already sheds gp120 to the media at a very low level, but in the 
mutations, gp120 was completely undetectable in the supernatant fraction, even 
after extended exposure (Figure 4.3.A). This result seems to indicate a change in 
envelope processing, as it appears that no gp160 is being cleaved into gp120. 
This phenotype also correlated to a major reduction in the processing index, 
further supporting the observation that processing was severely impaired in these 
mutants (Table 4.1).  When the same mutants were used in a fusion assay, there 
was a significant reduction in cell-cell fusion, as was the case with both 
SIVmac239 and HIV-2 ST. This is not surprising, as cleavage of gp160 by furin 
proteases in the Golgi apparatus is required for its functional activity [42, 70, 339, 
340]. The removal of the twin cysteines may directly affect the cleavage site or 
the accessibility for the protease. To further characterize this phenomenon, the 
envelope gene of an additional SIVagm strain, SIVagm155-4, was cloned into 
pCDNA3.1+ by RT-PCR for expression and mutagenesis. This strain also carries 
the twin cysteine motif. These residues were removed by site-directed 
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mutagenesis both individually and doubly. These mutations were then used to 
perform a cell-cell fusion assay, and the same phenomenon was observed as in 
SIVmac239, SIVagmTan-1 and HIV-2 ST. The single and double mutations all 
significantly reduced the fusion capability of these envelopes (Figure 4.3.C). The 
shedding experiment was not performed using agm155, because pull-down of 
this envelope glycoprotein was not achieved using the infected serums available, 
so a more specific SIVagm infected serum would be needed to complete this 
experiment.  
 
Addition of the twin-cysteine motif to the V2 loop of HIV-1 species alters 
processing and reduces envelope functionality.  
To explore the hypothesis that the twin cysteine motif was evolutionarily 
lost during the transition from SIV to HIV-1, the twin cysteine motif was added 
back to HIV-1 species. Because of a well-conserved proline residue in HIV-1 
species, three types of addition mutants were generated. The first was a direct 
substitution of the twin cysteine motif into HIV-1 based on sequence alignment 
(Figure 4.4). This addition mutant substituted proline 183 and serine 191 of HIV-1 
for cysteine residues, coined “SubCC”. Because proline is an amino acid that has 
important structural role in making turns in proteins, insertion mutations to both 
the left and right of proline 183 alongside an insertion mutation between serine 
191 and tyrosine 192 were generated, coined “insL” and “insR” respectively 
(Figure 4.4). The shedding assay using the SubCC and insL mutants in both 
ADA and JRFL revealed another altered processing phenotype. As is the case in 
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SIVagmTan-1, these mutations retain very little gp120 in the cellular fraction, and 
uncleaved gp160 is found at higher levels than in WT. However, in the HIV-1 
SubCC and insL mutations, shedding of gp120 appears to be increased over 
WT, suggesting that any gp120 that is cleaved is released into the supernatant 
immediately. The insR mutants did not exhibit this phenomenon to the same 
extent, so in the case of insR constructs, any changes in envelope shedding do 
not appear to be due to as drastic of an alteration in envelope processing. The 
processing index was calculated from the shedding gels for all of these 
mutations, and the SubCC and insL mutations resulted in a major reduction in 
this value, while the insR mutation showed a value closer to 1.0, indicating a 
lesser effect on envelope processing (Table 4.1).  This was consistent in both 
ADA and JRFL HIV-1 strains (Figures 4.5 A-B). Interestingly, this change in 
envelope processing correlated well with changes in envelope functionality. In 
both ADA and JRFL, the SubCC and insL mutations significantly reduced the 
ability of these envelope proteins to initiate cell-cell fusion, but the insR did not, 
causing only a small, though significant, decrease in JRFL and no significant 
change in ADA (Figure 4.5 C-D). This fusion phenotype correlated with the ability 
of the mutant pseudoviruses to enter cells, as the JRFL insR mutation did not 
deviate significantly from WT, while the SubCC and insL mutations completely 
abolished viral entry. Unlike JRFL, ADA insR mutation did significantly reduce 
viral entry, though the decrease was not as severe as in the case of SubCC and 
insL (Figure 4.5 E-F). This reduction is likely because the unprocessed gp160 is 
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not being expressed on the cell surface, and any gp120 being transported to the 
cell surface appears to be shed into the media.  
To attempt to characterize this altered processing in more detail, a pulse-
chase assay was performed to track the envelope processing of these mutations 
over a period of 8 hours. This assay revealed that at no point after expression of 
the protein is gp120 ever retained in the cell lysate fraction, it is immediately 
shed. This assay did not show the gp160 retention in the cell lysate to the 
extreme level seen in the shedding assay, likely due to the limited amount of 
labeled envelope protein from a one hour pulse label, but did show the same 
gp120 shedding phenotype seen previously (Figure 4.6).  
 
HIV-1 envelopes containing the V2 region from HIV-2 ST and SIVmac239 do 
not exhibit the altered processing phenotype. 
Because SIV species and HIV-2 contain the twin cysteine residues, but do 
not exhibit the altered processing phenotype seen when the twin cysteines were 
added to HIV-1, we added the entire V2 twin cysteine region from SIVmac239 
and HIV-2 ST to both HIV-1 ADA and JRFL species by overlapping PCR as 
described in the methods section and shown in figures 2.1 and 2.2. The HIV-1 
envelopes with the mac239 V2 twin cysteine region did not show any notable 
differences in gp120 shedding, and only HIV-1 ADA with the V2 twin cysteine 
region from HIV-2 ST showed an increase in envelope shedding, JRFL ST V2 
Swap showed no difference in envelope shedding. Importantly, in addition to no 
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change in envelope shedding levels, the processing of these envelopes was 
normal, and gp120 was observed in the cell lysate fraction. When these 
envelopes were used to test cell-cell fusion capabilities, largely, there were no 
significant changes in envelope fusion except for ADA SIVmac239 V2 Swap 
which demonstrated a minor significant increase in envelope fusion (Figure 
4.7.B-C). To further test the phenotype of the V2 swap mutations, the envelopes 
were used to make single round luciferase virus and TZM-bl cells were infected. 
The SIVmac239 V2 Swap constructs did not alter the entry level of these viruses 
when compared to WT, but interestingly, the HIV-2 ST V2 Swap constructs 
caused a significant reduction in viral entry (Figure 4.7.D-E). It is unclear what 
causes this decrease in infectivity, but the slight increase in envelope shedding 
seen in ADA may be the cause. 
 
Molecular modeling shows the formation of a disulfide bond by the TCM in 
SIVmac251 
The twin-cysteine motif is an important feature in envelope trimer stabilization in 
primate lentiviruses, but we cannot know the exact mechanism of how this 
stabilization works since there is no structural information available for the twin-
cysteine region in the V2 loop from any solved monomer or trimer based 
structures. For this reason, we have conducted structural modelling to predict the 
twin-cysteine structure in the model of SIVmac251 envelope trimer generated from 
the HIV-1 SOSIP structure (PDB: 4ZMJ) [1] (Figure 4.8). According to this 
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structural model, the twin-cysteines clearly formed a disulfide bond and generated 
a twin-cysteine loop (TCL), which interacts with the V1 loop. In SIVs, such as 
SIVmac251, the gp120 usually has a large V1 loop which can circle each subunit 
and covers the trimer apex along with the V2 loop (Figure 4.8, 4.9.A-B). The results 
from our gp120 experiments also imply that the twin-cysteines may act through the 
loop motif because the removal of single or double cysteines has the same effect. 
In this structural model, it appears that an intra-subunit disulfide bond can be 
formed, but not an inter-disulfide bond that connects subunits. It is evident that the 
intra-subunit disulfide-bond can help in stabilizing the V2 loop as well as the V1 
loop (Figure 4.9.C and D). In addition, based on the interactions between the TCL 
and the V1 loop (Figure 4.9.E), it is likely that the TCL may have the potential role 
of regulating the V1 loop to affect trimer stability, which is noteworthy for further 
investigation.  
 
DISCUSSION 
 In this study, we have shown that although the twin cysteine motif is 
conserved in primate lentiviruses, and that the effects of removing the twin 
cysteine motif from PLVs where the motif is present are species specific. 
Removal of the twin cysteine motif from HIV-2 ST resulted in a significant loss of 
envelope trimer stability which caused in turn, a reduction in envelope 
functionality. This result agreed with our previously published data, where a 
similar effect was observed in SIVmac239 [6]. Interestingly, removal of the twin 
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cysteine motif from SIVagmTan1 resulted in an altered processing state wherein 
gp160 is not appropriately cleaved into gp120 and presented on the cell surface. 
Because the envelope protein of this virus sheds at a very low level naturally, our 
evidence suggests that this does not cause a decrease in envelope stability, but 
instead a change in the processing of gp160 into gp120. However, the removal of 
this motif did result in a significant decrease in envelope functionality, as 
envelope fusion was reduced to background level in both single and double twin 
cysteine mutations. This indicates that the removal of these residues does affect 
the structure of the envelope protein in a way that renders it non-functional.  
 We also examined the effects of adding this twin cysteine motif back into 
the HIV-1 envelope, where it was lost along the path of evolution from SIVcpz to 
HIV-1. A simple substitution or insertion of these residues into the sequence did 
not stabilize the envelope trimer as we hypothesized. Instead, we saw a 
processing phenotype similar to SIVagmTan-1. In both the ADA and JRFL HIV-1 
strains, the SubCC and insL mutations resulted in an accumulation of gp160 in 
the cell lysate fraction along with a complete lack of cellular gp120 and no major 
change in shed gp120. This indicated that gp120 is produced to a lesser extent 
than in WT HIV-1, and all the protein that was produced was shed, leaving none 
bound to the cell surface. Interestingly, the insR mutation resulted in a 
processing phenotype like WT, though there was a slight increase in gp160 
retention in the cell lysate fraction. This WT processing phenotype correlated to a 
partial or complete rescue of envelope functionality. It is likely that the insR 
sequence of amino acids is closer in functionality to the TCM, when present in 
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SIV, though simply adding this motif to the HIV-1 sequence was not capable of 
stabilizing the envelope trimer to the level of SIV on its own. It is very likely that 
there are compensatory amino acid differences in other parts of the envelope 
sequence that work in cooperation with the TCM to stabilize the envelope trimers 
of SIV and HIV-1. The advent of high resolution structures of HIV-1 will help to 
dissect this interaction, though comparisons with an equally high resolution 
structure of an SIV or HIV-2 species where the motif is present will be essential 
to truly understanding how these structures differ. Our modeling does suggest 
that the TCM indeed forms an intra-disulfide bond that stabilizes the gp120 
monomer, and can be used to identify additional trimer stabilizing features of the 
SIV and HIV-2 envelope proteins.  
 Processing changes were found consistently in these experiments, 
thought the exact effects that these mutations have on envelope processing 
remain unknown. Our pulse chase data reveal that at no point is soluble gp120 
found in the cellular fraction, and that all gp120 that is produced is released into 
the media. Future experiments would be needed to elucidate the role that this 
region of the V2 loop is playing in HIV envelope processing, but it is possible that 
an alteration to the overall structure of the gp120 molecule is reducing the furin 
recognition of the envelope protein. It seems unlikely that these mutations 
directly alter the furin recognition site however, as the furin protease cleaves the 
gp160 at the junction between gp120 and gp41, which is distant from the V2 
loop. It is more likely that an overall change in the flexibility or structure of the 
envelope protein could cause this site to be masked in some way, or cause a 
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level of allosteric interference. Antibody binding and structural experiments would 
be necessary to fully understand this process.  
 Identifying the role of features within the envelope sequence that 
contribute to the stability of the trimer is an important step in developing an 
effective trimer based envelope vaccine. Many important broadly neutralizing 
HIV-1 antibodies, like PG9, PG16, and PGT-145, target trimer specific 
quaternary epitopes so targeting the immune response to these epitopes only 
found when the envelope is in the unbound trimeric state is crucial [225, 243, 
274, 328]. Previous vaccines that have attempted to do this have largely failed, 
though the advent of the SOSIP structure is likely to enhance the generation of 
whole trimer-based and trimer-specific epitope based vaccines. 
 In the future, it will be interesting to investigate the twin cysteine motif in 
more depth in the population of SIVcpz envelope proteins. The TCM is present in 
a few SIVcpz species, but is largely not present in most published sequences. It 
is also important to note that SIVcpz causes a much more drastic disease in its 
natural host than other SIVs, notably SIVagm and SIVsmm [126, 341, 342]. 
SIVcpz results in CD4+ T cell depletion and studies suggest that naturally 
infected chimpanzees have a much higher mortality rate than their uninfected 
counterparts [343]. Based on sequence analysis, it seems like the twin cysteine 
motif was lost within the SIVcpz population, so it will be interesting to see if the 
presence of this motif correlates with changes in pathogenesis. It will also be 
important in future studies to examine how the twin-cysteine motif is involved in 
stabilization of the envelope trimer since the structures of SIV or HIV-2 envelope 
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are yet to be solved. According to our modelling, the twin-cysteines form a 
disulfide-bond that can stabilize this region in the V2 loop. It is also anticipated 
that this twin-cysteine loop can interact with the V1 loop, which is able to exert its 
effect for stabilization on the apex of the trimer. It seems possible that the 
alteration of the twin-cysteine motif may destabilize the whole envelope complex 
by disrupting the interaction of these two loops, causing a massive destabilization 
of the envelope complex. Interestingly, the SIV V1 loop has been shown to be 
immunodominant, and a linear neutralizing epitope in the SIV V1 loop region has 
been identified [344, 345]. Additionally, the interactions between V1 and V2 
appear to be significant for virus genetic diversity in nature [346]. The lengths of 
the major loops (V1, V2 and V3) of HIV-1 are indispensable for envelope 
structural integrity and virus entry [239], and their variation are also found to be 
involved in viral envelope function and disease progression [347]. 
 It will also be important in future studies to examine how the twin cysteine 
motif interacts with surrounding residues. Results described in chapter 3 of this 
work explain that the V2 and V3 loops fit together in a key-in-lock conformation, 
with hydrophobic residues of both the V2 and V3 loops forming a hydrophobic 
core at the center of the gp120 molecule. It seems possible that the alteration of 
the twin cysteine motif may destabilize the whole envelope complex by disrupting 
the interaction of these two loops, and in turn potentially the core of the gp120 
molecule, causing a massive destabilization of the envelope complex. Further 
mutational studies should be performed in this region to verify the structural 
importance of the hydrophobic core.  
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FIGURE 4.1 
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FIGURE 4.1. Alignment of the primate lentiviral species V2 loops. This 
alignment shows the presence of the twin cysteine motif in SIV species and HIV-
2 and the notable absence of the residues in HIV-1. The amino acids involved in 
the TCM are highlighted in yellow. 
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FIGURE 4.2 
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FIGURE 4.2. Effects of the removal of twin cysteines from HIV-2 ST on 
envelope stability and envelope fusion. (A). The twin cysteine residues of 
HIV-2 ST were substituted for alanine residues by site directed mutagenesis 
individually (C183A, C191A) or in tandem (C183A/C191A) and a shedding assay 
were performed to determine the effect on envelope stability. The association 
index was calculated as previously described [293] and is shown below the 
shedding gel, values are representative of the average of three separate 
experiments. (B). The same mutants were used to perform a fusion assay (as 
described in the materials and methods as well as chapter 2), and the results are 
included as a percent of WT. Significance was determined by Student’s T-test 
(p≤0.05).  
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FIGURE 4.3 
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FIGURE 4.3. Effects of the removal of the twin cysteine motif from 
SIVagmTan-1 and SIVagm155 on envelope stability and envelope fusion. 
(A). Alanine substitutions were made to the twin cysteine motif individually 
(C183A, C191A) or in duplicate (C183A/C191A) and the mutants were used to 
express protein followed by metabolic labeling with 35S and a shedding assay. 
Because gp120 was not detectable and is required to determine the association 
index, it was not calculated. The image shown is representative of three separate 
experiments. (B). The same SIVagmTan-1 mutations were used to perform a 
fusion assay. (C). Fusion assay was also performed on twin-cysteine removal 
mutants in an additional SIVagm strain, agm155. Experiments were performed 
three separate times in quadruplicate. Significance was determined by Student’s 
t-test (p≤0.05). 
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FIGURE 4.4 
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FIGURE 4.4. Diagram of the twin cysteine addition mutants in HIV-1. 
Alignment demonstrates the positioning of the twin cysteine mutations addition 
mutants in JR-FL and ADA (not shown). Numbering is based on the standard 
HXBc2 numbering system. SubCC, direct substitution of P183 and S191 with 
cysteine residues; insL, insertion of the cysteines to the right of 183 proline (P183) 
residue and between S191 and Y192; insR, insertion of cysteines to the left side 
of 183 proline (P) and between S191 and Y192; TCM swap, replaced the whole 
corresponding region from TCM element of other species.  
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FIGURE 4.5 
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FIGURE 4.5. Addition of the twin-cysteine motif to HIV-1 strains in envelope 
processing and envelope function. (A-B). Twin cysteine mutations were added 
to the envelopes of HIV-1 strains ADA and JR-FL and the mutants were 
expressed in 293T cells followed by 35S labeling and shedding assay. Because 
gp120 was undetectable in the CL fractions of most of the mutants, the 
association index was not calculated. Each gel is representative of three 
separate experiments. (C-D). Readdition mutations were used to conduct a 
fusion assay. Fusion of the mutants is shown as a percentage of the WT. Effector 
cells transfected with Tat only were used as a negative control for this 
experiment. (E-F). Mutants were used to produce single-round luciferase tagged 
viruses which were quantified by RT assay. Normalized quantities of virus based 
on RT value were used to infect TZM-bl cells. Cells were mock infected with 
media alone as a negative control for viral entry. Mutants are shown as a 
percentage of the WT virus. In the case of the fusion and entry assays, 
significance was determined using the Student’s t-test (p≤0.05). 
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FIGURE 4.6 
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FIGURE 4.6. Processing of gp120 in ADA twin cysteine substitution 
mutants. Pulse chase assay was performed to characterize the processing error 
seen in readdition mutants. Cells were transfected with ADA WT or ADA SubCC 
and the following day were pulse labeled with 35S-cys-met containing media for 1 
hour followed by replenishment with unlabeled complete media. After the pulse, 
the supernatants and cell lysate were harvested from each well separately at 0, 
2, 4 and 8 hours’ post followed by IP with HIV infected patient serum.  
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FIGURE 4.7 
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FIGURE 4.7. Envelope gp120 shedding, fusion and viral infectivity in HIV-1 
SIVmac239 and HIV-2 ST V2 Swap Mutants. (A). The shedding of the V2 swap 
mutants in both ADA and JRFL were investigated. The envelope constructs were 
expressed in 293T cells in a 6 well plate, were 35S labeled and the supernatants 
and cell lysates from each well was harvested separately and 
immunoprecipitation with infected patient serum was performed on each fraction 
followed by analysis via SDS-PAGE. The association index is included below. (B-
C). Following shedding analysis, the same envelope constructs (B- ADA, C-
JRFL) were investigated for their ability to initiate cell-cell fusion. Mutant cell-cell 
fusion is expressed as a percentage of WT fusion. Cells expressing only Tat 
served as a negative control in this experiment. (D-E). V2 swap mutants were 
also used to generate single round, luciferase tagged HIV-1, were normalized by 
RT assay and used to infect TZM-bl cells. V2 swap envelope viral entry is 
expressed as a percentage of WT. Cells were mock infected with non-virus 
containing DMEM as a negative control in these experiments. In both the fusion 
and infectivity assay Student’s T-test was used to determine statistical 
significance (p≤0.05). 
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FIGURE 4.8 
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FIGURE 4.8. Molecular modeling of the SIV Envelope Trimer. Model of SIV 
envelope trimer from SIVmac251 (sequence accession number: M19499) based 
on the HIV-1 SOSIP structure (PDB: 4ZMJ) [1]. The V2 loop is colored in cyan and 
the twin-cysteine loop (TCL) in magenta.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 139 
FIGURE 4.9 
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FIGURE 4.9. Molecular modeling of the twin-cysteine loop in SIVmac251 
envelope. (A-B) The relationships of V1, V2 and TCM in the envelope trimer 
apex based on the model of the SIV envelope trimer of SIVmac251 depicted in 
figure 9. (C-E) The twin-cysteine loop (TCL), disulfide-bond and the interactions 
between TCM and V1 loop. The V2 loop is depicted in cyan, the V1 loop is 
depicted in gray. The TCL is shown in magenta and the disulfide bond formed by 
the TCM is shown in orange. 
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TABLE 4.1 
 
 
 
 
 
Association 
Index a
Processing 
Index b
Cell-cell 
Fusion (%) c
Infectivity 
(%) d
HIV-2 ST
WT 1 1 100 n.d.
C183A 0.36 0.63 11.82 n.d.
C191A 0.36 0.36 10.26 n.d.
C183A/C191A 0.26 0.69 10.73 n.d.
SIVagmTan1
WT 1 1 100 n.d.
C183A 0.89 0.18 27.24 n.d.
C191A 0.73 0.24 28.96 n.d.
C183A/C191A 0.69 0.19 34.11 n.d.
SIVagm155
WT n.d. n.d. 100 n.d.
C183A n.d. n.d. 7.45 n.d.
C191A n.d. n.d. 4.06 n.d.
C183A/C191A n.d. n.d. 5.98 n.d.
HIV-1 ADA
WT 1 1 100 100
SubCC 0.4 0.38 0.96 3.21
insL 0.31 0.42 0.66 3.27
insR 0.67 0.65 102.08 15.62
Mac V2 Swap 0.7 0.58 127.11 133.27
ST V2 Swap 0.38 0.63 93.44 45
HIV-1 JRFL
WT 1 1 100 100
SubCC 0.1 0.36 28.85 1.58
insL 0.21 0.47 8.28 0.61
insR 0.49 0.87 86.56 88.28
Mac V2 Swap 1.16 1.12 110.63 102.44
ST V2 Swap 0.94 1.02 88 67.27
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TABLE 4.1. Phenotypes of primate lentivirus twin cysteine mutants. 	
a. gp120 shedding assays were performed by immunoprecipitating 35S labeled 
gp120 from the cell lysate and supernatant fractions of WT or mutant env 
expressing 293T cells. Bands for gp120 in the cell lysate and supernatant were 
quantified and the association index was calculated using the equation ([mutant 
gp120cell * WT gp120supernatant] / [mutant gp120supernatant * WT gp120cell]). A lower 
association index indicates a lower level of gp120 association with the cells. Each 
association index value is the representative average of three separate 
experiments. 	
b. gp120 processing index was calculated from gp120 shedding gels. 293T cells 
expressing 35S labeled WT or mutant env protein were analyzed by SDS-PAGE 
and the bands for gp160 in the cells, gp120 in the cells and gp120 in the 
supernatant were quantified. The processing index was then calculated using 
these values using the equation, ([total gp120mutant * gp160WT] / [total gp120WT * 
gp160mutant]). Each processing index value is the representative average of three 
separate experiments. 	
c. Cell-cell fusion was calculated by cotransfecting 293T effector cells to express 
WT or mutant env and HIV-1 tat. These cells were counted and coincubated with 
target TZMbl cells at a ratio of 1:1. TZMbl cells stably express CD4 and CCR5 as 
well as the gene for luciferase under a Tat-inducible promoter. Following 
coincubation, luciferase values were determined. WT cells were set to 100% 
fusion, and the mutants were expressed as a percentage. Each value is the mean 
of three separate experiments performed in triplicate. 	
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d. Viral infectivity values were determined by producing single round, replication 
deficient viruses expressing WT or mutant envelope proteins. These viruses were 
quantified based on reverse transcriptase activity, and normalized volumes were 
used to transduce TZMbl cells. Luciferase values were measured, and the WT 
virus values were set to 100%, and mutants were normalized to these values. Each 
value represented in the table is the representative mean of three separate 
experiments performed with quadruplicate replicate values. 	
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CHAPTER 5- CONCLUDING REMARKS AND FUTURE DIRECTIONS 
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Despite tireless efforts and decades of research, HIV continues to be a global 
health crisis, with 36.7 million people living with the virus, 1.8 million new 
infections and 1.0 million AIDS related deaths in 2016. Due to the use of  
antiretroviral therapy (ART) and education about HIV/AIDS, new infections and 
death rates are declining, but the effects of this virus are still staggering [8]. 
Despite the advent of more effective antiretroviral drugs and effective pre-
exposure prophylactic drugs, an effective vaccine is critical to preventing new 
infections and to stopping the HIV epidemic. The HIV envelope protein, as the 
primary antigen of the virus is a prime candidate for the development of a 
vaccine, and has been the subject of extensive vaccine trials and studies, though 
these trials have shown limited success [247, 273, 278]. One of the targets of 
many recent vaccine studies is the generation of broadly neutralizing antibodies, 
many of which target quaternary, trimer-specific epitopes [244, 274, 277, 330]. 
An important idea that currently permeates the literature is that soluble trimeric 
envelope immunogens will elicit the production of these antibodies more 
effectively than monomeric envelope [273, 278]. This is supported by the fact that 
envelope gp120 oligomers induce a more potent immune response than 
monomers [271, 276, 348].To this end, several groups have attempted to use the 
SOSIP soluble envelope trimer as an immunogen and preliminary studies have 
resulted in the promising production of antibodies, some of which are trimer 
specific, though a consistent broadly neutralizing heterologous response is yet to 
be seen, so more research must be done [219, 220, 257]. Advancements in 
structural biology have yielded a near atomic structure of a soluble envelope 
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trimer, which has furthered our understanding of the assembly and structure of 
this trimer, including confirmation that the variable loops are packaged into the 
apex of the trimer as a part of the trimer association domain [1-3, 275]. Trimer 
based immunogens and trimer-specific epitope based vaccines are promising in 
the generation of a sterilizing vaccine, and will likely include features of the trimer 
association domain, including the V2 and V3 loops [4]. To successfully generate 
these immunogens, it will be crucial to understand the features of the envelope 
protein that actively contribute to the stability of the envelope trimer complex. 
The aim of this work was to further investigate the role of the variable regions 
V3 and V2 in envelope trimer stability by focusing on two motifs: the hydrophobic 
patch in the V3 loop, which is conserved in all PLVs; and the Twin Cysteine motif 
(TCM) that is found in the V2 loop of SIVs and HIV-2, but is notably absent from 
HIV-1. We sought to investigate the roles of these specific amino acids by 
performing mutational studies that remove these motifs when present, and 
introduce them when absent, followed by observation of envelope stability and 
functionality. Our hypothesis that the V3 loop hydrophobic patch is conserved in 
function was largely supported by our results. Our hypothesis that the twin 
cysteine motif in the V2 loop contributes to envelope trimer stability was 
supported and revealed an additional crucial role for this motif in appropriate 
envelope processing. We also sought to add this motif back to HIV-1 to 
determine whether this motif could stabilize the envelope trimer in HIV-1 and 
again found that this region is critical for envelope functionality and processing. 
Altogether, the molecular data generated in these studies strongly supports the 
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structural models published. This demonstrates that the variable loops, which 
were often disregarded in early structural studies, are indeed important structural 
components of the PLV envelope trimer. 
The V3 loop has been shown previously to be involved in trimer stability in 
HIV-1 subtype B species [5]. In chapter 3, we expanded on this knowledge, 
demonstrating the same results in subtype C HIV-1, but also in an HIV-2 strain 
as well as in SIVs from two species. We show that the length of V3 loop is 
important across PLV species, and insertions to the V3 loop cause a massive 
destabilization of the envelope complex resulting in high amounts of shedding of 
gp120 into the media. The hydrophobic patch of the V3 loop is conserved in 
sequence in subtype C HIV-1, HIV-2 and SIVs, and we have shown that it is also 
conserved in function. Disruption of the residues involved in this motif by site 
directed mutagenesis causes a decrease in envelope stability, evidenced by 
increased shedding of gp120 into the media. This decrease in envelope trimer 
stability correlated with a decrease in envelope functionality evidenced by cell 
fusion and viral entry. The hydrophobicity and space filling nature of the residues 
is especially important. Substitution of the residues in this patch with hydrophilic 
and small neutral amino acids resulted in the most drastic decrease in envelope 
stability, while substitution with alternative hydrophobic residues partially rescued 
this reduced stability. Altogether, these results indicate that the hydrophobic 
patch has been conserved through the evolutionary history of HIV. The 
hydrophobic patch represents an important conserved motif within the variable 
loop, in addition to the previously characterized conserved features [234]. Part of 
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this dissertation is the exploration of a phenomenon present in HIV-1 subtype B 
and subtype C. Because of the differences in pathogenesis, transmission and 
antigenic capabilities shown in subtype C, and because of the high prevalence of 
this subtype, it is paramount that more studies explore the differences in subtype-
C viruses. A successful anti-HIV vaccine or novel viral inhibitor will need to be 
functional against all viral subtypes and strains to be truly effective.  
We propose that the hydrophobic patch plays an important role in trimer 
stability, but also in functionality in both the CD4 bound and unbound 
conformations. Based on modeling, in the unbound conformation, the V3 loop 
hydrophobic patch is clearly positioned within a hydrophobic cavity in the V2 
loop, which cradles and supports the V3 loop. This interaction helps to stabilize 
the envelope trimer (Figure 3.8). When insertions are made to the length of the 
V3 loop, this initiates a crash of the V3 loop with the V2 loop, where the 
increased length of the V3 loop presses against the V2 loop, destabilizing the 
trimer. Also, because this interaction is reliant on hydrophobic interactions, 
mutation of these hydrophobic residues to hydrophilic or neutral amino acids 
reduces this interaction, also destabilizing the trimer. In the CD4 bound 
conformation, the V3 loop is rearranged and exposed outwardly where it 
participates in forming the CCR5 binding site. Contact with the V3 loop is 
dependent on a specific V3 loop length, which is supported by the fact that the 
length of the V3 loop is very well conserved at approximately 35 residues. The 
V3 loop has been demonstrated to contact CCR5 via residues both in the base 
and crown, and indicate that the length of the V3 loop is crucial to this function 
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[349-351]. The exact nature of the contacts between the V3 loop and CCR5 are 
still unknown since a complex structure of gp120 bound to CCR5 or CXCR4 is 
unavailable, so additional structural studies will be required to fully characterize 
this interaction.  
Chapter 4 describes the role of the TCM in envelope trimer stability. Our data 
clearly demonstrates that this motif is not evolutionarily conserved in HIV-1 from 
SIV (Figure 4.1). Disruption of the TCM in PLVs in the SIVsm lineage clearly 
cause a reduction in envelope trimer stability that correlated with a decreased 
functionality, which is demonstrated by a reduction in cell-cell fusion. 
Interestingly, in SIVagm species, this motif is conserved, but the removal of this 
motif results in an unexpected change in envelope processing, as indicated by a 
stronger presence of uncleaved gp160 in the cellular fraction, with no detectable 
gp120 protein in either the cells or the supernatant. Similarly, the addition of the 
twin cysteine motif back to HIV-1 species also resulted in a similar processing 
phenotype, though it appears that any processed gp120 is immediately shed into 
the media. As expected based on this envelope stability profile and lack of gp120 
at the cell surface, cell-cell fusion and viral entry were abolished by these 
mutations. The exact mechanism by which processing is altered is unknown, but 
is unexpected as furin proteases cleave gp160 at a conserved Lys/Arg-X-
Lys/Arg-Arg motif located at the junction of gp120 and gp41, approximately 
amino acid positions 516 [42, 339]. This process could be affected either directly 
via forming a barrier to the cleavage site, or indirectly by blocking the furin 
protease accessibility. It should be investigated further through additional 
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processing studies and additional mutational configurations. The release of high 
resolution structures of the trimer, and the experimental data that we gathered 
suggest that a bond is indeed formed by the TCM within the envelope monomer. 
The TCM appears to contact the V1 loop to stabilize the envelope trimer 
structure. Removal of this bond from some PLV species may also change the 
conformation of envelope and leading to masking of the cleavage site, thus 
altering the processing of the envelope protein in SIVsyk/SIVagm lineage. 
Additional experiments should be performed in SIVcpz species, as this is the only 
PLV species where the TCM is present in some strains and absent in others. It is 
likely that the TCM was lost in the process of evolution from SIVcpz to HIV-1, and 
this would be an interesting problem to explore further. Regardless of the 
phenotype, we have shown clearly that the TCM is critical for the stability and 
functionality of the envelope protein of PLVs, though its exact role differs within 
PLV lineages. 
Structural analysis of the HIV envelope trimer has shown that the V2 and V3 
loops are packaged together in apex of the trimer, and that the V3 loop is cradled 
by the V1/V2 loop, forming the trimer association domain (Figure 3.7) [1-3, 211]. 
Despite contributing to the formation of the trimer association domain, there have 
been relatively few studies in the literature that demonstrate the V2 and V3 loops 
contribution to trimer association aside from previous work by our laboratory [5, 
6]. The V2 and V3 loops sit atop a larger conglomerate of hydrophobic residues 
that we have preliminary coined the hydrophobic core. Molecular modeling has 
elucidated that the hydrophobicity of these residues is crucial to maintain gp120 
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structure and stability, and a future direction for this research would be to perform 
similar mutational studies with these residues to validate our modeling, and to 
further explore the interaction of the variable loops located in the apex of the 
trimer with more deeply buried hydrophobic residues in the gp120 core. 
In conclusion, the work shown in this dissertation has further characterized 
the role of the variable loops in the stability of the envelope trimer of primate 
lentiviruses. The studies presented here are basic research into the overall 
structure of the envelope protein of primate lentiviruses and the role of the 
variable loops in maintaining these structures. While the goal of this work was not 
to directly create an HIV immunogen, the knowledge garnered from these studies 
could be used to aid in the stabilization of the HIV envelope trimer for this 
purpose. This work took a broad approach to this problem by exploring amino 
acid motifs that were thought to play a role in envelope stability, by performing 
mutational studies and molecular analysis in subtype C HIV-1, HIV-2 and SIV 
species to further the understanding of the PLV envelope structure and function. 
Because a neutralizing vaccine against HIV is still unavailable, understanding the 
biology of the envelope protein, the primary immunogen on the virus, is crucial. 
This work contributes to the understanding of the stabilization of the envelope 
trimer and will hopefully aid in the development of epitope and trimer-based 
vaccines and antiviral therapies.  
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APPENDIX A- Primers for ZM249 V3 Loop Mutagenesis 
 
	 
 
 
 
 
 
 
 
 
 
 
Env and Mutation Direction Primer Sequence (5'-3')
HIV-1 ZM249M_B10
F cgacccaataataatacaggaagaaaaagtataaggata
R tatccttatactttttcttcctgtattattattgggtcg
F cccaataataatacaagaaaaagtgcaaggataggaccaggacaaacattc
R gaatgtttgtcctggtcctatccttgcactttttcttgtattattattggg
F aataatacaagaaaaagtgaaaggataggaccaggacaa
R ttgtcctggtcctatcctttcactttttcttgtattatt
F cccaataataatacaagaaaaagtttaaggataggaccaggacaaacattc
R gaatgtttgtcctggtcctatccttaaactttttcttgtattattattggg
F ccaataataatacaagaaaaagtataagggcaggaccaggacaaacattctatgcaacagg
R cctgttgcatagaatgtttgtcctggtcctgcccttatactttttcttgtattattattgg
F ccaataataatacaagaaaaagtataagggaaggaccaggacaaacattctatgcaacagg
R cctgttgcatagaatgtttgtcctggtccttcccttatactttttcttgtattattattgg
F acaagaaaaagtataaggctaggaccaggacaaacattc
R gaatgtttgtcctggtcctagccttatactttttcttgt
F ggataggaccaggacaaacagcctatgcaacaggagaaataatagg
R ctatttttcctattatttctcctgttgcataggctgtttgtcctggtcctatccttatactttttc
F ataggaccaggacaaacagagctatgcaacaggagaaat
R atttctcctgttgcatagctctgtttgtcctggtcctat
F ggataggaccaggacaaacattgtatgcaacaggagaaataatagg
R cttatttttcctattatttctcctgttgcatacaatgtttgtcctggtcctatccttatactttttc
Env and Mutation Direction Primer Sequence (5'-3')
HIV-1 1084i
F aggcccaacaataatacaggtaggaaaagtatgaggatag
R ctatcctcatacttttcctacctgtattattgttgggcct
F ttctatgcaacaggagaaggtataataggaaatataaga
R tcttatatttcctattataccttctcctgttgcatagaa
F aataatacaaggaaaagtgcaaggataggaccaggacaa
R ttgtcctggtcctatccttgcacttttccttgtattatt
F aataatacaaggaaaagtgagaggataggaccaggacaa
R ttgtcctggtcctatcctctcacttttccttgtattatt
F aataatacaaggaaaagtcttaggataggaccaggacaa
R ttgtcctggtcctatcctaagacttttccttgtattatt
F acaaggaaaagtatgagggcaggaccaggacaagcattc
R gaatgcttgtcctggtcctgccctcatacttttccttgt
F acaaggaaaagtatgagggagggaccaggacaagcattc
R gaatgcttgtcctggtccctccctcatacttttccttgt
F acaaggaaaagtatgaggcttggaccaggacaagcattc
R gaatgcttgtcctggtccaagcctcatacttttccttgt
F ataggaccaggacaagcagcatatgcaacaggagaaata
R tatttctcctgttgcatatgctgcttgtcctggtcctat
F ataggaccaggacaagcagagtatgcaacaggagaaata
R tatttctcctgttgcatactctgcttgtcctggtcctat
F ataggaccaggacaagcactttatgcaacaggagaaata
R tatttctcctgttgcataaagtgcttgtcctggtcctat
Env and Mutation Direction Primer Sequence (5'-3')
HIV-2 ST
F aagaggccaggaaacaagacaggggttgtaccaataacactcatg 
R catgagtgttattggtacaacccctgtcttgtttcctggcctctt 
F ggaaacaagacagttgtaccagcaacactcatgtcagggttagtg 
R cactaaccctgacatgagtgttgctggtacaactgtctgtttcc
F aagacagttgtaccaataacagccatgtcagggttagtgtttcac 
R gtgaaacactaaccctgacatggctgttattggtacaactgtctt  
F cactcatgtcagggttagtggctcactcccagccaatcaatag
R ctattgattggctgggagtgagccactaaccctgacatgagtg 
Env and Mutation Direction Primer Sequence (5'-3')
SIVmac239
F agaccaggaaataagacaggggttttaccagtcaccatt
R aatggtgactggtaaaacccctgtcttatttcctggtct
F aataagacagttttaccagccaccattatgtctggattg
R caatccagacataatggtggctggtaaaactgtcttatt
F caggaaataagacagttttaccagtcaccgctatgtctggattggttttccactcacaacc
R ggttgtgagtggaaaaccaatccagacatagcggtgactggtaaaactgtcttatttcctg
F cagtcaccattatgtctggattggttgcccactcacaaccaatcaatgataggcc
R ggcctatcattgattggttgtgagtgggcaaccaatccagacataatggtgactg
Env and Mutation Direction Primer Sequence (5'-3')
SIVagmTan-1
F agaccaggaaataagacaggggtcttaccagtaaccatc
R gatggttactggtaagacccctgtcttatttcctggtct
F aataagacagtcttaccagcaaccatcatggcaggtctc
R gagacctgccatgatggttgctggtaagactgtcttatt
F acagtcttaccagtaaccgccatggcaggtctcgtgttc
R gaacacgagacctgccatggcggttactggtaagactgt
F atcatggcaggtctcgtggcccactcacaacaatataat
R attatattgttgtgagtgggccacgagacctgccatgat
303 G Insert
I307A
I307E
I307L
I309A
I309E
I309L
F317A
I309E
322 G Insert
I309L
F317A
F317E
F317L
303 G Insert
M307A
M307E
M307L
I309A
F317A
F317E
303 G Insert
303 G Insert
V307A
I309A
F317A
F317A
I309A
V307A
F317L
V307A
I309A
303 G Insert
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APPENDIX B- Primers for 1084i V3 Loop Mutagenesis 
	 
 
 
 
 
 
 
 
Env and Mutation Direction Primer Sequence (5'-3')
HIV-1 ZM249M_B10
F cgacccaataataatacaggaagaaaaagtataaggata
R tatccttatactttttcttcctgtattattattgggtcg
F cccaataataatacaagaaaaagtgcaaggataggaccaggacaaacattc
R gaatgtttgtcctggtcctatccttgcactttttcttgtattattattggg
F aataatacaagaaaaagtgaaaggataggaccaggacaa
R ttgtcctggtcctatcctttcactttttcttgtattatt
F cccaataataatacaagaaaaagtttaaggataggaccaggacaaacattc
R gaatgtttgtcctggtcctatccttaaactttttcttgtattattattggg
F ccaataataatacaagaaaaagtataagggcaggaccaggacaaacattctatgcaacagg
R cctgttgcatagaatgtttgtcctggtcctgcccttatactttttcttgtattattattgg
F ccaataataatacaagaaaaagtataagggaaggaccaggacaaacattctatgcaacagg
R cctgttgcatagaatgtttgtcctggtccttcccttatactttttcttgtattattattgg
F acaagaaaaagtataaggctaggaccaggacaaacattc
R gaatgtttgtcctggtcctagccttatactttttcttgt
F ggataggaccaggacaaacagcctatgcaacaggagaaataatagg
R ctatttttcctattatttctcctgttgcataggctgtttgtcctggtcctatccttatactttttc
F ataggaccaggacaaacagagctatgcaacaggagaaat
R atttctcctgttgcatagctctgtttgtcctggtcctat
F ggataggaccaggacaaacattgtatgcaacaggagaaataatagg
R cttatttttcctattatttctcctgttgcatacaatgtttgtcctggtcctatccttatactttttc
Env and Mutation Direction Primer Sequence (5'-3')
HIV-1 1084i
F aggcccaacaataatacaggtaggaaaagtatgaggatag
R ctatcctcatacttttcctacctgtattattgttgggcct
F ttctatgcaacaggagaaggtataataggaaatataaga
R tcttatatttcctattataccttctcctgttgcatagaa
F aataatacaaggaaaagtgcaaggataggaccaggacaa
R ttgtcctggtcctatccttgcacttttccttgtattatt
F aataatacaaggaaaagtgagaggataggaccaggacaa
R ttgtcctggtcctatcctctcacttttccttgtattatt
F aataatacaaggaaaagtcttaggataggaccaggacaa
R ttgtcctggtcctatcctaagacttttccttgtattatt
F acaaggaaaagtatgagggcaggaccaggacaagcattc
R gaatgcttgtcctggtcctgccctcatacttttccttgt
F acaaggaaaagtatgagggagggaccaggacaagcattc
R gaatgcttgtcctggtccctccctcatacttttccttgt
F acaaggaaaagtatgaggcttggaccaggacaagcattc
R gaatgcttgtcctggtccaagcctcatacttttccttgt
F ataggaccaggacaagcagcatatgcaacaggagaaata
R tatttctcctgttgcatatgctgcttgtcctggtcctat
F ataggaccaggacaagcagagtatgcaacaggagaaata
R tatttctcctgttgcatactctgcttgtcctggtcctat
F ataggaccaggacaagcactttatgcaacaggagaaata
R tatttctcctgttgcataaagtgcttgtcctggtcctat
Env and Mutation Direction Primer Sequence (5'-3')
HIV-2 ST
F aagaggccaggaaacaagacaggggttgtaccaataacactcatg 
R catgagtgttattggtacaacccctgtcttgtttcctggcctctt 
F ggaaacaagacagttgtaccagcaacactcatgtcagggttagtg 
R cactaaccctgacatgagtgttgctggtacaactgtctgtttcc
F aagacagttgtaccaataacagccatgtcagggttagtgtttcac 
R gtgaaacactaaccctgacatggctgttattggtacaactgtctt  
F cactcatgtcagggttagtggctcactcccagccaatcaatag
R ctattgattggctgggagtgagccactaaccctgacatgagtg 
Env and Mutation Direction Primer Sequence (5'-3')
SIVmac239
F agaccaggaaataagacaggggttttaccagtcaccatt
R aatggtgactggtaaaacccctgtcttatttcctggtct
F aataagacagttttaccagccaccattatgtctggattg
R caatccagacataatggtggctggtaaaactgtcttatt
F caggaaataagacagttttaccagtcaccgctatgtctggattggttttccactcacaacc
R ggttgtgagtggaaaaccaatccagacatagcggtgactggtaaaactgtcttatttcctg
F cagtcaccattatgtctggattggttgcccactcacaaccaatcaatgataggcc
R ggcctatcattgattggttgtgagtgggcaaccaatccagacataatggtgactg
Env and Mutation Direction Primer Sequence (5'-3')
SIVagmTan-1
F agaccaggaaataagacaggggtcttaccagtaaccatc
R gatggttactggtaagacccctgtcttatttcctggtct
F aataagacagtcttaccagcaaccatcatggcaggtctc
R gagacctgccatgatggttgctggtaagactgtcttatt
F acagtcttaccagtaaccgccatggcaggtctcgtgttc
R gaacacgagacctgccatggcggttactggtaagactgt
F atcatggcaggtctcgtggcccactcacaacaatataat
R attatattgttgtgagtgggccacgagacctgccatgat
303 G Insert
I307A
I307E
I307L
I309A
I309E
I309L
F317A
I309E
322 G Insert
I309L
F317A
F317E
F317L
303 G Insert
M307A
M307E
M307L
I309A
F317A
F317E
303 G Insert
303 G Insert
V307A
I309A
F317A
F317A
I309A
V307A
F317L
V307A
I309A
303 G Insert
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APPENDIX C- Primers for HIV-2 ST V3 Loop Mutagenesis 
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APPENDIX D- Primers for SIVagmTan-1 V3 Mutagenesis 
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APPENDIX E- Primers for SIVmac239 V3 Mutagenesis 
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 APPENDIX H- Primers for Twin Cysteine Removal from HIV-2 and SIV 
Species 
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APPENDIX I- Primers for PLV Envelope Gene Amplification 
	  
PL
V 
Sp
ec
ie
s
D
ire
ct
io
n
Pr
im
er
 S
eq
ue
nc
e 
(5
'-3
')
En
ve
lo
pe
 G
en
e 
A
m
pl
ifi
ca
tio
n
F
gc
gc
gc
ct
ta
ag
gc
cg
cc
ac
ca
tg
tg
tg
gt
ag
ga
at
ca
ac
ta
ttt
gt
tg
cc
R
gc
gc
gc
gg
ta
cc
tc
ac
ag
ga
gg
gc
ga
ttt
ct
gc
cc
c
F
gg
cc
gg
ta
cc
gc
cg
cc
ac
ca
tg
gg
ac
ca
tta
ag
gg
ga
aa
ag
gg
gt
at
ta
tta
gt
aa
ttt
tg
gg
R
gg
cc
ga
at
tc
ct
ag
ttg
aa
cc
ac
cg
ttc
ca
gt
tc
ttg
tc
gc
at
tc
ttc
ttg
g
F
gg
cc
ct
cg
ag
gc
cg
cc
ac
ca
tg
gc
aa
ag
ttc
tta
gg
aa
ttt
tta
ta
g
R
gg
cc
tc
ta
ga
ct
aa
tg
cg
ta
ga
ttt
gc
ttt
tg
F
gg
cc
aa
gc
ttg
cc
gc
ca
cc
at
ga
ga
gt
ga
tg
gg
ga
ta
ct
g
R
gg
cc
ga
at
tc
tta
ta
gc
aa
ag
ct
ct
ttc
 ​
H
IV
-2
 S
T
SI
Va
gm
Ta
n-
1
SI
Va
gm
15
5
H
IV
-1
 Z
M
24
9M
_B
10
	 161 
BIBLIOGRAPHY 
 
1. Kwon, Y.D., et al., Crystal structure, conformational fixation and entry-
related interactions of mature ligand-free HIV-1 Env. Nat Struct Mol Biol, 
2015. 22(7): p. 522-31. 
2. Lyumkis, D., et al., Cryo-EM structure of a fully glycosylated soluble 
cleaved HIV-1 envelope trimer. Science, 2013. 342(6165): p. 1484-90. 
3. Julien, J.P., et al., Crystal structure of a soluble cleaved HIV-1 envelope 
trimer. Science, 2013. 342(6165): p. 1477-83. 
4. Xiang, S.H., Recent advances on the use of structural biology for the 
design of novel envelope immunogens of HIV-1. Curr HIV Res, 2013. 
11(6): p. 464-72. 
5. Xiang, S.H., et al., A V3 loop-dependent gp120 element disrupted by CD4 
binding stabilizes the human immunodeficiency virus envelope 
glycoprotein trimer. J Virol, 2010. 84(7): p. 3147-61. 
6. Bohl, C., et al., A twin-cysteine motif in the V2 region of gp120 is 
associated with SIV envelope trimer stabilization. PLoS One, 2013. 8(7): 
p. e69406. 
7. (WHO), W.H.O. HIV/AIDS Data and Statistics. 2016  [cited 2018; Available 
from: http://www.who.int/hiv/en/. 
8. UNAIDS, UNAIDS Data 2017. 2017, Joint United Nations Programme on 
HIV/AIDS (UNAIDS). 
9. Barre-Sinoussi, F., et al., Isolation of a T-lymphotropic retrovirus from a 
patient at risk for acquired immune deficiency syndrome (AIDS). Science, 
1983. 220(4599): p. 868-71. 
10. Gallo, R.C., et al., Isolation of human T-cell leukemia virus in acquired 
immune deficiency syndrome (AIDS). Science, 1983. 220(4599): p. 865-7. 
11. Sharp, P.M. and B.H. Hahn, Origins of HIV and the AIDS pandemic. Cold 
Spring Harb Perspect Med, 2011. 1(1): p. a006841. 
12. Muriaux, D. and J.L. Darlix, Properties and functions of the nucleocapsid 
protein in virus assembly. RNA Biol, 2010. 7(6): p. 744-53. 
13. Briggs, J.A., et al., Structural organization of authentic, mature HIV-1 
virions and cores. EMBO J, 2003. 22(7): p. 1707-15. 
14. Freed, E.O., HIV-1 gag proteins: diverse functions in the virus life cycle. 
Virology, 1998. 251(1): p. 1-15. 
	 162 
15. Tedbury, P.R. and E.O. Freed, The role of matrix in HIV-1 envelope 
glycoprotein incorporation. Trends Microbiol, 2014. 22(7): p. 372-8. 
16. Hill, M., G. Tachedjian, and J. Mak, The packaging and maturation of the 
HIV-1 Pol proteins. Curr HIV Res, 2005. 3(1): p. 73-85. 
17. Zhu, P., et al., Electron tomography analysis of envelope glycoprotein 
trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad 
Sci U S A, 2003. 100(26): p. 15812-7. 
18. Zhu, P., et al., Distribution and three-dimensional structure of AIDS virus 
envelope spikes. Nature, 2006. 441(7095): p. 847-52. 
19. Laboratory, L.A.N. HIV-1 Gene Map. 2017 Jan 24, 2017 [cited 2018 March 
31]; Available from: 
https://www.hiv.lanl.gov/content/sequence/HIV/MAP/landmark.html. 
20. Freed, E.O. and M.A. Martin, Human Immunodeficiency Viruses: 
Replication, in Field’s Virology, D.M. Knipe and P.M. Howley, Editors. 
2013, Lippincott, Williams & Wilkins: Philadelphia, PA. p. 1502-1560. 
21. Marcello, A., et al., Nuclear organization and the control of HIV-1 
transcription. Gene, 2004. 326: p. 1-11. 
22. Hu, W.S. and S.H. Hughes, HIV-1 reverse transcription. Cold Spring Harb 
Perspect Med, 2012. 2(10). 
23. Brin, E. and J. Leis, HIV-1 integrase interaction with U3 and U5 terminal 
sequences in vitro defined using substrates with random sequences. J 
Biol Chem, 2002. 277(21): p. 18357-64. 
24. Hindmarsh, P. and J. Leis, Retroviral DNA integration. Microbiol Mol Biol 
Rev, 1999. 63(4): p. 836-43, table of contents. 
25. Mondor, I., S. Ugolini, and Q.J. Sattentau, Human immunodeficiency virus 
type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 
dependent and requires cell surface heparans. J Virol, 1998. 72(5): p. 
3623-34. 
26. Arthos, J., et al., HIV-1 envelope protein binds to and signals through 
integrin alpha4beta7, the gut mucosal homing receptor for peripheral T 
cells. Nat Immunol, 2008. 9(3): p. 301-9. 
27. Geijtenbeek, T.B., et al., DC-SIGN, a dendritic cell-specific HIV-1-binding 
protein that enhances trans-infection of T cells. Cell, 2000. 100(5): p. 587-
97. 
	 163 
28. Kwong, P.D., et al., Structure of an HIV gp120 envelope glycoprotein in 
complex with the CD4 receptor and a neutralizing human antibody. 
Nature, 1998. 393(6686): p. 648-59. 
29. Miyauchi, K., et al., HIV enters cells via endocytosis and dynamin-
dependent fusion with endosomes. Cell, 2009. 137(3): p. 433-44. 
30. Stein, B.S., et al., pH-independent HIV entry into CD4-positive T cells via 
virus envelope fusion to the plasma membrane. Cell, 1987. 49(5): p. 659-
68. 
31. Wilen, C.B., J.C. Tilton, and R.W. Doms, HIV: cell binding and entry. Cold 
Spring Harb Perspect Med, 2012. 2(8). 
32. Shaharabany, M. and A. Hizi, The DNA-dependent and RNA-dependent 
DNA polymerase activities of the reverse transcriptases of human 
immunodeficiency viruses types 1 and 2. AIDS Res Hum Retroviruses, 
1991. 7(11): p. 883-8. 
33. Luo, G.X. and J. Taylor, Template switching by reverse transcriptase 
during DNA synthesis. J Virol, 1990. 64(9): p. 4321-8. 
34. di Marzo Veronese, F., et al., Characterization of highly immunogenic 
p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science, 1986. 
231(4743): p. 1289-91. 
35. Karageorgos, L., P. Li, and C. Burrell, Characterization of HIV replication 
complexes early after cell-to-cell infection. AIDS Res Hum Retroviruses, 
1993. 9(9): p. 817-23. 
36. Heinzinger, N.K., et al., The Vpr protein of human immunodeficiency virus 
type 1 influences nuclear localization of viral nucleic acids in nondividing 
host cells. Proc Natl Acad Sci U S A, 1994. 91(15): p. 7311-5. 
37. Bushman, F.D., T. Fujiwara, and R. Craigie, Retroviral DNA integration 
directed by HIV integration protein in vitro. Science, 1990. 249(4976): p. 
1555-8. 
38. Brown, P.O., et al., Retroviral integration: structure of the initial covalent 
product and its precursor, and a role for the viral IN protein. Proc Natl 
Acad Sci U S A, 1989. 86(8): p. 2525-9. 
39. Felber, B.K., et al., rev protein of human immunodeficiency virus type 1 
affects the stability and transport of the viral mRNA. Proc Natl Acad Sci U 
S A, 1989. 86(5): p. 1495-9. 
40. Sodroski, J., et al., A second post-transcriptional trans-activator gene 
required for HTLV-III replication. Nature, 1986. 321(6068): p. 412-7. 
	 164 
41. Yu, X.F., et al., Role of the C terminus Gag protein in human 
immunodeficiency virus type 1 virion assembly and maturation. J Gen 
Virol, 1995. 76 ( Pt 12): p. 3171-9. 
42. Checkley, M.A., B.G. Luttge, and E.O. Freed, HIV-1 envelope glycoprotein 
biosynthesis, trafficking, and incorporation. J Mol Biol, 2011. 410(4): p. 
582-608. 
43. Dilley, K.A., et al., Interactions between HIV-1 Gag and Viral RNA 
Genome Enhance Virion Assembly. J Virol, 2017. 91(16). 
44. Paillart, J.C., et al., Dimerization of retroviral RNA genomes: an 
inseparable pair. Nat Rev Microbiol, 2004. 2(6): p. 461-72. 
45. Morita, E., et al., ESCRT-III protein requirements for HIV-1 budding. Cell 
Host Microbe, 2011. 9(3): p. 235-242. 
46. Zhao, G., et al., Mature HIV-1 capsid structure by cryo-electron 
microscopy and all-atom molecular dynamics. Nature, 2013. 497(7451): p. 
643-6. 
47. Kohl, N.E., et al., Active human immunodeficiency virus protease is 
required for viral infectivity. Proc Natl Acad Sci U S A, 1988. 85(13): p. 
4686-90. 
48. Bryant, M. and L. Ratner, Myristoylation-dependent replication and 
assembly of human immunodeficiency virus 1. Proc Natl Acad Sci U S A, 
1990. 87(2): p. 523-7. 
49. Gottlinger, H.G., J.G. Sodroski, and W.A. Haseltine, Role of capsid 
precursor processing and myristoylation in morphogenesis and infectivity 
of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A, 1989. 
86(15): p. 5781-5. 
50. Gheysen, D., et al., Assembly and release of HIV-1 precursor Pr55gag 
virus-like particles from recombinant baculovirus-infected insect cells. Cell, 
1989. 59(1): p. 103-12. 
51. Mark-Danieli, M., et al., Single point mutations in the zinc finger motifs of 
the human immunodeficiency virus type 1 nucleocapsid alter RNA binding 
specificities of the gag protein and enhance packaging and infectivity. J 
Virol, 2005. 79(12): p. 7756-67. 
52. Amarasinghe, G.K., et al., NMR structure of the HIV-1 nucleocapsid 
protein bound to stem-loop SL2 of the psi-RNA packaging signal. 
Implications for genome recognition. J Mol Biol, 2000. 301(2): p. 491-511. 
	 165 
53. Harrison, G.P. and A.M. Lever, The human immunodeficiency virus type 1 
packaging signal and major splice donor region have a conserved stable 
secondary structure. J Virol, 1992. 66(7): p. 4144-53. 
54. Kondo, E., et al., The p6gag domain of human immunodeficiency virus 
type 1 is sufficient for the incorporation of Vpr into heterologous viral 
particles. J Virol, 1995. 69(5): p. 2759-64. 
55. Jenkins, Y., et al., Biochemical analyses of the interactions between 
human immunodeficiency virus type 1 Vpr and p6(Gag). J Virol, 2001. 
75(21): p. 10537-42. 
56. Gottlinger, H.G., et al., Effect of mutations affecting the p6 gag protein on 
human immunodeficiency virus particle release. Proc Natl Acad Sci U S A, 
1991. 88(8): p. 3195-9. 
57. Shehu-Xhilaga, M., S.M. Crowe, and J. Mak, Maintenance of the 
Gag/Gag-Pol ratio is important for human immunodeficiency virus type 1 
RNA dimerization and viral infectivity. J Virol, 2001. 75(4): p. 1834-41. 
58. Jacks, T., et al., Characterization of ribosomal frameshifting in HIV-1 gag-
pol expression. Nature, 1988. 331(6153): p. 280-3. 
59. Lv, Z., Y. Chu, and Y. Wang, HIV protease inhibitors: a review of 
molecular selectivity and toxicity. HIV AIDS (Auckl), 2015. 7: p. 95-104. 
60. Kurt Yilmaz, N., R. Swanstrom, and C.A. Schiffer, Improving Viral 
Protease Inhibitors to Counter Drug Resistance. Trends Microbiol, 2016. 
24(7): p. 547-557. 
61. Fu, T.B. and J. Taylor, When retroviral reverse transcriptases reach the 
end of their RNA templates. J Virol, 1992. 66(7): p. 4271-8. 
62. Sarafianos, S.G., et al., Structure and function of HIV-1 reverse 
transcriptase: molecular mechanisms of polymerization and inhibition. J 
Mol Biol, 2009. 385(3): p. 693-713. 
63. Jacobo-Molina, A., et al., Crystal structure of human immunodeficiency 
virus type 1 reverse transcriptase complexed with double-stranded DNA at 
3.0 A resolution shows bent DNA. Proc Natl Acad Sci U S A, 1993. 90(13): 
p. 6320-4. 
64. Kohlstaedt, L.A., et al., Crystal structure at 3.5 A resolution of HIV-1 
reverse transcriptase complexed with an inhibitor. Science, 1992. 
256(5065): p. 1783-90. 
65. Preston, B.D., B.J. Poiesz, and L.A. Loeb, Fidelity of HIV-1 reverse 
transcriptase. Science, 1988. 242(4882): p. 1168-71. 
	 166 
66. De Clercq, E., The nucleoside reverse transcriptase inhibitors, 
nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in 
the treatment of HIV infections (AIDS). Adv Pharmacol, 2013. 67: p. 317-
58. 
67. Usach, I., V. Melis, and J.E. Peris, Non-nucleoside reverse transcriptase 
inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and 
tolerability. J Int AIDS Soc, 2013. 16: p. 1-14. 
68. Craigie, R., The molecular biology of HIV integrase. Future Virol, 2012. 
7(7): p. 679-686. 
69. Yoder, K.E. and F.D. Bushman, Repair of gaps in retroviral DNA 
integration intermediates. J Virol, 2000. 74(23): p. 11191-200. 
70. Moulard, M., et al., Processing and routage of HIV glycoproteins by furin 
to the cell surface. Virus Res, 1999. 60(1): p. 55-65. 
71. Lasky, L.A., et al., Neutralization of the AIDS retrovirus by antibodies to a 
recombinant envelope glycoprotein. Science, 1986. 233(4760): p. 209-12. 
72. Wei, X., et al., Antibody neutralization and escape by HIV-1. Nature, 2003. 
422(6929): p. 307-12. 
73. Wyatt, R. and J. Sodroski, The HIV-1 envelope glycoproteins: fusogens, 
antigens, and immunogens. Science, 1998. 280(5371): p. 1884-8. 
74. Barin, F., et al., Virus envelope protein of HTLV-III represents major target 
antigen for antibodies in AIDS patients. Science, 1985. 228(4703): p. 
1094-6. 
75. Weiss, R.A., HIV receptors and cellular tropism. IUBMB Life, 2002. 53(4-
5): p. 201-5. 
76. Dayton, A.I., et al., The trans-activator gene of the human T cell 
lymphotropic virus type III is required for replication. Cell, 1986. 44(6): p. 
941-7. 
77. Fisher, A.G., et al., The trans-activator gene of HTLV-III is essential for 
virus replication. Nature, 1986. 320(6060): p. 367-71. 
78. Bartz, S.R. and M. Emerman, Human immunodeficiency virus type 1 Tat 
induces apoptosis and increases sensitivity to apoptotic signals by up-
regulating FLICE/caspase-8. J Virol, 1999. 73(3): p. 1956-63. 
79. Ensoli, B., et al., Tat protein of HIV-1 stimulates growth of cells derived 
from Kaposi's sarcoma lesions of AIDS patients. Nature, 1990. 345(6270): 
p. 84-6. 
	 167 
80. Clark, E., B. Nava, and M. Caputi, Tat is a multifunctional viral protein that 
modulates cellular gene expression and functions. Oncotarget, 2017. 
8(16): p. 27569-27581. 
81. Hammarskjold, M.L., et al., Regulation of human immunodeficiency virus 
env expression by the rev gene product. J Virol, 1989. 63(5): p. 1959-66. 
82. Fischer, U., et al., The HIV-1 Rev activation domain is a nuclear export 
signal that accesses an export pathway used by specific cellular RNAs. 
Cell, 1995. 82(3): p. 475-83. 
83. Conticello, S.G., R.S. Harris, and M.S. Neuberger, The Vif protein of HIV 
triggers degradation of the human antiretroviral DNA deaminase 
APOBEC3G. Curr Biol, 2003. 13(22): p. 2009-13. 
84. Feng, Y., et al., Suppression of APOBEC3-mediated restriction of HIV-1 
by Vif. Front Microbiol, 2014. 5: p. 450. 
85. Simon, J.H., et al., Evidence for a newly discovered cellular anti-HIV-1 
phenotype. Nat Med, 1998. 4(12): p. 1397-400. 
86. Madani, N. and D. Kabat, An endogenous inhibitor of human 
immunodeficiency virus in human lymphocytes is overcome by the viral Vif 
protein. J Virol, 1998. 72(12): p. 10251-5. 
87. Sheehy, A.M., et al., Isolation of a human gene that inhibits HIV-1 infection 
and is suppressed by the viral Vif protein. Nature, 2002. 418(6898): p. 
646-50. 
88. Batisse, J., et al., The role of Vif oligomerization and RNA chaperone 
activity in HIV-1 replication. Virus Res, 2012. 169(2): p. 361-76. 
89. Hoglund, S., et al., Role of vif during packing of the core of HIV-1. 
Virology, 1994. 201(2): p. 349-55. 
90. Cohen, E.A., et al., Identification of HIV-1 vpr product and function. J 
Acquir Immune Defic Syndr, 1990. 3(1): p. 11-8. 
91. Yuan, X., et al., Human immunodeficiency virus vpr gene encodes a 
virion-associated protein. AIDS Res Hum Retroviruses, 1990. 6(11): p. 
1265-71. 
92. Kogan, M. and J. Rappaport, HIV-1 accessory protein Vpr: relevance in 
the pathogenesis of HIV and potential for therapeutic intervention. 
Retrovirology, 2011. 8: p. 25. 
	 168 
93. Bachand, F., et al., Incorporation of Vpr into human immunodeficiency 
virus type 1 requires a direct interaction with the p6 domain of the p55 gag 
precursor. J Biol Chem, 1999. 274(13): p. 9083-91. 
94. Popov, S., et al., Viral protein R regulates nuclear import of the HIV-1 pre-
integration complex. EMBO J, 1998. 17(4): p. 909-17. 
95. Popov, S., et al., Viral protein R regulates docking of the HIV-1 
preintegration complex to the nuclear pore complex. J Biol Chem, 1998. 
273(21): p. 13347-52. 
96. Agostini, I., et al., Phosphorylation of Vpr regulates HIV type 1 nuclear 
import and macrophage infection. AIDS Res Hum Retroviruses, 2002. 
18(4): p. 283-8. 
97. Wang, L., et al., Interaction of virion protein Vpr of human 
immunodeficiency virus type 1 with cellular transcription factor Sp1 and 
trans-activation of viral long terminal repeat. J Biol Chem, 1995. 270(43): 
p. 25564-9. 
98. Agostini, I., et al., The human immunodeficiency virus type 1 Vpr 
transactivator: cooperation with promoter-bound activator domains and 
binding to TFIIB. J Mol Biol, 1996. 261(5): p. 599-606. 
99. Groschel, B. and F. Bushman, Cell cycle arrest in G2/M promotes early 
steps of infection by human immunodeficiency virus. J Virol, 2005. 79(9): 
p. 5695-704. 
100. Goh, W.C., N. Manel, and M. Emerman, The human immunodeficiency 
virus Vpr protein binds Cdc25C: implications for G2 arrest. Virology, 2004. 
318(1): p. 337-49. 
101. Goh, W.C., et al., HIV-1 Vpr increases viral expression by manipulation of 
the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med, 1998. 
4(1): p. 65-71. 
102. Tiganos, E., et al., Structural and functional analysis of the membrane-
spanning domain of the human immunodeficiency virus type 1 Vpu 
protein. Virology, 1998. 251(1): p. 96-107. 
103. Andrew, A. and K. Strebel, HIV-1 Vpu targets cell surface markers CD4 
and BST-2 through distinct mechanisms. Mol Aspects Med, 2010. 31(5): 
p. 407-17. 
104. Willey, R.L., et al., Human immunodeficiency virus type 1 Vpu protein 
induces rapid degradation of CD4. J Virol, 1992. 66(12): p. 7193-200. 
	 169 
105. Margottin, F., et al., A novel human WD protein, h-beta TrCp, that 
interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway 
through an F-box motif. Mol Cell, 1998. 1(4): p. 565-74. 
106. Lama, J., A. Mangasarian, and D. Trono, Cell-surface expression of CD4 
reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-
inhibitable manner. Curr Biol, 1999. 9(12): p. 622-31. 
107. Neil, S.J., T. Zang, and P.D. Bieniasz, Tetherin inhibits retrovirus release 
and is antagonized by HIV-1 Vpu. Nature, 2008. 451(7177): p. 425-30. 
108. Douglas, J.L., et al., Vpu directs the degradation of the human 
immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-
dependent mechanism. J Virol, 2009. 83(16): p. 7931-47. 
109. Mangeat, B., et al., HIV-1 Vpu neutralizes the antiviral factor 
Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent 
degradation. PLoS Pathog, 2009. 5(9): p. e1000574. 
110. Mitchell, R.S., et al., Vpu antagonizes BST-2-mediated restriction of HIV-1 
release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog, 
2009. 5(5): p. e1000450. 
111. Kestler, H.W., 3rd, et al., Importance of the nef gene for maintenance of 
high virus loads and for development of AIDS. Cell, 1991. 65(4): p. 651-
62. 
112. Jin, Y.J., et al., HIV Nef-mediated CD4 down-regulation is adaptor protein 
complex 2 dependent. J Immunol, 2005. 175(5): p. 3157-64. 
113. Gondim, M.V., et al., AP-2 Is the Crucial Clathrin Adaptor Protein for CD4 
Downmodulation by HIV-1 Nef in Infected Primary CD4+ T Cells. J Virol, 
2015. 89(24): p. 12518-24. 
114. Sol-Foulon, N., et al., HIV-1 Nef-induced upregulation of DC-SIGN in 
dendritic cells promotes lymphocyte clustering and viral spread. Immunity, 
2002. 16(1): p. 145-55. 
115. Swigut, T., N. Shohdy, and J. Skowronski, Mechanism for down-regulation 
of CD28 by Nef. EMBO J, 2001. 20(7): p. 1593-604. 
116. El-Far, M., et al., Down-regulation of CTLA-4 by HIV-1 Nef protein. PLoS 
One, 2013. 8(1): p. e54295. 
117. Schwartz, O., et al., Endocytosis of major histocompatibility complex class 
I molecules is induced by the HIV-1 Nef protein. Nat Med, 1996. 2(3): p. 
338-42. 
	 170 
118. Foster, J.L. and J.V. Garcia, HIV-1 Nef: at the crossroads. Retrovirology, 
2008. 5: p. 84. 
119. Moarefi, I., et al., Activation of the Src-family tyrosine kinase Hck by SH3 
domain displacement. Nature, 1997. 385(6617): p. 650-3. 
120. Arora, V.K., et al., Lentivirus Nef specifically activates Pak2. J Virol, 2000. 
74(23): p. 11081-7. 
121. Hahn, B.H., et al., AIDS as a zoonosis: scientific and public health 
implications. Science, 2000. 287(5453): p. 607-14. 
122. Gao, F., et al., Origin of HIV-1 in the chimpanzee Pan troglodytes 
troglodytes. Nature, 1999. 397(6718): p. 436-41. 
123. Apetrei, C., D.L. Robertson, and P.A. Marx, The history of SIVS and AIDS: 
epidemiology, phylogeny and biology of isolates from naturally SIV 
infected non-human primates (NHP) in Africa. Front Biosci, 2004. 9: p. 
225-54. 
124. Ma, D., et al., SIVagm infection in wild African green monkeys from South 
Africa: epidemiology, natural history, and evolutionary considerations. 
PLoS Pathog, 2013. 9(1): p. e1003011. 
125. Keele, B.F., et al., Chimpanzee reservoirs of pandemic and nonpandemic 
HIV-1. Science, 2006. 313(5786): p. 523-6. 
126. Keele, B.F., et al., Increased mortality and AIDS-like immunopathology in 
wild chimpanzees infected with SIVcpz. Nature, 2009. 460(7254): p. 515-
9. 
127. Sharp, P.M., G.M. Shaw, and B.H. Hahn, Simian immunodeficiency virus 
infection of chimpanzees. J Virol, 2005. 79(7): p. 3891-902. 
128. Hirsch, V.M. and P.R. Johnson, Pathogenic diversity of simian 
immunodeficiency viruses. Virus Res, 1994. 32(2): p. 183-203. 
129. Pandrea, I.V., et al., Acute loss of intestinal CD4+ T cells is not predictive 
of simian immunodeficiency virus virulence. J Immunol, 2007. 179(5): p. 
3035-46. 
130. Souquiere, S., et al., Simian immunodeficiency virus types 1 and 2 (SIV 
mnd 1 and 2) have different pathogenic potentials in rhesus macaques 
upon experimental cross-species transmission. J Gen Virol, 2009. 90(Pt 
2): p. 488-99. 
	 171 
131. Beer, B.E., et al., Immunodeficiency in the absence of high viral load in 
pig-tailed macaques infected with Simian immunodeficiency virus SIVsun 
or SIVlhoest. J Virol, 2005. 79(22): p. 14044-56. 
132. Chakrabarti, L.A., et al., Normal T-cell turnover in sooty mangabeys 
harboring active simian immunodeficiency virus infection. J Virol, 2000. 
74(3): p. 1209-23. 
133. Santiago, M.L., et al., Simian immunodeficiency virus infection in free-
ranging sooty mangabeys (Cercocebus atys atys) from the Tai Forest, 
Cote d'Ivoire: implications for the origin of epidemic human 
immunodeficiency virus type 2. J Virol, 2005. 79(19): p. 12515-27. 
134. Apetrei, C., et al., Kuru experiments triggered the emergence of 
pathogenic SIVmac. AIDS, 2006. 20(3): p. 317-21. 
135. Apetrei, C., et al., Molecular epidemiology of simian immunodeficiency 
virus SIVsm in U.S. primate centers unravels the origin of SIVmac and 
SIVstm. J Virol, 2005. 79(14): p. 8991-9005. 
136. Gardner, M., A historical perspective: Simian AIDS-an accidental windfall. 
J Med Primatol, 2016. 45(5): p. 212-4. 
137. Bailes, E., et al., Hybrid origin of SIV in chimpanzees. Science, 2003. 
300(5626): p. 1713. 
138. McCutchan, F.E., Global epidemiology of HIV. J Med Virol, 2006. 78 
Suppl 1: p. S7-S12. 
139. Peeters, M., et al., Geographical distribution of HIV-1 group O viruses in 
Africa. AIDS, 1997. 11(4): p. 493-8. 
140. Ayouba, A., et al., HIV-1 group O infection in Cameroon, 1986 to 1998. 
Emerg Infect Dis, 2001. 7(3): p. 466-7. 
141. Vessiere, A., et al., Diagnosis and monitoring of HIV-1 group O-infected 
patients in Cameroun. J Acquir Immune Defic Syndr, 2010. 53(1): p. 107-
10. 
142. Villabona-Arenas, C.J., et al., HIV-1 group O infection in Cameroon from 
2006 to 2013: Prevalence, genetic diversity, evolution and public health 
challenges. Infect Genet Evol, 2015. 36: p. 210-216. 
143. Rodgers, M.A., et al., Identification of rare HIV-1 Group N, HBV AE, and 
HTLV-3 strains in rural South Cameroon. Virology, 2017. 504: p. 141-151. 
144. Delaugerre, C., et al., HIV-1 group N: travelling beyond Cameroon. 
Lancet, 2011. 378(9806): p. 1894. 
	 172 
145. Ayouba, A., et al., HIV-1 group N among HIV-1-seropositive individuals in 
Cameroon. AIDS, 2000. 14(16): p. 2623-5. 
146. Vallari, A., et al., Confirmation of putative HIV-1 group P in Cameroon. J 
Virol, 2011. 85(3): p. 1403-7. 
147. Roques, P., et al., Phylogenetic characteristics of three new HIV-1 N 
strains and implications for the origin of group N. AIDS, 2004. 18(10): p. 
1371-81. 
148. Simon, F., et al., Identification of a new human immunodeficiency virus 
type 1 distinct from group M and group O. Nat Med, 1998. 4(9): p. 1032-7. 
149. D'Arc, M., et al., Origin of the HIV-1 group O epidemic in western lowland 
gorillas. Proc Natl Acad Sci U S A, 2015. 112(11): p. E1343-52. 
150. Van Heuverswyn, F., et al., Human immunodeficiency viruses: SIV 
infection in wild gorillas. Nature, 2006. 444(7116): p. 164. 
151. Plantier, J.C., et al., A new human immunodeficiency virus derived from 
gorillas. Nat Med, 2009. 15(8): p. 871-2. 
152. Hemelaar, J., The origin and diversity of the HIV-1 pandemic. Trends Mol 
Med, 2012. 18(3): p. 182-92. 
153. Korber, B., et al., Timing the ancestor of the HIV-1 pandemic strains. 
Science, 2000. 288(5472): p. 1789-96. 
154. Robertson, D.L., et al., HIV-1 nomenclature proposal. Science, 2000. 
288(5463): p. 55-6. 
155. Hemelaar, J., et al., Global trends in molecular epidemiology of HIV-1 
during 2000-2007. AIDS, 2011. 25(5): p. 679-89. 
156. John-Stewart, G.C., et al., Subtype C Is associated with increased vaginal 
shedding of HIV-1. J Infect Dis, 2005. 192(3): p. 492-6. 
157. Paxton, W.A., Why Are Some HIV-1 Subtypes More "Wimpy" at Causing 
Disease? EBioMedicine, 2016. 13: p. 27-28. 
158. Venner, C.M., et al., Infecting HIV-1 Subtype Predicts Disease 
Progression in Women of Sub-Saharan Africa. EBioMedicine, 2016. 13: p. 
305-314. 
159. Peeters, M., et al., Evidence for differences in MT2 cell tropism according 
to genetic subtypes of HIV-1: syncytium-inducing variants seem rare 
among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum 
Retrovirol, 1999. 20(2): p. 115-21. 
	 173 
160. Renjifo, B., et al., Preferential in-utero transmission of HIV-1 subtype C as 
compared to HIV-1 subtype A or D. AIDS, 2004. 18(12): p. 1629-36. 
161. Ball, S.C., et al., Comparing the ex vivo fitness of CCR5-tropic human 
immunodeficiency virus type 1 isolates of subtypes B and C. J Virol, 2003. 
77(2): p. 1021-38. 
162. Iordanskiy, S., et al., Subtype-associated differences in HIV-1 reverse 
transcription affect the viral replication. Retrovirology, 2010. 7: p. 85. 
163. Chen, Z., et al., Genetic characterization of new West African simian 
immunodeficiency virus SIVsm: geographic clustering of household-
derived SIV strains with human immunodeficiency virus type 2 subtypes 
and genetically diverse viruses from a single feral sooty mangabey troop. 
J Virol, 1996. 70(6): p. 3617-27. 
164. Ayouba, A., et al., Evidence for continuing cross-species transmission of 
SIVsmm to humans: characterization of a new HIV-2 lineage in rural Cote 
d'Ivoire. AIDS, 2013. 27(15): p. 2488-91. 
165. de Silva, T.I., M. Cotten, and S.L. Rowland-Jones, HIV-2: the forgotten 
AIDS virus. Trends Microbiol, 2008. 16(12): p. 588-95. 
166. Lemey, P., et al., Tracing the origin and history of the HIV-2 epidemic. 
Proc Natl Acad Sci U S A, 2003. 100(11): p. 6588-92. 
167. Pieniazek, D., et al., Predominance of human immunodeficiency virus type 
2 subtype B in Abidjan, Ivory Coast. AIDS Res Hum Retroviruses, 1999. 
15(6): p. 603-8. 
168. Peeters, M., C. Toure-Kane, and J.N. Nkengasong, Genetic diversity of 
HIV in Africa: impact on diagnosis, treatment, vaccine development and 
trials. AIDS, 2003. 17(18): p. 2547-60. 
169. Smith, S.M., et al., Isolation of a new HIV-2 group in the US. 
Retrovirology, 2008. 5: p. 103. 
170. Marlink, R., et al., Reduced rate of disease development after HIV-2 
infection as compared to HIV-1. Science, 1994. 265(5178): p. 1587-90. 
171. Gueudin, M., et al., Differences in proviral DNA load between HIV-1- and 
HIV-2-infected patients. AIDS, 2008. 22(2): p. 211-5. 
172. MacNeil, A., et al., Direct evidence of lower viral replication rates in vivo in 
human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 
infection. J Virol, 2007. 81(10): p. 5325-30. 
	 174 
173. Bjorling, E., et al., Autologous neutralizing antibodies prevail in HIV-2 but 
not in HIV-1 infection. Virology, 1993. 193(1): p. 528-30. 
174. Shi, Y., et al., Evolution of human immunodeficiency virus type 2 
coreceptor usage, autologous neutralization, envelope sequence and 
glycosylation. J Gen Virol, 2005. 86(Pt 12): p. 3385-96. 
175. Rodriguez, S.K., et al., Comparison of heterologous neutralizing antibody 
responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-
infected Senegalese patients: distinct patterns of breadth and magnitude 
distinguish HIV-1 and HIV-2 infections. J Virol, 2007. 81(10): p. 5331-8. 
176. Silvestri, G., et al., Divergent host responses during primary simian 
immunodeficiency virus SIVsm infection of natural sooty mangabey and 
nonnatural rhesus macaque hosts. J Virol, 2005. 79(7): p. 4043-54. 
177. Ling, B., et al., Classic AIDS in a sooty mangabey after an 18-year natural 
infection. J Virol, 2004. 78(16): p. 8902-8. 
178. Caffrey, M., HIV envelope: challenges and opportunities for development 
of entry inhibitors. Trends Microbiol, 2011. 19(4): p. 191-7. 
179. Vergne, L.P., M., The challenge of HIV sequence diversity in the envelope 
glycoprotein, in Entry Inhibitors in HIV Therapy, C.A.D. Jacqueline D. 
Reeves, Editor. 2007, Birkhauser. p. 17-30. 
180. Matthews, T., et al., Enfuvirtide: the first therapy to inhibit the entry of HIV-
1 into host CD4 lymphocytes. Nat Rev Drug Discov, 2004. 3(3): p. 215-25. 
181. Westby, M. and E. van der Ryst, CCR5 antagonists: host-targeted antiviral 
agents for the treatment of HIV infection, 4 years on. Antivir Chem 
Chemother, 2010. 20(5): p. 179-92. 
182. Tilton, J.C. and R.W. Doms, Entry inhibitors in the treatment of HIV-1 
infection. Antiviral Res, 2010. 85(1): p. 91-100. 
183. Patel, M., et al., Cell-surface heparan sulfate proteoglycan mediates HIV-1 
infection of T-cell lines. AIDS Res Hum Retroviruses, 1993. 9(2): p. 167-
74. 
184. McDougal, J.S., et al., Binding of HTLV-III/LAV to T4+ T cells by a 
complex of the 110K viral protein and the T4 molecule. Science, 1986. 
231(4736): p. 382-5. 
185. McDougal, J.S., et al., The T4 glycoprotein is a cell-surface receptor for 
the AIDS virus. Cold Spring Harb Symp Quant Biol, 1986. 51 Pt 2: p. 703-
11. 
	 175 
186. Maddon, P.J., et al., The T4 gene encodes the AIDS virus receptor and is 
expressed in the immune system and the brain. Cell, 1986. 47(3): p. 333-
48. 
187. Liu, J., et al., Molecular architecture of native HIV-1 gp120 trimers. Nature, 
2008. 455(7209): p. 109-13. 
188. Biscone, M.J., et al., Functional impact of HIV coreceptor-binding site 
mutations. Virology, 2006. 351(1): p. 226-36. 
189. Rizzuto, C. and J. Sodroski, Fine definition of a conserved CCR5-binding 
region on the human immunodeficiency virus type 1 glycoprotein 120. 
AIDS Res Hum Retroviruses, 2000. 16(8): p. 741-9. 
190. Rizzuto, C.D., et al., A conserved HIV gp120 glycoprotein structure 
involved in chemokine receptor binding. Science, 1998. 280(5371): p. 
1949-53. 
191. Berger, E.A., et al., A new classification for HIV-1. Nature, 1998. 
391(6664): p. 240. 
192. Chan, D.C., et al., Core structure of gp41 from the HIV envelope 
glycoprotein. Cell, 1997. 89(2): p. 263-73. 
193. Weissenhorn, W., et al., Atomic structure of the ectodomain from HIV-1 
gp41. Nature, 1997. 387(6631): p. 426-30. 
194. Buzon, V., et al., Crystal structure of HIV-1 gp41 including both fusion 
peptide and membrane proximal external regions. PLoS Pathog, 2010. 
6(5): p. e1000880. 
195. Cilliers, T., et al., Use of alternate coreceptors on primary cells by two 
HIV-1 isolates. Virology, 2005. 339(1): p. 136-44. 
196. Lackner, A.A., M.M. Lederman, and B. Rodriguez, HIV pathogenesis: the 
host. Cold Spring Harb Perspect Med, 2012. 2(9): p. a007005. 
197. Schuitemaker, H., A.B. van 't Wout, and P. Lusso, Clinical significance of 
HIV-1 coreceptor usage. J Transl Med, 2011. 9 Suppl 1: p. S5. 
198. Manches, O., D. Frleta, and N. Bhardwaj, Dendritic cells in progression 
and pathology of HIV infection. Trends Immunol, 2014. 35(3): p. 114-22. 
199. Smed-Sorensen, A., et al., Differential susceptibility to human 
immunodeficiency virus type 1 infection of myeloid and plasmacytoid 
dendritic cells. J Virol, 2005. 79(14): p. 8861-9. 
	 176 
200. Piguet, V. and R.M. Steinman, The interaction of HIV with dendritic cells: 
outcomes and pathways. Trends Immunol, 2007. 28(11): p. 503-10. 
201. Wu, L. and V.N. KewalRamani, Dendritic-cell interactions with HIV: 
infection and viral dissemination. Nat Rev Immunol, 2006. 6(11): p. 859-
68. 
202. Koppensteiner, H., R. Brack-Werner, and M. Schindler, Macrophages and 
their relevance in Human Immunodeficiency Virus Type I infection. 
Retrovirology, 2012. 9: p. 82. 
203. Koenig, S., et al., Detection of AIDS virus in macrophages in brain tissue 
from AIDS patients with encephalopathy. Science, 1986. 233(4768): p. 
1089-93. 
204. Groot, F., S. Welsch, and Q.J. Sattentau, Efficient HIV-1 transmission 
from macrophages to T cells across transient virological synapses. Blood, 
2008. 111(9): p. 4660-3. 
205. Kawamura, T., et al., R5 HIV productively infects Langerhans cells, and 
infection levels are regulated by compound CCR5 polymorphisms. Proc 
Natl Acad Sci U S A, 2003. 100(14): p. 8401-6. 
206. Keele, B.F., et al., Identification and characterization of transmitted and 
early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad 
Sci U S A, 2008. 105(21): p. 7552-7. 
207. Connor, R.I., et al., Change in coreceptor use correlates with disease 
progression in HIV-1--infected individuals. J Exp Med, 1997. 185(4): p. 
621-8. 
208. Castellano, P., L. Prevedel, and E.A. Eugenin, HIV-infected macrophages 
and microglia that survive acute infection become viral reservoirs by a 
mechanism involving Bim. Sci Rep, 2017. 7(1): p. 12866. 
209. Bhattacharya, A., Protein structures: Structures of desire. Nature, 2009. 
459(7243): p. 24-7. 
210. Mao, Y., et al., Subunit organization of the membrane-bound HIV-1 
envelope glycoprotein trimer. Nat Struct Mol Biol, 2012. 19(9): p. 893-9. 
211. Mao, Y., et al., Molecular architecture of the uncleaved HIV-1 envelope 
glycoprotein trimer. Proc Natl Acad Sci U S A, 2013. 110(30): p. 12438-43. 
212. Subramaniam, S., Structure of trimeric HIV-1 envelope glycoproteins. Proc 
Natl Acad Sci U S A, 2013. 110(45): p. E4172-4. 
	 177 
213. Mao, Y., L.R. Castillo-Menendez, and J.G. Sodroski, Reply to 
Subramaniam, van Heel, and Henderson: Validity of the cryo-electron 
microscopy structures of the HIV-1 envelope glycoprotein complex. Proc 
Natl Acad Sci U S A, 2013. 110(45): p. E4178-82. 
214. van Heel, M., Finding trimeric HIV-1 envelope glycoproteins in random 
noise. Proc Natl Acad Sci U S A, 2013. 110(45): p. E4175-7. 
215. Henderson, R., Avoiding the pitfalls of single particle cryo-electron 
microscopy: Einstein from noise. Proc Natl Acad Sci U S A, 2013. 110(45): 
p. 18037-41. 
216. Beddows, S., et al., Evaluating the immunogenicity of a disulfide-
stabilized, cleaved, trimeric form of the envelope glycoprotein complex of 
human immunodeficiency virus type 1. J Virol, 2005. 79(14): p. 8812-27. 
217. Kang, Y.K., et al., Structural and immunogenicity studies of a cleaved, 
stabilized envelope trimer derived from subtype A HIV-1. Vaccine, 2009. 
27(37): p. 5120-32. 
218. McCoy, L.E., et al., Holes in the Glycan Shield of the Native HIV Envelope 
Are a Target of Trimer-Elicited Neutralizing Antibodies. Cell Rep, 2016. 
16(9): p. 2327-38. 
219. Voss, J.E., et al., Elicitation of Neutralizing Antibodies Targeting the V2 
Apex of the HIV Envelope Trimer in a Wild-Type Animal Model. Cell Rep, 
2017. 21(1): p. 222-235. 
220. Sanders, R.W., et al., HIV-1 VACCINES. HIV-1 neutralizing antibodies 
induced by native-like envelope trimers. Science, 2015. 349(6244): p. 
aac4223. 
221. Stewart-Jones, G.B., et al., Trimeric HIV-1-Env Structures Define Glycan 
Shields from Clades A, B, and G. Cell, 2016. 165(4): p. 813-26. 
222. Gristick, H.B., et al., Natively glycosylated HIV-1 Env structure reveals 
new mode for antibody recognition of the CD4-binding site. Nat Struct Mol 
Biol, 2016. 23(10): p. 906-915. 
223. Lee, J.H., G. Ozorowski, and A.B. Ward, Cryo-EM structure of a native, 
fully glycosylated, cleaved HIV-1 envelope trimer. Science, 2016. 
351(6277): p. 1043-8. 
224. Sullivan, N., et al., Effect of amino acid changes in the V1/V2 region of the 
human immunodeficiency virus type 1 gp120 glycoprotein on subunit 
association, syncytium formation, and recognition by a neutralizing 
antibody. J Virol, 1993. 67(6): p. 3674-9. 
	 178 
225. Walker, L.M., et al., Broad neutralization coverage of HIV by multiple 
highly potent antibodies. Nature, 2011. 477(7365): p. 466-70. 
226. Chojnacki, J., et al., Maturation-dependent HIV-1 surface protein 
redistribution revealed by fluorescence nanoscopy. Science, 2012. 
338(6106): p. 524-8. 
227. Brandenberg, O.F., et al., The HIV-1 Entry Process: A Stoichiometric 
View. Trends Microbiol, 2015. 23(12): p. 763-774. 
228. Magnus, C., et al., Estimating the stoichiometry of human 
immunodeficiency virus entry. J Virol, 2009. 83(3): p. 1523-31. 
229. Herrera, C., et al., Dominant-negative effect of hetero-oligomerization on 
the function of the human immunodeficiency virus type 1 envelope 
glycoprotein complex. Virology, 2006. 351(1): p. 121-32. 
230. Klasse, P.J., Modeling how many envelope glycoprotein trimers per virion 
participate in human immunodeficiency virus infectivity and its 
neutralization by antibody. Virology, 2007. 369(2): p. 245-62. 
231. Yang, X., et al., Stoichiometry of envelope glycoprotein trimers in the entry 
of human immunodeficiency virus type 1. J Virol, 2005. 79(19): p. 12132-
47. 
232. Sougrat, R., et al., Electron tomography of the contact between T cells 
and SIV/HIV-1: implications for viral entry. PLoS Pathog, 2007. 3(5): p. 
e63. 
233. Starcich, B.R., et al., Identification and characterization of conserved and 
variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of 
AIDS. Cell, 1986. 45(5): p. 637-48. 
234. Jiang, X., et al., Conserved structural elements in the V3 crown of HIV-1 
gp120. Nat Struct Mol Biol, 2010. 17(8): p. 955-61. 
235. Chen, B., et al., Structure of an unliganded simian immunodeficiency virus 
gp120 core. Nature, 2005. 433(7028): p. 834-41. 
236. Zolla-Pazner, S., et al., Structure/Function Studies Involving the V3 
Region of the HIV-1 Envelope Delineate Multiple Factors That Affect 
Neutralization Sensitivity. J Virol, 2016. 90(2): p. 636-49. 
237. Powell, R.L.R., et al., Plasticity and Epitope Exposure of the HIV-1 
Envelope Trimer. J Virol, 2017. 91(17). 
	 179 
238. Zolla-Pazner, S. and T. Cardozo, Structure-function relationships of HIV-1 
envelope sequence-variable regions refocus vaccine design. Nat Rev 
Immunol, 2010. 10(7): p. 527-35. 
239. Yuan, T., J. Li, and M.Y. Zhang, HIV-1 envelope glycoprotein variable 
loops are indispensable for envelope structural integrity and virus entry. 
PLoS One, 2013. 8(8): p. e69789. 
240. Wyatt, R., et al., Functional and immunologic characterization of human 
immunodeficiency virus type 1 envelope glycoproteins containing 
deletions of the major variable regions. J Virol, 1993. 67(8): p. 4557-65. 
241. Cao, J., et al., Replication and neutralization of human immunodeficiency 
virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope 
glycoprotein. J Virol, 1997. 71(12): p. 9808-12. 
242. Perez, L.G., et al., Envelope glycoprotein binding to the integrin 
alpha4beta7 is not a general property of most HIV-1 strains. J Virol, 2014. 
88(18): p. 10767-77. 
243. Walker, L.M., et al., Broad and potent neutralizing antibodies from an 
African donor reveal a new HIV-1 vaccine target. Science, 2009. 
326(5950): p. 285-9. 
244. Gorny, M.K., et al., Identification of a new quaternary neutralizing epitope 
on human immunodeficiency virus type 1 virus particles. J Virol, 2005. 
79(8): p. 5232-7. 
245. O'Connell, R.J., J.H. Kim, and J.L. Excler, The HIV-1 gp120 V1V2 loop: 
structure, function and importance for vaccine development. Expert Rev 
Vaccines, 2014. 13(12): p. 1489-500. 
246. Haynes, B.F., et al., Immune-correlates analysis of an HIV-1 vaccine 
efficacy trial. N Engl J Med, 2012. 366(14): p. 1275-86. 
247. Karasavvas, N., et al., The Thai Phase III HIV Type 1 Vaccine trial 
(RV144) regimen induces antibodies that target conserved regions within 
the V2 loop of gp120. AIDS Res Hum Retroviruses, 2012. 28(11): p. 1444-
57. 
248. Gu, L., et al., Adenoviral vectors elicit humoral immunity against variable 
loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" 
strategy. Virology, 2016. 487: p. 75-84. 
249. LaRosa, G.J., et al., Conserved sequence and structural elements in the 
HIV-1 principal neutralizing determinant. Science, 1990. 249(4971): p. 
932-5. 
	 180 
250. Chandramouli, B., et al., Importance of V3 loop flexibility and net charge in 
the context of co-receptor recognition. A molecular dynamics study on HIV 
gp120. J Biomol Struct Dyn, 2012. 29(5): p. 879-91. 
251. Watabe, T., et al., Fold recognition of the human immunodeficiency virus 
type 1 V3 loop and flexibility of its crown structure during the course of 
adaptation to a host. Genetics, 2006. 172(3): p. 1385-96. 
252. Sander, O., et al., Structural descriptors of gp120 V3 loop for the 
prediction of HIV-1 coreceptor usage. PLoS Comput Biol, 2007. 3(3): p. 
e58. 
253. Chiou, S.H., et al., Studies on the role of the V3 loop in human 
immunodeficiency virus type 1 envelope glycoprotein function. AIDS Res 
Hum Retroviruses, 1992. 8(9): p. 1611-8. 
254. Davis, K.L., et al., High titer HIV-1 V3-specific antibodies with broad 
reactivity but low neutralizing potency in acute infection and following 
vaccination. Virology, 2009. 387(2): p. 414-26. 
255. Gorny, M.K., et al., The v3 loop is accessible on the surface of most 
human immunodeficiency virus type 1 primary isolates and serves as a 
neutralization epitope. J Virol, 2004. 78(5): p. 2394-404. 
256. Hioe, C.E., et al., Anti-V3 monoclonal antibodies display broad neutralizing 
activities against multiple HIV-1 subtypes. PLoS One, 2010. 5(4): p. 
e10254. 
257. de Taeye, S.W., et al., Immunogenicity of Stabilized HIV-1 Envelope 
Trimers with Reduced Exposure of Non-neutralizing Epitopes. Cell, 2015. 
163(7): p. 1702-15. 
258. de Taeye, S.W., et al., Stabilization of the gp120 V3 loop through 
hydrophobic interactions reduces the immunodominant V3-directed non-
neutralizing response to HIV-1 envelope trimers. J Biol Chem, 2018. 
293(5): p. 1688-1701. 
259. Gilbert, P.B., et al., Correlation between immunologic responses to a 
recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in 
a phase 3 HIV-1 preventive vaccine trial. J Infect Dis, 2005. 191(5): p. 
666-77. 
260. Flynn, N.M., et al., Placebo-controlled phase 3 trial of a recombinant 
glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis, 2005. 
191(5): p. 654-65. 
261. Pitisuttithum, P., et al., Randomized, double-blind, placebo-controlled 
efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine 
	 181 
among injection drug users in Bangkok, Thailand. J Infect Dis, 2006. 
194(12): p. 1661-71. 
262. Gray, G.E., et al., Safety and efficacy of the HVTN 503/Phambili study of a 
clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, 
placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis, 
2011. 11(7): p. 507-15. 
263. Buchbinder, S.P., et al., Efficacy assessment of a cell-mediated immunity 
HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-
controlled, test-of-concept trial. Lancet, 2008. 372(9653): p. 1881-1893. 
264. Rerks-Ngarm, S., et al., Vaccination with ALVAC and AIDSVAX to prevent 
HIV-1 infection in Thailand. N Engl J Med, 2009. 361(23): p. 2209-20. 
265. Jones, A.T., et al., A Trimeric HIV-1 Envelope gp120 Immunogen Induces 
Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits 
and Rhesus Macaques. J Virol, 2018. 92(5). 
266. Hammer, S.M., et al., Efficacy trial of a DNA/rAd5 HIV-1 preventive 
vaccine. N Engl J Med, 2013. 369(22): p. 2083-92. 
267. Hu, D., et al., Tryptophan 375 stabilizes the outer-domain core of gp120 
for HIV vaccine immunogen design. Vaccine, 2017. 35(23): p. 3067-3075. 
268. Torrents de la Pena, A., et al., Immunogenicity in Rabbits of HIV-1 SOSIP 
Trimers from Clades A, B, and C, Given Individually, Sequentially, or in 
Combination. J Virol, 2018. 92(8). 
269. Klasse, P.J., et al., Sequential and Simultaneous Immunization of Rabbits 
with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B 
and C. PLoS Pathog, 2016. 12(9): p. e1005864. 
270. Ringe, R.P., et al., Reducing V3 Antigenicity and Immunogenicity on 
Soluble, Native-Like HIV-1 Env SOSIP Trimers. J Virol, 2017. 91(15). 
271. Forsell, M.N., W.R. Schief, and R.T. Wyatt, Immunogenicity of HIV-1 
envelope glycoprotein oligomers. Curr Opin HIV AIDS, 2009. 4(5): p. 380-
7. 
272. Chuang, G.Y., et al., Structure-Based Design of a Soluble Prefusion-
Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved 
Immunogenicity. J Virol, 2017. 91(10). 
273. Sanders, R.W. and J.P. Moore, Native-like Env trimers as a platform for 
HIV-1 vaccine design. Immunol Rev, 2017. 275(1): p. 161-182. 
	 182 
274. Julien, J.P., et al., Asymmetric recognition of the HIV-1 trimer by broadly 
neutralizing antibody PG9. Proc Natl Acad Sci U S A, 2013. 110(11): p. 
4351-6. 
275. Pancera, M., et al., Structure and immune recognition of trimeric pre-
fusion HIV-1 Env. Nature, 2014. 514(7523): p. 455-61. 
276. Kovacs, J.M., et al., HIV-1 envelope trimer elicits more potent neutralizing 
antibody responses than monomeric gp120. Proc Natl Acad Sci U S A, 
2012. 109(30): p. 12111-6. 
277. Cheng, C., et al., Immunogenicity of a Prefusion HIV-1 Envelope Trimer in 
Complex with a Quaternary-Structure-Specific Antibody. J Virol, 2015. 
90(6): p. 2740-55. 
278. Medina-Ramirez, M., R.W. Sanders, and Q.J. Sattentau, Stabilized HIV-1 
envelope glycoprotein trimers for vaccine use. Curr Opin HIV AIDS, 2017. 
12(3): p. 241-249. 
279. Karlsson Hedestam, G.B., et al., The challenges of eliciting neutralizing 
antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol, 2008. 6(2): 
p. 143-55. 
280. Graham, F.L., et al., Characteristics of a human cell line transformed by 
DNA from human adenovirus type 5. J Gen Virol, 1977. 36(1): p. 59-74. 
281. Wei, X., et al., Emergence of resistant human immunodeficiency virus type 
1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob 
Agents Chemother, 2002. 46(6): p. 1896-905. 
282. Derdeyn, C.A., et al., Sensitivity of human immunodeficiency virus type 1 
to the fusion inhibitor T-20 is modulated by coreceptor specificity defined 
by the V3 loop of gp120. J Virol, 2000. 74(18): p. 8358-67. 
283. Platt, E.J., et al., Effects of CCR5 and CD4 cell surface concentrations on 
infections by macrophagetropic isolates of human immunodeficiency virus 
type 1. J Virol, 1998. 72(4): p. 2855-64. 
284. Montefiori, D.C., Measuring HIV neutralization in a luciferase reporter 
gene assay. Methods Mol Biol, 2009. 485: p. 395-405. 
285. Nelson-Rees, W.A., et al., Source, alterations, characteristics and use of a 
new dog cell line (Cf2Th). In Vitro, 1976. 12(10): p. 665-9. 
286. Kong, L.I., et al., West African HIV-2-related human retrovirus with 
attenuated cytopathicity. Science, 1988. 240(4858): p. 1525-9. 
	 183 
287. Kumar, P., et al., Molecular characterization of an attenuated human 
immunodeficiency virus type 2 isolate. J Virol, 1990. 64(2): p. 890-901. 
288. Soares, M.A., et al., A full-length and replication-competent proviral clone 
of SIVAGM from tantalus monkeys. Virology, 1997. 228(2): p. 394-9. 
289. Johnson, P.R., et al., Simian immunodeficiency viruses from African green 
monkeys display unusual genetic diversity. J Virol, 1990. 64(3): p. 1086-
92. 
290. Ivey-Hoyle, M., et al., Envelope glycoproteins from biologically diverse 
isolates of immunodeficiency viruses have widely different affinities for 
CD4. Proc Natl Acad Sci U S A, 1991. 88(2): p. 512-6. 
291. Reimann, K.A., et al., Immunopathogenic events in acute infection of 
rhesus monkeys with simian immunodeficiency virus of macaques. J Virol, 
1994. 68(4): p. 2362-70. 
292. Mulligan, M.J., et al., Human immunodeficiency virus type 2 envelope 
glycoprotein: differential CD4 interactions of soluble gp120 versus the 
assembled envelope complex. Virology, 1992. 187(1): p. 233-41. 
293. Finzi, A., et al., Topological layers in the HIV-1 gp120 inner domain 
regulate gp41 interaction and CD4-triggered conformational transitions. 
Mol Cell, 2010. 37(5): p. 656-67. 
294. Parolin, C., et al., Use of cis- and trans-acting viral regulatory sequences 
to improve expression of human immunodeficiency virus vectors in human 
lymphocytes. Virology, 1996. 222(2): p. 415-22. 
295. Helseth, E., et al., Rapid complementation assays measuring replicative 
potential of human immunodeficiency virus type 1 envelope glycoprotein 
mutants. J Virol, 1990. 64(5): p. 2416-20. 
296. Moore, J.P., Simple methods for monitoring HIV-1 and HIV-2 gp120 
binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 
has a 25-fold lower affinity than HIV-1 for soluble CD4. AIDS, 1990. 4(4): 
p. 297-305. 
297. Clapham, P.R., et al., Soluble CD4 blocks the infectivity of diverse strains 
of HIV and SIV for T cells and monocytes but not for brain and muscle 
cells. Nature, 1989. 337(6205): p. 368-70. 
298. Bahraoui, E., et al., Study of the interaction of HIV-1 and HIV-2 envelope 
glycoproteins with the CD4 receptor and role of N-glycans. AIDS Res Hum 
Retroviruses, 1992. 8(5): p. 565-73. 
	 184 
299. Hill, C.M., et al., Envelope glycoproteins from human immunodeficiency 
virus types 1 and 2 and simian immunodeficiency virus can use human 
CCR5 as a coreceptor for viral entry and make direct CD4-dependent 
interactions with this chemokine receptor. J Virol, 1997. 71(9): p. 6296-
304. 
300. Trkola, A., et al., CD4-dependent, antibody-sensitive interactions between 
HIV-1 and its co-receptor CCR-5. Nature, 1996. 384(6605): p. 184-7. 
301. Wu, L., et al., CD4-induced interaction of primary HIV-1 gp120 
glycoproteins with the chemokine receptor CCR-5. Nature, 1996. 
384(6605): p. 179-83. 
302. Basmaciogullari, S., et al., Identification of conserved and variable 
structures in the human immunodeficiency virus gp120 glycoprotein of 
importance for CXCR4 binding. J Virol, 2002. 76(21): p. 10791-800. 
303. Shioda, T., J.A. Levy, and C. Cheng-Mayer, Small amino acid changes in 
the V3 hypervariable region of gp120 can affect the T-cell-line and 
macrophage tropism of human immunodeficiency virus type 1. Proc Natl 
Acad Sci U S A, 1992. 89(20): p. 9434-8. 
304. Huang, C.C., et al., Structure of a V3-containing HIV-1 gp120 core. 
Science, 2005. 310(5750): p. 1025-8. 
305. Cashin, K., et al., CoRSeqV3-C: a novel HIV-1 subtype C specific V3 
sequence based coreceptor usage prediction algorithm. Retrovirology, 
2013. 10: p. 24. 
306. Hartley, O., et al., V3: HIV's switch-hitter. AIDS Res Hum Retroviruses, 
2005. 21(2): p. 171-89. 
307. Foda, M., S. Harada, and Y. Maeda, Role of V3 independent domains on 
a dualtropic human immunodeficiency virus type 1 (HIV-1) envelope 
gp120 in CCR5 coreceptor utilization and viral infectivity. Microbiol 
Immunol, 2001. 45(7): p. 521-30. 
308. Cocchi, F., et al., The V3 domain of the HIV-1 gp120 envelope 
glycoprotein is critical for chemokine-mediated blockade of infection. Nat 
Med, 1996. 2(11): p. 1244-7. 
309. Cardozo, T., et al., Structural basis for coreceptor selectivity by the HIV 
type 1 V3 loop. AIDS Res Hum Retroviruses, 2007. 23(3): p. 415-26. 
310. Buonaguro, L., M.L. Tornesello, and F.M. Buonaguro, Human 
immunodeficiency virus type 1 subtype distribution in the worldwide 
epidemic: pathogenetic and therapeutic implications. J Virol, 2007. 81(19): 
p. 10209-19. 
	 185 
311. Taylor, B.S., et al., The challenge of HIV-1 subtype diversity. N Engl J 
Med, 2008. 358(15): p. 1590-602. 
312. Shet, A., P. Nagaraja, and N.M. Dixit, Viral Decay Dynamics and 
Mathematical Modeling of Treatment Response: Evidence of Lower in vivo 
Fitness of HIV-1 Subtype C. J Acquir Immune Defic Syndr, 2016. 73(3): p. 
245-251. 
313. Zolla-Pazner, S., Improving on nature: focusing the immune response on 
the V3 loop. Hum Antibodies, 2005. 14(3-4): p. 69-72. 
314. White-Scharf, M.E., et al., Broadly neutralizing monoclonal antibodies to 
the V3 region of HIV-1 can be elicited by peptide immunization. Virology, 
1993. 192(1): p. 197-206. 
315. Krachmarov, C.P., et al., V3-specific polyclonal antibodies affinity purified 
from sera of infected humans effectively neutralize primary isolates of 
human immunodeficiency virus type 1. AIDS Res Hum Retroviruses, 
2001. 17(18): p. 1737-48. 
316. Xiang, S.H., et al., Characterization of a dual-tropic human 
immunodeficiency virus (HIV-1) strain derived from the prototypical X4 
isolate HXBc2. Virology, 2013. 438(1): p. 5-13. 
317. Huang, C.C., et al., Structures of the CCR5 N terminus and of a tyrosine-
sulfated antibody with HIV-1 gp120 and CD4. Science, 2007. 317(5846): 
p. 1930-4. 
318. Cimbro, R., et al., Tyrosine sulfation in the second variable loop (V2) of 
HIV-1 gp120 stabilizes V2-V3 interaction and modulates neutralization 
sensitivity. Proc Natl Acad Sci U S A, 2014. 111(8): p. 3152-7. 
319. Wu, L., et al., Interaction of chemokine receptor CCR5 with its ligands: 
multiple domains for HIV-1 gp120 binding and a single domain for 
chemokine binding. J Exp Med, 1997. 186(8): p. 1373-81. 
320. Maeda, K., et al., Involvement of the second extracellular loop and 
transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: 
insights into the mechanism of allosteric inhibition. J Mol Biol, 2008. 
381(4): p. 956-74. 
321. Abayev, M., et al., An extended CCR5 ECL2 peptide forms a helix that 
binds HIV-1 gp120 through non-specific hydrophobic interactions. FEBS J, 
2015. 282(10): p. 1906-1921. 
322. Korber B., F.B.T., Kuiken C., Pillai S.K., Sodroski J.G., Numbering 
Positions in HIV Relative to HXB2CG. The Human Retroviruses and AIDS 
	 186 
1998 Compendium Los Alamos National Laboratories, 1998: p. III-102- III-
111. 
323. Mourez, T., F. Simon, and J.C. Plantier, Non-M variants of human 
immunodeficiency virus type 1. Clin Microbiol Rev, 2013. 26(3): p. 448-61. 
324. Gao, F., et al., Human infection by genetically diverse SIVSM-related HIV-
2 in west Africa. Nature, 1992. 358(6386): p. 495-9. 
325. de Silva, T.I., et al., Potent autologous and heterologous neutralizing 
antibody responses occur in HIV-2 infection across a broad range of 
infection outcomes. J Virol, 2012. 86(2): p. 930-46. 
326. Kong, R., et al., Broad and potent neutralizing antibody responses elicited 
in natural HIV-2 infection. J Virol, 2012. 86(2): p. 947-60. 
327. Ozkaya Sahin, G., et al., Potent intratype neutralizing activity distinguishes 
human immunodeficiency virus type 2 (HIV-2) from HIV-1. J Virol, 2012. 
86(2): p. 961-71. 
328. Lee, J.H., et al., A Broadly Neutralizing Antibody Targets the Dynamic HIV 
Envelope Trimer Apex via a Long, Rigidified, and Anionic beta-Hairpin 
Structure. Immunity, 2017. 46(4): p. 690-702. 
329. Blattner, C., et al., Structural delineation of a quaternary, cleavage-
dependent epitope at the gp41-gp120 interface on intact HIV-1 Env 
trimers. Immunity, 2014. 40(5): p. 669-80. 
330. Derking, R., et al., Comprehensive antigenic map of a cleaved soluble 
HIV-1 envelope trimer. PLoS Pathog, 2015. 11(3): p. e1004767. 
331. Huang, J., et al., Broad and potent HIV-1 neutralization by a human 
antibody that binds the gp41-gp120 interface. Nature, 2014. 515(7525): p. 
138-42. 
332. Barnes, C.O., et al., Structural characterization of a highly-potent V3-
glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 
envelope. Nat Commun, 2018. 9(1): p. 1251. 
333. Willey, R.L., et al., Identification of conserved and divergent domains 
within the envelope gene of the acquired immunodeficiency syndrome 
retrovirus. Proc Natl Acad Sci U S A, 1986. 83(14): p. 5038-42. 
334. Catasti, P., et al., Local and global structural properties of the HIV-MN V3 
loop. J Biol Chem, 1995. 270(5): p. 2224-32. 
335. Torres, O.B., et al., Heroin-HIV-1 (H2) vaccine: induction of dual 
immunologic effects with a heroin hapten-conjugate and an HIV-1 
	 187 
envelope V2 peptide with liposomal lipid A as an adjuvant. NPJ Vaccines, 
2017. 2: p. 13. 
336. Mansfield, K.G., et al., Origins of simian immunodeficiency virus infection 
in macaques at the New England Regional Primate Research Center. J 
Med Primatol, 1995. 24(3): p. 116-22. 
337. Hirsch, V.M., et al., An African primate lentivirus (SIVsm) closely related to 
HIV-2. Nature, 1989. 339(6223): p. 389-92. 
338. Courgnaud, V., et al., Characterization of a novel simian 
immunodeficiency virus from guereza colobus monkeys (Colobus 
guereza) in Cameroon: a new lineage in the nonhuman primate lentivirus 
family. J Virol, 2001. 75(2): p. 857-66. 
339. Freed, E.O., D.J. Myers, and R. Risser, Mutational analysis of the 
cleavage sequence of the human immunodeficiency virus type 1 envelope 
glycoprotein precursor gp160. J Virol, 1989. 63(11): p. 4670-5. 
340. McCune, J.M., et al., Endoproteolytic cleavage of gp160 is required for the 
activation of human immunodeficiency virus. Cell, 1988. 53(1): p. 55-67. 
341. Rudicell, R.S., et al., Impact of simian immunodeficiency virus infection on 
chimpanzee population dynamics. PLoS Pathog, 2010. 6(9): p. e1001116. 
342. Rudicell, R.S., et al., High prevalence of simian immunodeficiency virus 
infection in a community of savanna chimpanzees. J Virol, 2011. 85(19): 
p. 9918-28. 
343. Etienne, L., et al., Characterization of a new simian immunodeficiency 
virus strain in a naturally infected Pan troglodytes troglodytes chimpanzee 
with AIDS related symptoms. Retrovirology, 2011. 8: p. 4. 
344. Jurkiewicz, E., et al., Identification of the V1 region as a linear neutralizing 
epitope of the simian immunodeficiency virus SIVmac envelope 
glycoprotein. J Virol, 1997. 71(12): p. 9475-81. 
345. Petry, H., et al., Naturally occurring V1-env region variants mediate simian 
immunodeficiency virus SIVmac escape from high-titer neutralizing 
antibodies induced by a protective subunit vaccine. J Virol, 2000. 74(23): 
p. 11145-52. 
346. Ondoa, P., et al., Genetic variability of the V1 and V2 env domains of 
SIVcpz-ant and neutralization pattern of plasma viruses in a chimpanzee 
infected naturally. J Med Virol, 2001. 65(4): p. 765-76. 
347. Curlin, M.E., et al., HIV-1 envelope subregion length variation during 
disease progression. PLoS Pathog, 2011. 6(12): p. e1001228. 
	 188 
348. Yang, X., R. Wyatt, and J. Sodroski, Improved elicitation of neutralizing 
antibodies against primary human immunodeficiency viruses by soluble 
stabilized envelope glycoprotein trimers. J Virol, 2001. 75(3): p. 1165-71. 
349. Dogo-Isonagie, C., et al., Peptides from second extracellular loop of C-C 
chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1. J Biol 
Chem, 2012. 287(18): p. 15076-86. 
350. Bobyk, K.D., et al., Design of HIV Coreceptor Derived Peptides That 
Inhibit Viral Entry at Submicromolar Concentrations. Mol Pharm, 2017. 
14(8): p. 2681-2689. 
351. Cormier, E.G. and T. Dragic, The crown and stem of the V3 loop play 
distinct roles in human immunodeficiency virus type 1 envelope 
glycoprotein interactions with the CCR5 coreceptor. J Virol, 2002. 76(17): 
p. 8953-7. 
 
 
 
 
 
 
	
